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SUMMARY 
 
Cystic Fibrosis (CF) is the most common autosomal disease in Caucasians, with an 
estimated incidence of 1:6000 births in Portugal. The most relevant clinical aspect of its classic 
manifestation is chronic lung disease, which is the main cause of morbidity and mortality. 
Other symptoms include, pancreatic dysfunction, male infertility and high concentrations of 
chloride (Cl-) in sweat. However, even though the classic form of the disease is well defined, 
its pathophysiology is not completely understood with this pleiotropic disease having highly 
variable manifestations of clinical phenotypes. Novel therapies aim to correct the basic defect, 
specifically focusing on the rescue of Cystic fibrosis transmembrane conductance regulator 
(CFTR) function in CF airways. Most of these CFTR modulator strategies target the F508del, 
the most common mutation. 
Nevertheless, widespread evidence has demonstrated that a significant number of CF-
causing mutations affect splicing efficiency and the stability of mRNA molecules. Here, we 
propose to elucidate the regulatory mechanisms underlying these CF-associated mutations. 
To this end, our aims are: 1) to identify CFTR gene mutations in individuals with non-CF 
chronic lung diseases, namely chronic obstructive pulmonary disease (COPD), asthma and 
disseminated bronchiectasis (DB); 2) to identify CFTR gene mutations in individuals with a 
suspicion of CF, followed by the analysis of CFTR expression in their native tissues to 
characterize the impact of CFTR splicing or premature termination codon (PTC) mutations in 
the structure and levels of mRNA; 3) to identify key factors in the nonsense/mediated decay 
(NMD) pathway by automated microscopy screens using a cell model expressing a novel 
CFTR NMD-PTC/read-through mini-gene reporter; and 4) to screen for novel compounds 
suppressing PTC mutations by automated microscopy screens using the previous cell-based 
model, as potential corrective therapies for CF. The expected results will provide knowledge 
on RNA-processing dysfunction and on the efficacy of novel RNA modulator compounds 
towards a "personalised medicine" approach. 
Regarding the first objective, our data show that 7 (out of 136) patients with non-CF 
respiratory diseases presented CFTR mutations in one allele, in contrast with the control 
group, in which no mutations were detected. We analysed the association of CFTR gene 
mutations with each of the three respiratory diseases considered. For asthma our data did not 
show an increase in mutation frequency when compared to the control group. For DB, we 
found an increase in the frequency of CFTR gene mutations, albeit with no statistical 
significance, which is in agreement with previous reports. For COPD however, we found a 
statistically significant increase in CFTR gene mutation incidence, relative to the control group. 
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Our data reinforce the importance of characterizing CFTR gene mutations on non-CF 
respiratory diseases in Portuguese patients, to gain a better understanding of the 
epidemiology and etiology of these diseases. The results also lead to the identification of 
groups of patients who may benefit from the new therapeutic compounds currently under 
development to correct the basic CFTR protein defect in CF.  
 
Concerning the second objective, we have developed a novel RNA-based approach to 
detect unknown CFTR mutations [Felício et al (2017) Clin Genet 91: 476-481]. We are 
currently using this protocol for patients with a suspicion of CF and none or just one CFTR 
mutation identified. With this method we identified one mutation (711+3A>T) which had been 
previously reported but had not been characterized. We can conclude that this is a rapid, 
robust and inexpensive method to detect rare mutations, and therefore a method that can be 
easily used after a first screen. 
 
Regarding the third objective, we used this CFTR-NMD reporter to identify novel NMD 
factors by screening a previously validated shRNA library – a subset of The RNAi Consortium 
(TRC) – which is enriched in shRNAs targeting genes with a known or predicted involvement 
in transcript processing (425 genes), using HT microscopy. We selected the 24 top hits for the 
confirmation: 11 genes with NMD score ≥ 2 and more than 2 shRNAs with the same 
phenotype; 2 genes from the screen that showed read-through activity; and 11 other genes 
resulting from a high-throughput screen (HTS) aimed at the identification of CFTR splicing 
regulators (unpublished data). We chose these genes related to splicing because this is a 
process known to be required for NMD to occur and thus the knock-down of such genes can 
lead to NMD inhibition. The confirmation screen was performed using a library of siRNAs 
targeting the previously selected genes, however the results were inconclusive due to the low 
NMD score obtained. We have identified 4 genes with higher values but NMD score ≤ 1, three 
(eIF4A3, SREK1 and RPS19) are related to splicing, elF4A3 is directly and RPS19 is indirectly 
related to NMD, SREK1 is related only to splicing, with the fourth gene, ADIRF, having 
unknown functional properties. Some of the hits identified within this screen may be potential 
drug targets by their effects in inhibiting NMD, when knocked-down. With the results obtained 
in the confirmation screen we decided to follow the 24 genes identified in the primary screen 
for validation studies using two different techniques: WB and qRT-PCR (study in progress).  
Lastly, the fourth objective was to restore functional protein production to PTC mutations 
using read-through compounds, with the ultimate aim of CF patient treatment. The CFTR-
NMD construct used has the G542X nonsense mutation, mCherry at the N terminus and eGFP 
fused at the CFTR C-terminus. Through the screen of the library, we identified new small-
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molecule compounds that induced PTC read-through. To confirm the read-through efficiency 
future experiments are needed using additional techniques, such as, WB and transcript 
analysis by semi-quantitative PCR and qRT-PCR. Finally, to validate the top hit compounds, 
it is necessary to test them in patient’s materials, including nasal primary cells for functional 
activity and intestinal organoids to determine a dose response and to test these compounds 
in combination with potentiators and correctors. 
The studies presented in this dissertation had the overall aims of advancing the current 
knowledge on RNA-processing dysfunction and of identifying novel RNA modulator 
compounds towards a "personalised medicine" approach. The results obtained have indeed 
provided new insights into: 1) the relationship of other respiratory diseases with the presence 
of CFTR mutations; 2) new approaches to detect CFTR mutations in DNA and RNA; and 3) 
our understanding of key factors in NMD and read-through activity in relation to CFTR 
nonsense mutations.  
 
Keywords: CF diagnosis; genotyping; intronic mutations; rare mutations; splicing; nonsense 
mutations; premature termination codons (PTC); Nonsense mediated decay (NMD): Read-
through activity 
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RESUMO 
 
A Fibrose Quística (FQ) é a doença autossómica recessiva letal mais comum na população 
Caucasiana, afetando cerca de 1 em 2500-6000 nados vivos, dependendo da região 
geográfica do globo, e com uma frequência de portadores de 1 em cada 25-40 indivíduos. 
Esta doença é causada por mutações no gene CFTR (do inglês Cystic Fibrosis 
Transmembrane Conductance Regulator) localizado no cromossoma 7. A proteína CFTR é 
expressa na membrana apical das células epiteliais onde funciona como um canal de cloreto 
(Cl-), regulando o transporte iónico e de água. Clinicamente, a FQ é caracterizada por 
múltiplas manifestações em diferentes órgãos, sendo, contudo, a doença a nível pulmonar a 
principal causa de morbilidade e mortalidade. Outros sintomas clássicos da FQ incluem 
insuficiência pancreática exócrina, obstrução intestinal, infertilidade masculina e 
concentração elevada de eletrólitos no suor (característica utilizada no principal teste de 
diagnóstico).  
Foram já descritas mais de 2000 mutações no gene CFTR, supondo-se ser grande parte 
delas causadoras de FQ. Assume-se que cerca de 13% das variantes não sejam patogénicas, 
mas para a grande maioria (~85%) ainda não estão definidas as respetivas consequências 
funcionais e clínicas. Existem estudos que sugerem estarem as mutações no gene CFTR 
também associadas a outras doenças respiratórias, como Bronquiectasias difusas (BD), 
Doença Pulmonar Obstrutiva Crónica (DPOC) ou Asma Brônquica. A elucidação dos efeitos 
moleculares e funcionais das mutações é uma importante fonte de informação para 
prognóstico clínico, mas também sobre a estrutura e função da proteína CFTR, 
nomeadamente para desenvolver compostos terapêuticos para correção do defeito específico 
de cada mutação. Assim, a classificação de mutações CFTR de acordo com seu defeito 
funcional permite conceber uma estratégia terapêutica comum para mutações na mesma 
classe, tendo sido propostas sete classes de mutações, que mais recentemente evoluíram 
para "teratipos".  
Porém, muitos desafios permanecem na conceção de terapias para pacientes com FQ que 
apresentam mutações raras e que não podem ser tratadas com as terapêuticas aprovadas. 
Uma fração significativa (~ 24%) gera um codão de terminação prematura ou PTC (do inglês, 
"Premature Termination Codon"), incluindo: 8,4% nonsense e 15,7% mutações frameshift. As 
mutações PTC levam em geral a uma redução significativa, ou ausência total, de expressão 
de mRNA e proteína normais, e estão normalmente associadas a um fenótipo clínico grave. 
A redução nos níveis de transcritos ocorre através do mecanismo de degradação do mRNA 
denominado NMD (do inglês "Nonsense-Mediated Decay") que degrada seletivamente os 
transcritos portadores de PTCs. Até ao momento, não há terapias para tratar especificamente 
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pacientes portadores de mutações PTC. O NMD é um mecanismo essencial de regulação 
genética conservado em eucariotas, desempenhando um papel importante na modulação dos 
fenótipos clínicos, bem como na resposta a terapias. Espera-se que os pacientes que 
expressam níveis mais altos de mRNA contendo PTC devido a NMD menos eficiente, 
respondam de forma mais robusta às terapias de supressão / read-through.  
Assim, o NMD representa assim um potencial alvo terapêutico para doenças causadas por 
PTCs, sendo de grande relevância identificar drogas alvo que inibam/ reduzam o NMD, 
levando ao amento dos níveis de transcritos contendo PTC. Esta redução do NMD acoplada 
à administração de agentes de read-through podem levar à produção de proteína CFTR 
completa ("full-length") funcional. 
O objetivo geral deste trabalho centrou-se na compreensão do efeito das mutações CFTR 
a nível fenotípico e posteriormente na caracterização do efeito das mutações que afetam os 
transcritos quer ao nível splicing quer da estabilidade (NMD). Assim, os objetivos específicos 
do presente trabalho eram: 1) identificar mutações no gene CFTR em indivíduos com doenças 
respiratórias não-FQ; 2) identificar mutações CFTR em indivíduos com suspeita de FQ (e 
apenas com uma ou nenhuma mutação identificada) e analisar tecidos nativos de alguns 
desses pacientes para caracterizar o impacto de mutações que afetam a estrutura/níveis de 
mRNA; 3) identificar novos fatores de NMD usando um inovador modelo celular expressando 
um triplo repórter de CFTR com uma mutação PTC baseado na fluorescência e caracterizar 
os respetivos mecanismos de NMD; e por fim, 4) testar novos compostos quanto à sua 
atividade de read-through (supressão de mutações de PTC) naquele modelo celular.  
O primeiro objetivo do presente trabalho pretendia determinar se a presença de 
mutações CFTR está associada a um risco elevado de asma, bronquiectasias disseminadas 
(BD) ou doença pulmonar obstrutiva crónica (DPOC). Foram analisados, para as mutações 
mais comuns em Portugal, 187 indivíduos portugueses, divididos em dois grupos distintos: o 
primeiro incluiu indivíduos com doenças respiratórias não-FQ (n=136): asma (n = 54), DPOC 
(n = 51) ou BD (n = 31); e o segundo incluiu indivíduos controlo saudáveis (n = 51). Os nossos 
dados mostraram que 7/136 pacientes com doenças respiratórias não-FQ apresentaram 
mutações CFTR em um alelo vs nenhum no grupo controlo, sendo que não identificámos 
diferenças significativas na frequência de mutações vs o grupo controlo para a asma, nem 
para DB (embora aqui tenha sido encontrada uma tendência para um aumento na frequência 
de mutações). Para DPOC, no entanto, encontramos um aumento estatisticamente 
significativo na frequência de mutações do gene CFTR vs o grupo controlo. Confirmámos 
assim a importância das mutações CFTR em DPOC (e uma tendência em BD) em pacientes 
portugueses, levando não só a uma melhor perceção da epidemiologia e etiologia destas 
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doenças, mas também à identificação de grupos de pacientes que podem vir a beneficiar das 
novas terapias moduladoras da proteína CFTR para a FQ. 
No estudo acima referido, identificámos numa paciente com DPOC (fumadora) com 67 
anos uma mutação FQ grave (G542X) e mais duas variantes no outro alelo (G576A-R668C), 
uma delas associada a fenótipo FQ variável por splicing alternativo (por skipping do exão 13). 
Assim, analisamos esta paciente para averiguar os níveis de CFTR funcional em biópsia retal 
por camara de Ussing e confirmar/excluir um possível diagnóstico de FQ. Estes testes 
demonstraram níveis de função normais, revelando assim que o alelo complexo de 
prognóstico desconhecido, não era neste caso causador de FQ, em concordância com o 
fenótipo clínico, levando à exclusão do diagnóstico de FQ. Mostrou-se assim que em casos 
selecionados, o estudo funcional da proteína CFTR pode ser uma ajuda preciosa para 
confirmar / excluir um diagnóstico de FQ. 
Quanto ao segundo objetivo, desenvolvemos uma nova abordagem baseada em RNA 
para deteção de mutações desconhecidas no gene CFTR [Felício et al (2017) Clin Genet 91: 
476-481]. Atualmente este protocolo é usado para pacientes com suspeita de FQ e nenhuma 
ou apenas uma mutação CFTR identificada. Com este método, identificámos uma mutação 
(711 + 3A> T) já relatada, mas não caracterizada anteriormente. Podemos concluir que este 
é um método rápido, robusto e barato para detetar mutações raras que podem ser facilmente 
utilizadas após uma primeira deteção dum painel de mutações mais comuns. 
O terceiro objetivo do presente trabalho, consistiu na identificação de novos fatores que 
modulam o NMD de transcritos CFTR com mutações PTC. Para tal, construímos um novo 
modelo celular expressando um mini-gene CFTR (isto é, o cDNA CFTR completo contendo 
ainda os intrões IVS14, 15 e 16) e com a mutação G542X (exão 12), que promove NMD. 
Dado conter mCherry em N-terminal, permite detetar uma redução no NMD bem como 
atividade de read-through através do eGFP em C-terminal. Este modelo foi então usado para 
rastrear uma biblioteca de 425 genes, envolvidos no processamento de transcritos. Foram 
selecionados 13 top hits para confirmação: 11 genes com de NMD scrore ≥ 2 e mais de 2 
shRNA com o mesmo fenótipo. Para além destes 11 genes foram identificados 2 genes que 
mostraram atividade read-through. Aos 13 genes identificados no screen de NMD foram 
adicionados 11 genes que demonstram ter impacto no processo de splicing (S Igreja, MD 
Amaral, resultados não publicados) pelo que considerámos serem assim relevantes para o 
estudo de fatores que inibem NMD. Em resumo, o estudo de confirmação utilizando uma 
biblioteca de siRNA foi inconclusivo, visto que os NMD scores foram muito baixos, mas 
podemos mesmo assim identificar 4 genes com maior relevância nos resultados. Assim, tendo 
em conta os resultados do screen de confirmação, seguimos para um screen de validação 
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com os mesmos 24 genes selecionados, utilizando duas técnicas distintas: análise dos 
transcritos por qRT-PCR e da proteína resultante por Western blotting. 
O quarto e último objetivo do presente trabalho, focou-se na identificação de compostos 
com atividade de read-through para o tratamento final de pacientes com FQ. Para este fim 
utilizámos o modelo em cima descrito, utilizando a fluorescência de eGFP em C-terminal para 
quantificar a proteína completa (full-length) produzida. Assim, por HTS analisámos 24 
compostos análogos ou derivados do Ataluren/ PTC124, bem como outros não análogos, que 
foram sintetizados quimicamente por um grupo com quem colaboramos (Prof. Cristina 
Moiteiro, FCUL, Lisboa). Identificámos nesta biblioteca alguns compostos que levaram ao 
aparecimento de fluorescência verde, no entanto para serem considerados verdadeiros 
compostos de read-through, mais estudos têm de ser realizados para confirmar o efeito dos 
mesmos ao nível do RNA e da proteína.  
Os resultados obtidos nesta dissertação contribuíram para uma maior compreensão da 
relação entre doenças respiratórias não-FQ e a presença de mutações CFTR, bem como 
para o desenvolvimento duma nova metodologia para detetar mutações a nível do mRNA. 
Contribuíram ainda para o avanço do conhecimento dos mecanismos de processamento de 
mRNA com mutações PTC, ao identificar novos fatores moduladores de NMD e compostos 
potencialmente moduladores deste processo para abordagens terapêuticas inovadoras de 
"medicina personalizada". 
Palavras-chave: Diagnóstico FQ; genotipagem; mutações intrónicas; mutações raras; 
mutações nonsense; codão stop prematuro (PTC); Nonsense mediated decay (NMD); 
atividade "read-through". 
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De acordo com o disposto no artigo 31º do Regulamento de Estudos Pós-Graduados da 
Universidade de Lisboa, Despacho nº 2950/2025, publicado no Diário da República - 2ª Série 
- nº 57 – 23 de Março de 2015, foram utilizados nesta dissertação resultados incluídos nos 
seguintes artigos:  
1. Felício V, Ramalho AS, Clarke LA, Awatade NT, Lopes C, Barreto C, Amaral MD. Incidence 
of mutations in the CFTR gene in Portuguese individuals with respiratory diseases. 
[Manuscript in preparation]. 
2. Gonska T, Avolio J, Ip W, Griffin K, Dupuis A, Felício V, Souza CG, Dalge S, Ribeiro MA, 
Ribeiro AF, Amaral MD, Ribeiro JD, Tullis E, Sousa M, Servidoni M. Comparing β–adrenergic 
sweat secretion to rectal biopsy and nasal potential difference measurements as adjunctive 
diagnostic test for Cystic fibrosis. Manuscript submitted. 
3. Clarke LA, Awatade NT, Felício V, Calucho M, Pereira L, Azevedo P, Cavaco J, Barreto C, 
Bertuzzo C, Gartner S, Beekman J, Amaral MD. The effect of PTC mutations on CFTR mRNA 
abundance: A basis for read-through therapies in Cystic Fibrosis. Manuscript submitted. 
4. Felício V, Ramalho AS, Igreja S, Amaral MD (2017) mRNA-based Detection of Rare CFTR 
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1 Cystic Fibrosis- Clinical Phenotype, Diagnosis & Prognosis 
1.1 Clinical Phenotype 
Cystic Fibrosis (CF, MIM#2109700) is the most common lethal autosomal recessive 
disorder in the Caucasian population, affecting 1 in 2,500-6,000 newborns in Europe with 
currently ~34,000 patients listed in the European Registry. The disease frequency is variable 
among ethnic groups, being highest in North-eastern European populations and quite rare 
among oriental populations. In Portugal it is estimated that 1 in 6000 newborns are affected 
(De Boeck and Amaral, 2016; Santos et al., 2017). 
The disease was first described in 1938, based on autopsy studies of malnourished infants, 
who showed a recessive autosomal pattern of inheritance (Andersen, 1938). Although the 
biochemical basis of CF was not identified for 50 years, the disease was known to be 
associated with abnormalities of chloride (Cl-) and sodium (Na+) transport in several epithelia 
(Quinton, 1983). In 1989, using a positional cloning strategy, it was determined that a single 
gene was responsible for the disease onset (Kerem et al., 1989; Riordan et al., 1989; 
Rommens et al., 1989). The discovery of the CF gene led to the demonstration that the 
impaired chloride transport is due to failure of a cAMP regulated Cl- channel. This gene was 
shown to be expressed at the apical cell membrane in a large number of epithelial tissues, 
and was cautiously named Cystic Fibrosis Transmembrane conductance Regulator (CFTR; 
MIM*602421) (Kerem et al., 1989; Riordan et al., 1989; Rommens et al., 1989). 
The pathophysiology of CF can be described by the so-called "CF pathogenesis cascade" 
which starts with the presence of two defective CFTR genes associated with the CF phenotype 
(Figure 1.1). At the cellular level, this is characterised by the lack of, or reduced, cAMP-
mediated Cl-/HCO3- secretion. In other words, the cells from CF patients do not have the ability 
to transport cAMP-mediated Cl-/HCO3- to the same extent as normal cells (Amaral and 
Kunzelmann, 2007; Amaral, 2014). 
By acting as a negative regulator of the epithelial Na+ channel (ENaC), CFTR is also a 
general regulator of ion and water transport in epithelia (Rich et al., 1990). Due to the fact that 
water follows the direction of Na+ transport across the epithelia, the CF defect is also 
associated with enhanced water reabsorption. This event, according to some authors leads to 
increased salt concentration in the airway surface liquid (ASL) (Puchelle et al., 2002). 
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Figure 1.1 - CF Pathogenesis Cascade: From primary gene defect to lung disease. The 
mechanism of CF dysfunction starts with the primary CFTR gene defect and ultimately leading to 
severe lung deficiency. CFTR, cystic fibrosis transmembrane conductance regulator; ASL, airway 
surface liquid; ENaC, epithelial Na+ channel. Adapted from (Amaral, 2014) 
 
CF is a multi-system disease but the main cause of morbidity and mortality is chronic lung 
disease (Collins, 1992). In the respiratory tract, CF is manifested by the obstruction of the 
airways by thick, dehydrated mucus that prevents proper mucociliary clearance (MCC). This 
leads to recurring bacterial infections, especially by Pseudomonas aeruginosa and 
Staphylococcus aureus, that generate a hyper inflammation environment in the lungs of 
patients from a very early age, which leads to exacerbated tissue remodelling and fibrosis 
(Amaral and Kunzelmann, 2007). 
Other CF symptoms include exocrine pancreatic insufficiency (PI, 85%), intestinal 
obstruction, elevated sweat electrolytes and male infertility (95%) (Collins, 1992; Jarvi et al., 
1995; Welsh and Smith, 1995; Zielenski and Tsui, 1995). Additional (rarer) clinical 
manifestations include hepatobiliary disease (7%) and diabetes mellitus (Welsh and Smith, 
1995).  
Even though CF is a monogenic disease, the genotype-phenotype correlation is not 
straightforward. Nevertheless, homozygosity for the most common mutation F508del is 
usually associated with the ‘classical’ CF phenotype: progressive obstructive lung disease, PI, 
male infertility and very high concentrations of Cl- in sweat (Boucher, 2004). Each organ 
affected in CF requires a different level of CFTR function. Decreasing levels of CFTR function 
are associated with progressive involvement of more organs or systems and with a more 
severe phenotype (Rowe et al., 2005). The primary organ systems involved are the airways, 
in which mucus plugging and inflammation lead to progressive small airways obstruction and 
bronchiectasis; the gastrointestinal tract, liver, and exocrine pancreas, in which inspissation of 
viscid secretions leads to intestinal obstruction, cholestasis, and malabsorption of fat and 
protein; and the male reproductive tract, in which obstructive azoospermia leads to infertility. 
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However, some patients can have only one (or some) of these clinical phenotypes and still 
have no CF, being diagnosed with a CFTR-related disorder (CFTR-RD) or "CFTR-opathy" 
(Amaral, 2014). 
A CFTR-RD is thus defined as: "a clinical entity associated with CFTR dysfunction that 
does not fulfil the diagnostic criteria for CF" (Bombieri et al., 2011). Three main clinical entities 
illustrate these phenotypes when associated with CFTR dysfunction: congenital bilateral 
absence of the vas deferens (CBAVD), acute recurrent or chronic pancreatitis and 
disseminated bronchiectasis. Careful attention should be paid to exclude other known 
aetiologies, to the degree of screening for CFTR mutations and to the evaluation of CFTR 
function in these patients (Paranjape and Zeitlin, 2008; Michl et al., 2016).  
1.2 Diagnosis 
Initially a diagnosis of CF relied on the clinical phenotype, with recognition of the 
characteristic signs and symptoms of "classical" CF. There has been a surprising degree of 
difficulty encountered worldwide in establishing the diagnosis in a minority of cases and 
consequently, healthcare providers continue to face uncertain cases and challenging 
diagnostic dilemmas (Farrell et al., 2017c). However, the increased use of prenatal screening 
for maternal CF carrier status, prenatal ultrasound screening (that might reveal meconium 
ileus, meconium peritonitis, bowel obstruction, or echogenic bowel), and newborn screening 
(NBS) has resulted in the routine diagnosis of asymptomatic or minimally symptomatic infants 
and provided an opportunity to foster their normal growth and development (Farrell et al., 
2017b). Nevertheless, the extensive NBS programmes implemented have identified 
increasing numbers of asymptomatic CF patients merely by identifying elevated serum 
concentrations of immunoreactive trypsinogen (IRT). This, poses new challenges to the CF 
diagnosis paradigm, especially when associated with borderline sweat Cl- (see below) and/or 
inconclusive CFTR genotypes (Farrell et al., 2017c). These inconclusive CF diagnosis through 
NBS, are designated as "CF screen positive with an inconclusive diagnosis" (CFSPID), also 
called "CFTR-related metabolic syndrome" (CRMS) (Farrell et al., 2017a). Diagnosis of CF in 
non-screened populations can be challenging because the age of onset and severity of 
symptoms can differ greatly as a result of highly variable degrees of CFTR dysfunction.  
Figure 1.2 provides a simplified algorithm for the application of these consensus criteria to 
individuals with a suspicion of CF due to a positive NBS result, the appearance of signs or 
symptoms, or recognition of an immediate family member with history of CF (most often a 
sibling but may also include a parent or child). It should be noted that a positive NBS result 
does not mean the infant has CF; the probability of a CF diagnosis following a positive result 
varies greatly depending on the NBS method used (Farrell et al., 2017c). 
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Figure 1.2- Schematic representation of CF Diagnosis. Established guidelines to diagnose CF 
according to clinical presentation and other types of evidence. Adapted from (Farrell et al., 2017c) 
A confirmed CF diagnosis can only be established when an individual has both a clinical 
presentation of the disease and evidence of CFTR dysfunction. The tests conducted to 
establish CFTR dysfunction are done hierarchically, with sweat chloride being usually the first, 
followed by CFTR genetic analysis, and then CFTR functional tests like altered transepithelial 
nasal potential difference (NPD) or intestinal current of voltage measurements (ICM/IVM) 
(Sousa et al., 2012). For a positive diagnosis of CF two positive sweat tests are required and/or 
two CF-causing mutations identified. Only very rarely can an individual with a negative sweat 
chloride <30 mmol/L (see below) be considered to have CF and this diagnosis is only 
considered if all possible alternative diagnoses are excluded and if additional tests (genetic, 
functional tests) demonstrate dysfunctional CFTR. If only 1 CFTR gene variant is identified, 
further ("extended") CFTR gene analysis should be performed. CF is confirmed if both alleles 
possess CF-causing mutations. If two (or one) of these mutations is undefined, or if a mutation 
of varying clinical consequence (MVCC) is present CF is possible but not confirmed; CF is 
unlikely if the only mutations found have been described as non-CF-causing. If a CF diagnosis 
is not resolved, it can be considered as CRMS or CFSPID, if following NBS, or CFTR-RD 
(Farrell et al., 2017c).  
However, depending on the ethnic background of the populations tested (Bobadilla et al., 
2002), there are cases positively diagnosed with CF, from infancy to adulthood, that present 
"non-classical", or milder forms of the disease, representing 2% to 10% of all CF diagnoses. 
Most non-classical CF patients meet the same diagnostic criteria as classic CF patients, 
however, they may have a later presentation or have involvement of only one or two organ 
systems and usually with milder symptoms (Paranjape and Zeitlin, 2008). The majority of 
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patients with non-classical CF carry one severe and one mild or two mild CFTR mutations. A 
mild mutation is categorized as a gene alteration that still allows the resulting CFTR protein to 
partially function to a variable degree (Groman et al., 2005; Sousa et al., 2012). 
Certain individuals show conflicting results from the diagnostic tools available, such as 
inconclusive genetic testing, borderline sweat tests with both non-CF and CF features. For 
such individuals with clinical phenotypes not fully meeting the CF diagnostic criteria it is also 
difficult to exclude CF and as such additional functional tests (NPD or ICM/IVM) should be 
carried out. 
Sweat test 
Although NBS is now widely implemented, to confirm a diagnosis of CF two positive sweat 
tests are required, with values ≥ 60 mmol/L indicating a diagnosis of CF and < 30 mmol/L 
indicating CF as very unlikely. For individuals with a clinical phenotype or positive NBS and 
sweat chloride levels 30-59 mmol/L further testing for CFTR mutations and function (such as 
NPD and ICM/IVM are indicated. 
Genetic tests for CFTR 
The discovery of the CF gene in 1989 (Riordan et al., 1989)  provided a valuable tool for 
the genetic diagnosis of the disease. However, there are a large number of identified variants 
of the CFTR gene (currently more than 2000), most of which of unknown disease prognosis 
(Cystic Fibrosis Mutation Database, 2017). A more recent CFTR mutation database (CFTR2: 
https://cftr2.org) reports just the mutations of known disease prognosis. 
All patients with clinical suspicion of CF and positive or borderline sweat test should be 
evaluated through genotype analysis. Traditionally, identification of CFTR mutations was 
performed by testing a panel of a given number of mutations (usually 5-150 mutations), usually 
customized for the most common mutations present in the local populations. In Europe, it has 
become clear which mutations should be analysed in an initial screening, since 90% of CF 
related mutations can be detected using specific methods for only 30 mutations (De Boeck, et 
al., 2011). However, there is a wide geographic variability and in the South of Europe the 
spectrum of mutations is much wider than in the North. So, other strategies can be used to 
identify mutations, with the direct DNA sequencing of the complete gene (or at least of all 27 
exons and the respective flanking intronic regions) being the ultimate gold standard.  
 
Nasal Potential Difference (NPD) 
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Active transport of ions across the nasal epithelium results in a potential difference (PD), 
which can be measured by a voltmeter between two electrodes: 1) an exploring electrode 
placed on the surface of the nasal epithelium and 2) a reference electrode (generally 
subcutaneous), which represents the internal surface (Keenan et al., 2015). NPD 
measurements should be performed in both nostrils and reported as an averaged result. This 
approach reduces variability between both nostrils and repeated measurements. This 
diagnosis method has become the standard reporting method in CF diagnostic and is widely 
used in research applications. Basal values for NPD are usually interpreted as normal (< -12 
mV), intermediate (-12 to -7.7 mV) or abnormal (> -7.7 mV) (Ooi et al., 2012). CF patients 
usually present an increased magnitude of baseline PD (reflecting Na+ hyperabsorption), a 
dramatic response to amiloride, a transient or blunted response to low Cl- solution and 
isoproterenol (β-adrenergic agonist) and an exaggerated response to ATP (reflecting Cl- 
secretion through Calcium-activated chloride channels (CaCC)) (Taylor et al., 2009). 
Intestinal Current/Voltage Measurements (ICM/IVM) 
Bioelectrical measurements on rectal epithelia can be applied as a functional diagnostic 
tool to aid in establishing a diagnosis of CF, if sweat test results are equivocal and/or if CFTR-
disease causing mutations are not readily identified by genetic testing. For Intestinal 
Current/Voltage Measurement (ICM/IVM), an intestinal biopsy (obtained by suction or forceps) 
and a special micro-Ussing chamber are needed. Through this method the ex vivo 
transepithelial short-circuit current (Isc) or transepithelial voltage (Vte) is measured and reflects 
the net ion fluxes across the tissue, which is calculated as equivalent current (Ieq-sc) by Ohm’s 
law in the case of voltage measurements. In CF, the intestinal CFTR-mediated Cl- secretion 
is impaired, while absorptive processes remain unchanged or may be enhanced. The values 
of Isc (or Ieq-sc) in response to forskolin (Fsk), an activator of CFTR, can lead to normal, absent 
or reduced currents. Under normal conditions, the Isc responds to Fsk alone and to Fsk with 
carbachol (CCH), which enhance the driving force for Cl- to exit the cell by stimulating basal 
K+ channels. This response consists of two components: a first lumen-negative current that is 
caused by the apical chloride efflux, followed by a larger lumen-negative current, caused by 
apical chloride secretion under the higher driving force (Sousa et al., 2012). In ICM/IVM of CF 
individuals, the apical Cl- efflux in response to Fsk and CCH does not occur, instead only a 
lumen-positive peak in response to CCH is observed corresponding to K+ efflux. A biphasic 
response may also be observed under CCH+Fsk (first lumen-positive corresponding to K+ 
channels efflux and then lumen-negative corresponding to Cl- efflux) due to residual CFTR-
mediated Cl- efflux in milder forms of CF (Sousa et al., 2012). 
Neonatal Screening 
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Crossley and colleagues (Crossley et al., 1979) from Auckland, New Zealand, established 
the foundation for CF NBS in the 1970s by measuring immunoreactive trypsinogen (IRT) on a 
dried blood spot specimen, using a radioimmunoassay. In CF, the trypsinogen release into 
the circulation appears to be enhanced by abnormal pancreatic duct secretions. Thus, IRT 
levels are found to be elevated in CF and determination of IRT levels in newborns constitutes 
the assay used in most CF neonatal screening programmes (Rosenfeld et al., 2016). IRT 
values tend to remain raised for several months in newborns with CF, whereas in false 
positives they usually return to normal within the first weeks of life. Screening for CF can have 
different algorithms and use an increased IRT level from the dried blood spot specimen as the 
first stage. Most frequently, the second stage incorporates molecular testing for CFTR 
mutations on the first specimen (IRT/DNA). In some programmes, IRT concentrations are 
analysed on a second specimen collected between 1 and 2 weeks of life (IRT/IRT), whereas 
other programmes combine the two strategies, following 2 increased IRT results with CFTR 
mutation analysis performed on the second specimen (IRT/IRT/DNA) (Farrell et al., 2017b). 
An important outcome of recent studies is the discovery that Pancreatitis Associate Protein 
(PAP) may provide advantages for programmes that routinely collect samples after 36h of age 
and can be incorporated into these programmes in different ways (Farrell et al., 2017c). The 
careful selection of the mutations on the CFTR screening panel is critical in order to ensure 
adequate coverage for the racial and ethnic composition of the population being screened. 
The most important is that each programme adopts an algorithm that is adapted to the 
characteristics of the population being tested and also matches the health system conditions 
of each country. This approach has demonstrated long-term benefits such as early nutritional 
treatment, reduced hospitalizations (due to pulmonary exacerbations) and improved survival. 
In the 1950s, median life expectancy for patients with CF was a few months; the main 
causes of death were meconium ileus and malnutrition subsequent to pancreatic 
malabsorption. During the past six decades, median age of survival has increased 
progressively, and is now more than 40 years in developed countries (Farrell et al., 2017b). 
Replacement of pancreatic enzymes and intensive therapy guided by multidisciplinary teams 
have brought a major improvement in the treatment of CF and survival. Besides, the new 
guidelines for diagnosis of CF are very important to identify the patients as CF and begin 
health care at the earliest possible stage (Table 1.1). 
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Table 1.1 – Guidelines for CF diagnosis. Summary from the 2015 CF Foundation guidelines for 
diagnosis of CF. Adapted from (Farrell et al., 2017c) 
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2. CFTR: from Gene to Protein and Function: CFTR Mutations & 
Functional Classes 
2.1 – CFTR: From Gene to Protein and Function 
The CFTR gene is located on the long (q) arm of chromosome 7, bands 31-32 (7q31-7q32), 
and is one of the largest human genes, spanning ~190 kb. After transcription and splicing, the 
mRNA comprising 6.5 Kb is translated into the CFTR protein (or ABCC7) with 1480 amino 
acid (aa) residues (Riordan et al., 1989). The gene consists of 27 exons and 26 introns 
(Figure.1.3). The sizes of both exons and introns vary greatly, with the exons ranging from 38 
bp in exon 16 to 724 bp in exon 14. Regarding intron length, the smallest intron (intron 25) 
comprises 600 bp, and the largest (intron 11) 28,085 bp (Ellsworth et al., 2000).  
 
Figure.1.3 - Schematic representation of the CFTR gene, mRNA and protein. N– N-terminus; 
TM– transmembrane domain; NBD – nucleotide-binding domain; R – regulatory domain; C – C 
terminus CFTR gene consist of 27 exons and introns. After transcription and mRNA splicing, a 1480 
amino acid sequence is translated. Post-transcriptional modification of the protein glycosylation, 
occurs before translation to the cell membrane. The CFTR protein act at the apical membrane of 
epithelial cells (more details in section 2.2.1). [Image from MD Amaral, with permission]. 
As mentioned above, CFTR is a multidomain protein containing 1480 aa residues, that 
functions as a cAMP-activated and phosphorylation-regulated Cl- and bicarbonate channel at 
the apical membrane of epithelial cells. CFTR is a member of the ATP-binding cassette (ABC) 
transporter superfamily, also known as ABCC7 (Gadsby et al., 2006). Like other ABC 
transporters, it has two membrane spanning domains (MSDs) with six transmembrane 
segments each, portions of which form the pore through which anions pass. Additionally, it 
has two nucleotide binding domains (NBD1 and NBD2) and a regulatory domain (RD). Both 
NBDs bind and hydrolyse ATP, which drives channel opening and closure, respectively. The 
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RD, which is absent in all other ABC transporters, contains multiple consensus sites for 
phosphorylation by various kinases. Phosphorylation of the RD by protein kinase A (PKA) in 
response to cyclic AMP is regarded as the major determinant for opening of the channel 
(Riordan et al., 1989; Riordan, 2005).  
Proteins belonging to the ABC transporter family are responsible for active transport of 
substrates across cell membranes, where ATP hydrolysis serves as the source of energy to 
drive the transport. However, CFTR is functionally distinct from other ABC transporters as it 
enables bidirectional permeation of anions, rather than vectorial transport of solutes (Riordan, 
2005). Several hypotheses were raised regarding the function of CFTR protein. The model 
currently accepted for the mechanism of channel function and regulation proposes that  
(Figure 1.4) the first step is the phosphorylation of the RD by cAMP-dependent PKA (and by 
PKC) then ATP binds to the NBDs, which subsequently dimerize opening the channel 
(Sheppard and Welsh, 1999; Hwang and Sheppard, 2009) with the consequent alteration in 
the MSDs conformation, leading to the opening of the channel pore. It has also been shown 
that intramolecular interaction between the RD and both the N-terminus and NBD1 are 
required to regulate CFTR function (Baker et al., 2007). Even though the mechanism of CFTR 
channel gating is not fully understood, opening and closing of this Cl- channel is tightly 
regulated by the cellular balance of kinase and phosphatase activity and by ATP levels. 
Furthermore, the open probability (Po) of the channel is controlled by the extent of RD 
phosphorylation at its multiple sites (Hwang and Sheppard, 2009). 
 
Figure 1.4 - Conformational changes of the CFTR Cl− channel during channel gating. The 
simplified model shows a CFTR channel under quiescent (left) and activated (right) conditions. 
Communication between the NBDs and MSDs via the intracellular loops is either orthogonal (e.g. 
NBD1–MSD2) according to the most recent CFTR structural models based on Sav168834. P 
(phosphorylation of the RD); Pi (inorganic phosphate); PKA (cAMP-dependent protein kinase); 
PPase (protein phosphatase). In and Out denote the intra- and extracellular sides of the membrane, 
respectively. [Image reproduced from Hwang and Sheppard, 2009]. 
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Besides its function as Cl- channel, CFTR has also been shown to regulate several other 
channels and transporters, thus being a general regulator of ion transport in epithelia. CFTR 
was found to be expressed in luminal membranes of both secretory and absorptive epithelia, 
playing a predominant role in both cAMP- and, as more recently shown (Faria et al., 2009; 
Lérias et al., 2018) in Ca2+-activated Cl- secretion. 
2.2 – CFTR mutations & Functional Classification 
As to date, 2026 mutations have been reported in the CFTR gene (Cystic Fibrosis Mutation 
Database, 2017), a number that comprises both disease causing mutations and 
polymorphisms that do not affect the CF phenotype. From these mutations, 39% are missense 
mutations, 16% frameshift mutations, 11% splicing mutations, 8% nonsense mutations, 2% In 
frame in/dels, 3% large in/dels, 0.8% mutations in the promoter, 13% sequence variation and 
7% are of unknown consequences (Cystic Fibrosis Mutation Database, 2017). Currently these 
mutations are grouped into 7 functional classes defined according to the molecular changes 
caused by the different CFTR variants, with these evolving into theratypes, i.e., groups of 
mutations which can be corrected by the same therapeutic strategy (Figure 1.5).  
 
Figure 1.5 – Functional classes of CFTR mutations/ theratypes. Wild-type CFTR protein at the 
plasma membrane of epithelial cells properly functioning as a Cl- channel; (I) class I mutations: 
prevent translation; (II) class II: defective processing; (III) class III: defective regulation; (IV) class IV: 
defective conductance; (V) class V: reduced synthesis; (VI) class VI: decreased stability; (VII) class 
VII: no mRNA. Adapted from (De Boeck and Amaral, 2016) 
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Class I – Mutations that lead to no protein production  
Class I mutations are those that can give origin to premature terminations codons (PTCs), 
such as nonsense mutations or some frameshift mutations, which are thus associated with 
more severe CF phenotypes (Elborn, 2016). Examples of class I mutations include 
modification of the codons that codify for the glycine in the position 542, the arginine in position 
553, or the glutamine in position 637, into a stop codon (G542x, R553X and Q637X, 
respectively). G542X and R553X are two of the most common mutations in Europe following 
the F508del mutation (WHO, 2004). These mutations lead to significant degradation of the 
respective transcripts by nonsense mediated decay (NMD) so as to prevent production of 
truncated proteins that might be translated from these transcripts (De Boeck and Amaral, 
2016). These mutations will be discussed in greater detail in section 3. 
Class II – Mutants that affect intracellular traffic 
Class II mutations are those that lead to incorrect folding and processing and thus prevent 
the protein from reaching the apical membrane of epithelial cells. F508del, the most common 
CF causing mutation, is a member of this class. By not being correctly folded, F508del CFTR 
protein is retained in the endoplasmic reticulum (ER) and targeted for degradation, thus not 
being fully-glycosylated in the Golgi nor transported to the apical membrane. 
Class III - Mutations affecting channel gating 
These mutations cause a defective response of CFTR to the phosphorylation of the RD by 
PKA after activation by cAMP. They are often located in the NBDs, affecting their interaction 
with ATP, and thus interfering with the correct gating of the channel. An example of a class III 
mutation is G551D (glycine to aspartate) which is quite frequent in Ireland (14%) and is thus 
also called the "Celtic mutation". 
Class IV - Mutations that lead to defective chloride transport  
Class IV mutations, such as R334W (mutation of an arginine to a histidine), lead to the 
synthesis of proteins which can be transported to the membrane and respond to stimulus, but 
have a reduced ion transport function due to defective conductance. Patients with these 
mutations have a milder CF phenotype.  
Class V – Mutations that lead to reduced levels of protein 
This class includes mutations that lead to reduced levels of protein, such as those affecting 
splicing of pre-mRNA such as 3272-26A>G or the TG12T5 sequence in intron 8 or missense 
mutations such as A455E (alanine to glutamate), which lead to reduced levels of transcripts 
15 
 
and thus low levels of functional protein. These mutations are also associated with milder CF 
phenotypes. 
Class VI – Reduced stability or altered regulation of separate ion channels 
In this group are included membrane-rescued mutations such as F508del, 120del23 (the 
deletion of the first codon), N287Y (asparagine to tyrosine). This class also includes variants 
with nonsense or frameshift mutations that originate PTCs in the last exon of the CFTR gene 
and lead to the production of carboxyl terminus (C-terminus)-truncated proteins. These 
proteins while being correctly processed, transported to the membrane and presenting normal 
function, are unstable and have an increased turnover at the cell surface. This is another class 
of mutations that leads to a milder CF phenotype. 
Class VII – No mRNA, unrescuable mutations 
Class VII mutations are the so-called "unrescuable mutations", because CFTR cannot be 
pharmacologically rescued per se, and include for example large deletions such as the 
del2,3(21kb) mutation. 
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3 Nonsense-mediated mRNA decay and CFTR nonsense mutations 
The expression of protein-coding genes in eukaryotes involves the orchestration of 
transcriptional and posttranscriptional processes. To ensure the fidelity of these processes, 
the eukaryotic cell has evolved several quality control mechanisms. The best characterized 
mRNA quality control system in eukaryotes is the nonsense mediated decay (NMD) of mRNA. 
This surveillance mechanism detects and ensures the rapid degradation of faulty mRNAs 
harbouring premature translation termination codons (PTCs) that would otherwise have 
resulted in the synthesis of C-terminally truncated proteins. Hence, the quality control function 
of NMD relies on protecting the cell from the deleterious dominant-negative or gain-of-function 
effects of these truncated proteins (Kurosaki and Maquat, 2016; Nickless et al., 2017).  
Nonsense-mediated mRNA decay 
First discovered in yeast and then extensively studied in Caenorhabditis elegans, 
Drosophila, mouse, human cells, and other model systems, NMD is a RNA surveillance 
pathway that acts at the interface between transcription and translation (Nickless et al., 2017). 
Three key steps constitute the NMD pathway: 1) the identification of the PTC; 2) the assembly 
of the surveillance complex on the mRNA and 3) the degradation of the targeted RNA. The 
mechanism by which PTCs are recognized and discriminated from natural stop codons is 
translation-dependent and leads to the recruitment of NMD trans-acting factors, called 
upframeshift (UPF) proteins, such as UPF1, UPF2 and UPF3 (Lykke-Andersen and Heick 
Jensen, 2015).  
During translation, stop codons are recognized by eukaryotic release factors (eRFs) eRF1 
and eRF3, which are present in the translation apparatus, and in turn recruit UPF1, followed 
by the recruitment of the serine/threonine protein kinase SMG1. These proteins, together with 
the eRFs form the surveillance complex (SURF), and eventually lead to translation termination 
involving ribosomal dissociation (Figure 1.6). However, recognition of PTCs leads to the 
interaction of the SURF complex with UPF2 and 3 present at a downstream exon junction 
complex (EJC) leading to UPF1 phosphorylation that triggers transcript degradation (Hug et 
al., 2015; Nickless et al., 2017). 
Within the nucleus, pre-mRNAs are synthesized and immediately undergo cis modifications 
binding various proteins during pre-mRNA processing, prior to mRNA formation. These 
include capping at the 5′ end, i.e., addition of a 7-methylguanosine residue (Cap) to protect 
the transcript from 5′-to-3′ exoribonucleases and provide a binding platform for the Cap-
binding protein (CBP) complex (CBC), composed of CBP80–CBP20 (Da Costa et al., 2017). 
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In mammalian cells, and according to the classical EJC-dependent model, NMD depends 
on the interaction of the translation termination complex with a dynamic multiprotein assembly, 
the so-called EJC (Lykke-Andersen and Heick Jensen, 2015). NMD is tightly intertwined with 
mRNA biogenesis even at its earliest stages, since it is promoted by both the CBC and EJC. 
The latter consists of four core proteins- eukaryotic translation initiation factor 4A3 (eIF4A3), 
cancer susceptibility candidate 3 (CASC3), RNA-binding motif protein 8A (RBM8A or Y14), 
and mago-nashi homolog (MAGOH)- which are deposited ~20-24 nucleotides (nt) upstream 
of ~80% of all exon-exon junctions (Hir et al., 2016; Kurosaki and Maquat, 2016). This splicing-
dependent "mark" serves to guide the NMD machinery once the mRNA is exported to the 
cytoplasm for translation-dependent inspection by NMD factors. 
EJCs upstream of and within mRNA coding regions are removed by ribosomes during 
translation in the cytoplasm, however, because PTCs shorten the length of the coding region, 
any downstream EJCs that normally reside within the coding region would fail to be removed 
from what becomes the 3′UTR thus triggering NMD (Kurosaki and Maquat, 2016). 
Initially, UPF1 associates with SMG1 and acts as a "clamp", interacting directly with eRF1 
and eRF3 to form the SURF complex in the vicinity of the PTC (Hug et al., 2015; Da Costa et 
al., 2017) (Figure 1.6). UPF1 is the central NMD factor, it is an ATP-dependent RNA helicase 
containing an abundance of serine and threonine residues located within its N- and C- termini 
that function as phosphate-acceptor sites (Popp and Maquat, 2017). SMG1 is a 
phosphatidylinositol 3-kinase-related protein kinase that phosphorylates many of these 
residues, and this activity is initially held in check by the SMG8-SMG9 complex (Yamashita, 
2013). Two subunits of the SMG1c complex, the SMG8 and SMG9 associate tightly with 
SMG1 and regulate its activity through the induction of conformational changes, with SMG8 
binding to the preformed SMG9-SMG1 complex and maintaining the kinase in its inactive state 
(Yamashita et al., 2009; Arias-Palomo et al., 2011). Subsequently, the SURF complex 
interacts with UPF2, UPF3b and an EJC downstream of the PTC to form the decay-inducing 
complex (DECID), that triggers UPF1 phosphorylation and dissociation of eRF1 and eRF3 
(Figure 1.6) (Da Costa et al., 2017). UPF1 phosphorylation has two consequences: first, 
phosphorylated UPF1 represses further translation initiation through an interaction with eIF3 
that is critical for mRNA decay; second, phosphorylated UPF1 residues form platforms 
exposing new regions of UPF1 onto which RNA-degradative enzymes are either directly or 
indirectly recruited, resulting in targeted, rather than indiscriminate, mRNA destruction (Lykke-
Andersen and Heick Jensen, 2015). As a consequence of the remodelling of NMD complexes, 
UPF1 adopts its active helicase conformation, due to the reorganization of its inhibitory 
domains through association with UPF2. The activated NMD complex (UPF1, UPF2 and 
UPF3b) is translocated from its position upstream of the EJC towards the 3’ of the EJC (Hug 
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et al., 2015). Subsequently, phosphorylated UPF1 associates with the phospho-binding 
proteins SMG5, SMG6 and SMG7, and general mRNA degradation factors. Further 
rearrangements of this complex lead to mRNA degradation. SMG5, SMG6 and SMG7 share 
a common 14-3-3-like domain, which is usually associated with protein-protein interactions. 
This domain in SMG7 is thought to promote the dephosphorylation of UPF1 by binding 
phospho-UPF1 (Fukuhara et al., 2005). SMG6 itself is an endonuclease, which can form both 
phospho-dependent and phospho-independent interactions with UPF1. SMG6 cleaves NMD 
targets in the vicinity of the PTC, leading to the initiation of NMD-mediated RNA degradation. 
This canonical mammalian NMD pathway is not universal, since alternative NMD branches 
that are independent of UPF2, UPF3b or the EJC have been described (Lykke-Andersen and 
Heick Jensen, 2015; Raxwal and Riha, 2016; Popp and Maquat, 2017). 
The EJC is involved in translation, mRNA transport, turnover, and the identification of UPF2 
and UPF3 as EJC components suggests an additional role of this complex in NMD. The 
heterodimer Y14/MAGOH stabilizes the high affinity of eIF4A3 for RNA by preventing the ATP 
hydrolysis of eIF4A3 and further primes it to bind to CASC3 (Barentsz homologue). This 
arrangement allows eIF4A3 to clamp several proteins onto RNA in a stable and sequence 
independent manner, which in turn is used by the NMD machinery to recognize an aberrant 
PTC (Hug et al., 2015). Thereby, a short motif of the core NMD factor UPF3b binds to the EJC 
core factors and serves as a platform to assemble an active NMD complex. Two other DEAD 
box proteins, DDX5 and DDX17, have also recently been shown to interact with UPF3b and 
this interaction appears to be crucial for the degradation of a limited subset of NMD substrates. 
It was recently demonstrated that the RNA helicase DHX34, a member of the DExH/D box 
family of proteins, associates with the SURF complex and promotes the transition to the 
DECID complex (Hug et al., 2015; Kurosaki and Maquat, 2016; Raxwal and Riha, 2016). 
Thereby, DHX34 probably affects the remodelling of the SURF complex by promoting the 
dissociation of the eukaryotic release factor eRF1 and eRF3 in an ATP dependent manner 
from the SURF complex (López-Perrote et al., 2015). 
Pioneer round of translation 
The 5’end of mRNAs acquires a modified guanine residue during transcription that binds 
to the nuclear cap-binding protein (CBP) complex CBP80-CBP20 (CBC), which supports the 
pioneer round of translation (Ishigaki et al., 2001). The Cap is then replaced by eIF4E that 
directs subsequent rounds of translation. Spliced CBC-bound mRNAs, unlike eIF4E bound 
mRNAs, are typically associated with one or more EJCs. This feature suggests a role for CBC 
in NMD. Indeed, it has been proposed that NMD occurs exclusively during the pioneer round 
of translation and that transcripts bound to eIF4E are NMD-insensitive (Ishigaki et al., 2001; 
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Trcek et al., 2013). Additionally, CBC-bound complexes contain the nuclear poly(A) binding 
protein 1 (PABPN1) (Chiu et al., 2004; Kashima et al., 2006). The distinguishing features 
between the pioneer round of translation complexes and the steady-state translation initiation 
complexes contribute to the specialized functions of each complex. Although translation 
contributes to remodelling of the pioneer translation complexes by augmenting the 
displacement of EJC components, the replacement of CBC by eIF4E is promoted by the 
binding of the nuclear transport receptor importin β (Kurosaki and Maquat, 2016). In support 
of a role for CBC in NMD, a recently study has shown that interaction of CBP80 with UPF1 
promotes NMD in two sequential steps (Hwang et al, 2011). First CBP80 chaperones SMG1-
UPF1 interacts with eRF1-eRF3 at the PTC, promoting SURF complex assembly; and 
subsequently CBP80 physically joins the distal-EJC while still chaperoning SMG1-UPF1, 
which results in SMG1-mediated UPF1 phosphorylation (Hwang et al., 2011). Phosphorylated-
UPF1 binds eIF3 of the 43S preinitiation complex positioned at the translation initiation codon 
and inhibits 60S subunit joining, thereby eliciting translation repression (Isken et al., 2008). 
The decision of whether an mRNA will be targeted or not for degradation by the NMD 
pathway is made when the ribosome is poised at the termination codon. During normal 
translation termination, when the Stop codon enters the A-site, it is recognized by the 
termination factor eRF1, which forms a complex with eRF3 that involves the C-terminal 
domains of both proteins. In turn, eRF3, through its N-terminal domain, also interacts with the 
C-terminal domain of PABPC1 (Peixeiro et al., 2012) and this interaction results in stimulation 
of efficient translation termination (Brogna and Wen, 2009). 
CFTR nonsense mutations 
PTCs, account for ~8% of all CFTR variations (Cystic Fibrosis Mutation Database, 2017). 
These are classified as class I mutations and include both nonsense and frameshift, or even 
splicing mutations that result in a frameshift of the CFTR open reading frame (ORF) and 
ultimately introduce a premature stop codon. Thus, leading to total, or almost total, 
degradation of the respective transcripts by NMD, and therefore preventing any production of 
full length CFTR protein. These mutations are associated with "classical" severe CF 
phenotypes.  
CFTR transcripts bearing mutations such as G542X and W1282X are prone to degradation 
by the NMD pathway. However, transcripts bearing the nonsense mutation Q39X, do not 
undergo NMD. Previous in vitro studies have shown that β-globin nonsense mutations in close 
proximity to the initiation codon also protect messengers from undergoing NMD (Inácio et al., 
2004). It has been proposed that this might have two causes. Firstly, the interaction of the 
PABPC1 with the translation termination complex at the nonsense mutation site thus inhibiting 
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the activation of NMD pathway intermediaries and their interaction with the EJC complex 
present downstream of the PTC (Nagy and Maquat, 1998). Secondly, alternatively mRNA 
protection from NMD could result from re-initiation of translation at a Kozak consensus 
downstream of the mutation which would stabilize these PTC-containing transcripts (Neu-Yilik 
et al., 2011). The presence of alternative initiation codons downstream of this mutation was 
indeed shown for CFTR (Ramalho et al., 2009) with this being the most plausible reason why 
E39X mRNA is not an NMD substrate. Inhibiting NMD should increase the abundance of PTC-
containing mRNAs, which could then potentially be targeted by read-through drugs to 
upregulate the production of full-length proteins during translation. 
 
Figure 1.6 - The nonsense-mediated mRNA decay pathway. During splicing, exon junction 
complexes (EJCs) assemble 20-24 nucleotides (nt) upstream of exon-exon junctions. The translating 
ribosome displaces the EJCs during the pioneer round of translation. If a PTC is located more than 
50-54 nt upstream from the last EJC, the termination complex is able to interact with EJC-associated 
NMD factors. The CBP80 protein at the mRNA 5’end can bridge UPF1-SMG-1 to eRF1-eRF3 at the 
PTC, leading to the formation of the SURF complex. The interaction of UPF1 with EJC-bound UPF2 
induces the SMG1-mediated phosphorylation of UPF1 and dissociation of eRF1-eRF3. 
Phosphorylated UPF1 recruits SMG-7 and SMG-5 proteins and EJC recruits SMG-6, triggering the 
decay of the PTC containing transcript [Adapted from da Costa et al., 2017].  
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3.1 – PTC-definition and read-through compounds 
The mechanism of discrimination between a premature and a natural termination codon 
has been one of the central questions regarding the NMD mechanism. As mentioned in the 
previous sections, not all PTC-containing transcripts undergo NMD. To trigger NMD, at least 
one EJC must be present downstream of the PTC, in fact mRNAs from intronless genes or 
with a PTC in the last exon or with a PTC that spans two exons are immune to NMD (Lykke-
Andersen and Heick Jensen, 2015). The involvement of splicing and the EJC in NMD led to a 
formulation of a model for PTC definition where the EJCs would function as a “mark” to 
discriminate PTCs from natural termination codons. It is assumed that during the first round of 
translation the elongating ribosomes have the ability to displace the EJC that were assembled 
during splicing. The PTC must also be located >50-55 nts upstream of the 3’-most EJC in 
order to reduce the mRNA abundance (Nagy and Maquat, 1998). The presence of an EJC 
downstream of the terminating ribosome would allow the interplay between UPF2 and/or 
UPF3b at the EJC with the SURF complex at the ribosome, culminating in NMD triggering. 
In most organisms, three codons do not code for amino acids but are signals to indicate 
the end of an amino acid chain. These nonsense codons are UAG (amber), UAA (ochre) and 
UGA (opal). Under normal conditions, translation termination is a very efficient process with 
an estimated error rate of approximately 0.1% (Keeling et al., 2014a). However, eRF1 and 
near-cognate aminoacyl-tRNAs (aminoacyl-tRNAs with an anticodon complementary to two 
of the three nucleotides of the stop codon) normally compete for the ribosome A site binding. 
Under certain conditions, the rate at which near-cognate aminoacyl-tRNAs successfully 
compete with eRF1 at a stop codon can be increased, resulting in incorporation of an amino 
acid carried by a near-cognate aminoacyl-tRNA into the nascent polypeptide (Roy et al., 
2015). This process is termed “termination suppression” or “read-through”. In the case of a 
premature stop mutation, read-through normally results in the continued elongation of the 
polypeptide chain in the correct reading frame and the production of “full-length” protein 
(Kulyté et al., 2005; Keeling et al., 2014b). 
Therapeutic approaches aimed at promoting translational read-through of the PTCs, and 
thus enabling the synthesis and expression of “full-length” functional proteins, have been 
developed with relatively positive results. Several pharmacologic approaches to induce read-
through have been discovered, yet none has yielded an optimal combination of efficacy and 
safety (Mutyam et al., 2016). For instance, in vitro work has demonstrated that certain 
aminoglycosides (such as G418, gentamicin or tobramycin) can promote read-through 
(Keeling et al., 2014b; Solomon et al., 2016) but clinical trials studies have shown contradictory 
results (Clancy et al., 2001, 2007). In addition, these drugs have been shown to be unsuitable 
for long-term use. Synthetic aminoglycoside derivatives optimized for translation suppression 
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of the eukaryotic ribosome have exhibited improved read-through and reduced toxicity when 
compared in vitro (Mutyam et al., 2016).  
 A high-throughput screening (HTS) aimed at the identification of non-aminoglycosides 
capable of promoting read-through, revealed a small molecule, Ataluren (also known as 
PTC124), capable of inducing PTC read-through without severe side effects (Welch et al., 
2007). Unfortunately, clinical trials for this molecule in CF patients, did not shown the expected 
effects and the trial was terminated. 
4 CFTR Modulator Treatments  
CF is a very severe disease with a current median age of life expectancy in the fourth 
decade of life. The mainstay of treatment in CF is symptomatic and focuses on compensating 
for exocrine pancreatic insufficiency with pancreatic enzymes, fat- soluble vitamins and high 
caloric intake; and slowing lung disease progression with inhaled and physical therapies that 
improve airway clearance, and antibiotic therapy (Amaral, 2014; Michl et al., 2016). 
An enormous research effort and progress has been made in understanding the 
consequences of these mutations on the CFTR protein structure and function. Several studies, 
have led to the approval of two new drug therapies, ivacaftor (vx770) and Orkambi 
(ivacaftor/lumacaftor; vx770/vx809), that are able to bind to defective CFTR proteins and 
partially restore their function. At present time these drugs are mutation-specific therapies. 
They are the first personalized medicine for CF with a possible disease-modifying effect. Other 
strategic approaches include the PTC read-through drugs, antisense oligonucleotides that 
correct the basic defect at the mRNA level or gene editing to restore the defective gene as 
well as gene therapy. All these strategies are needed to develop disease-modifying therapies 
for all patients with CF (Harman et al., 2018).  
The goals of innovative approaches to therapy include the development of drugs that 
correct the basic defect in CF, that in turn can delay the progression, or even prevent 
respiratory disease, if administrated in the onset of the patient’s life (Figure 1.7). 
Mutation-Specific Approaches 
The advent of CFTR modulator therapy in the last decade has revolutionized the approach 
to CF treatment by targeting the underlying CFTR defect. The fast progression from preclinical 
trials to clinical use of these novel agents, and the expanding research effort in identifying 
more potent drugs targeting a broader range of mutation classes brings, at the same time, 
excitement and challenge to field. 
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Correction of class I mutations 
High-throughput drug screens have been carried out to identify compounds that inhibit 
NMD (Durand et al., 2007; Dang et al., 2009; Iwatani-Yoshihara et al., 2017). Aminoglycoside 
antibiotics have some ability to suppress PTCs by promoting the ribosomal read-through 
activity and restoring "full-length" CFTR production (Wilschanski et al., 2003; Altamura et al., 
2013). They interact with the ribosome and instead of the PTC being read, they facilitate the 
random addition of an amino acid to the polypeptide chain allowing the translation to continue 
on to the normal Stop codon. However, aminoglycosides have severe side effects, such as 
nephrotoxicity and ototoxicity, when used at high concentrations and/or when used long-term 
(Durante-Mangoni et al., 2009; Fajac and Wainwright, 2017). Ataluren was also developed as 
a read-through agent by PTC Therapeutics, with no structural similarities to aminoglycosides. 
Studies with oral administration of Ataluren in patients with CF, bearing at least one CFTR 
nonsense mutation, have shown improved nasal epithelial Cl- transport. However, the results 
from a Phase III clinical trial for CF showed no significant benefit and thus the drug was 
discontinued (PTC Therapeutics, 2017). Other strategies have been attempted, such as 
suppressor tRNAs i.e., modified tRNAs whose anticodons were altered to recognize a stop 
codon, thus allowing the incorporation of an amino acid at the stop codon and a bypass of 
translation termination (Keeling et al., 2014b).  
Correction of class II mutations 
Mutations in this class have a folding defect that results in the rapid targeting of the resulting 
protein for degradation in the proteasome by the ER quality control (ERQC), thus preventing 
it from reaching the plasma membrane (PM). The most common CFTR mutation, F508del, 
belongs to this class. Pharmacological rescue of F508del-CFTR requires two types of 
compounds: correctors that promote folding and restore mislocalized protein to the PM, and 
also potentiators to increase CFTR Cl- channel function as this mutant also displays a gating 
defect similarly to those in class III (see below). Combination therapy with lumacaftor 
(corrector) and ivacaftor (potentiator) was assessed in phase 3 trials involving patients 
homozygous for F508del aged 12 years and older. Significant, although modest, improvement 
in lung function and nutrition, and reduction in the rate of pulmonary exacerbations were 
observed (Hubert et al., 2017). The combined therapy using lumacaftor and ivacaftor 
(Orkambi) was approved by the Food and Drug Administration (FDA) in 2015 for patients aged 
12 years and older who are homozygous for Phe508del-CFTR and for patients with 6 years 
in 2016 (Fajac and Wainwright, 2017). Recently, the combination of another corrector, (VX-
661, tezacaftor) and potentiator ivacaftor (Symdeko), has been also approved for F508del-
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homozygous patients. There are also several ‘next generation’ molecules which are in Phase 
III trials as a triple combination.  
Correction of class III mutations  
CFTR mutants in this class have reduced response to channel agonists. The most common 
mutation in this class is G551D. Also included in this group is the F508del mutation (see 
above). CFTR potentiators such as genistein and other flavonoids can activate Cl- 
conductance and overcome mutations in this class. The potentiator VX-770 has been shown 
to increase CFTR activity in CF patients carrying the G551D mutation. This was the first CFTR-
modulator drug approved that corrected the basic defect of a CFTR-mutant (Amaral, 2014; 
Michl et al., 2016). Moreover, VX-770 was also shown to correct other gating defect CFTR 
mutants located at the cell surface and consequently it was approved for clinical use in CF 
patients carrying those mutations.  
Correction of class IV mutations  
Class IV mutants are associated with reduced Cl- conductance. Stimulation of CFTR 
conductance can be achieved either by increasing the overall cell surface density of these 
mutants, thus compensating for the reduced conductance, and by augmenting the existing 
activity of channels with potentiators, namely the CFTR-potentiator VX-770 (lumafactor) which 
was approved for the treatment of some class IV mutants (Amaral, 2014). 
Correction of class V mutations  
This class includes mutations that reduce the amount of functional CFTR, such as 
alternative splicing mutations that generate both aberrant and correctly spliced mRNAs. The 
major therapeutic goal in these cases is to increase the levels of correctly spliced transcripts. 
However, modulation of the splicing process is a very complex approach, and most likely 
would have to be tissue specific. Nevertheless, combined therapy using both CFTR correctors 
(e.g., VX-809), and potentiators (e.g., VX770) can also bring clinical benefit by increasing both 
trafficking of CFTR to the PM and channel activity. Ivacaftor has been approved for five 
splicing mutations, for people age 2 or older with one of these splicing mutations. Another 
strategy would be to use the RNA-based antisense oligonucleotide (AON), which was shown 
to be promising in vitro in correcting alternative splicing (Igreja et al., 2016).  
Correction of class VI mutations 
Class VI mutants are less stable being associated with fast internalization and degradation 
of the protein. Therapies aimed at stabilizing the CFTR protein at the PM would be successful 
in correcting these mutants. These could include agents such as hepatocyte growth factor 
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(HGF) previously shown to increase PM stability of F508del-CFTR on its own or rescued by 
VX809 (Moniz et al., 2013). 
Correction of class VII mutations 
Patients with so-called unrescuable mutations are those in which there is no RNA 
production, the most straightforward approach would be to target alternative non-CFTR anion 
channels (Figure 1.7). Besides CFTR, other Cl- channels exist in epithelia, namely in the 
airways, being thus possible to envisage the development of strategies to modulate these 
other channels so as to compensate for the absence of functional CFTR. Since CFTR is a 
negative regulator of the epithelial Na+ channel (ENaC), its absence from the apical membrane 
leads to enhanced ENaC activity in the surface airway of epithelial cells and thus excessive 
Na+ absorption. Therefore, one pursued strategy for CF pharmacotherapy targets ENaC,  
specifically ENaC blocking by specific inhibitors such as amiloride, benzamil or phenamil and 
probably by PKC activation (Amaral and Kunzelmann, 2007). Stimulation of alternative Cl- 
channels, such as the calcium (Ca2+)-activated Cl- channels (CaCCs), could be an alternative 
approach. Stimulation of the CF airway epithelial cells by luminal P2Y2 purinergic receptors 
with ATP or UTP was shown to restore Cl- secretion (Knowles et al., 1991). Anoctamin 1 
(ANO1; also known as TMEM16A) is a CaCC present in many epithelial cells, namely in the 
airways and ANO6 (also known as TMEM16F) is an essential component of the outwardly 
rectifying Cl- channel. Both constitute good alternative channel candidates to compensate for 
the absence of functional CFTR. 
The Cl-–/HCO3- transporter SLC26A9 is associated with susceptibility to meconium ileus 
and diabetes (De Boeck and Amaral, 2016) and has been shown to function as an anion 
conductance channel itself in the apical membranes of HBE cells, as it contributes to 
transepithelial Cl- currents under basal and cAMP/protein kinase A–stimulated conditions, 
although its activity in HBE cells is stimulated by functional CFTR (Bertrand et al., 2009). 
SLC26A9-mediated Cl– secretion is essential for preventing airway obstruction in allergic 
airway disease (Anagnostopoulou et al., 2012). 
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Figure 1.7 - Gene therapy, gene editing and mRNA repair are strategies using 
oligonucleotides to target the DNA or the RNA in order to restore CFTR function. Read-through 
agents for class 1 mutations and CFTR modulators are small pharmacological molecules aiming at 
restoring CFTR function. ENaC inhibitors and activators of non-CFTR chloride channels could 
bypass the dysfunctional CFTR and restore normal sodium absorption and chloride secretion. 
Several of these approaches could be combined [Adapted from Fajac and Wainwright, 2017]. 
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5 Objectives of the present work 
 
The current work was aimed at understanding the mechanisms underlying CF-causing 
mutations that affect mRNA structure and/or stability and at testing novel therapeutic 
strategies aimed at correcting such basic defects. It comprises the following specific 
objectives: 
1) To identify CFTR gene mutations in individuals with non-CF lung diseases, namely 
chronic obstructive pulmonary disease (COPD), asthma and disseminated 
bronchiectasis (DB); 
2) To identify CFTR gene mutations in individuals with a suspicion of CF and to analyse 
CFTR expression directly in native tissues (respiratory cells and colon) from some of 
these patients, in order to identify alterations in the structure and levels of mRNA; 
3) To identify key factors in the NMD pathway by automated microscopy screens using a 
cell model expressing a novel CFTR NMD-PTC/ read-through mini-gene reporter; 
4) To screen for novel compounds suppressing PTC mutations by automated microscopy 
screens using the above cell-based model, as potential corrective therapies for CF. 
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II MATERIALS & METHODS 
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1 Characterization of Subjects in Study 
 
1.1 Ethical  
 
These studies were part of a research project that was approved by the ethical committee of 
Santa Maria Hospital, Lisbon, and included the establishment a DNA/RNA bank. This bank, 
as well as the anonymised DNA bank, followed the international ethical guidelines, which 
included informed consent, confidentiality, anonymity of personal data, and an abandonment 
option in case of expressed will.  
1.2 Subjects  
 
Data presented in Chapter 1 (section III. Results & Discussion), refers to the analysis of 
187 blood samples from Portuguese individuals divided in two distinct groups. The first group 
comprehends samples from individuals with different respiratory diseases and distributes as 
follow: Asthma (n=54), COPD (n=51) and Bronchiectasis (n=31). The second group 
comprehends samples from healthy individuals, without any symptom of respiratory disease, 
used as control (n=51).  
As for the data included in Chapter 2 (section III. Results & Discussion) we selected eight 
individuals with suspicion of CF (followed up at the Lisboa University CF Centre) that 
presented one or no CFTR mutation determined by DNA analysis. We also analysed non-CF 
subjects and p.F508del-homozygous patients, used as controls. Following informed consent, 
RNA samples were collected from CFTR-expressing tissues, including: (i) nasal cells obtained 
by nasal brushing; or (ii) colon epithelium obtained from rectal biopsies. 
The mutation nomenclature used in this dissertation is in accordance with the HGVS 
guidelines using as reference the CFTR sequence Genbank NM_000492 (legacy name is 
often also given for better recognition of the mutation) and the CFTR exons are numbered 
from 1–27.  
1.3 Study Design 
 
In Chapter 1 (section III. Results & Discussion) we intend to carry out a screening of 12 
more frequent CFTR mutations in Portuguese patients with CF in individuals with chronic lung 
diseases, such as Diffuse Bronchiectasis, Bronchial Asthma and COPD. Detection of CF 
mutations will be performed by the ARMS, Tetra-ARMS and RFLP technique  in our laboratory 
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to allow rapid detection in DNA or RNA samples or by sequencing. For the cases in which 
CFTR mutations are detected, the possible analysis of RNA samples and functional analysis 
of ionic transport mediated by CFTR in rectal biopsies are also foreseen. 
This experimental work will be performed by Verónica Felício, in the laboratory of the 
Functional Genomics and Proteostase Unit, coordinated by Prof. Margarida Amaral and 
integrated in BioISI (BioSystems and Integrative Sciences Institute) located at the Faculty of 
Sciences of the University of Lisboa. 
The laboratory studies will be carried out in collaboration with the Clinical University of 
Pneumology of the Faculty of Medicine of Lisboa (Dr. Carlos Lopes and Dr. Pilar Azevedo), 
where patients will be recruited (51 patients with smoking COPD, 54 patients with non-
smoking bronchial asthma , 31 patients with diffuse bronchiectasis, and 51 healthy 
individuals). After approval of the study by the ethics committee of the Santa Maria Hospital, 
informed consent will be obtained for participation in the study and collection of the necessary 
materials. Patients will be clinically analyzed according to a specific protocol, which will include 
review of clinical records, clinical, analytical, imaging and respiratory function evaluation, in 
order to obtain a precise clinical characterization of the different pathologies studied here. At 
any time patients can leave the study without any consequence for the clinical follow-up of 
their disease. The rectal biopsies will be performed by Dr Ana Isabel Lopes (HSM). 
This project will provide important data on the influence of CFTR mutations on respiratory 
diseases in Portuguese patients leading to a better perception of the epidemiology of these 
diseases. The results may also lead to the identification of patient groups that may benefit 
from the new therapeutic compounds currently under development to correct the basic CFTR 
protein defect in CF. 
2 Analysis of Patients’ Materials  
 
2.1 Rectal biopsies and Nasal epithelial cells 
 
Nasal epithelial cells were collected by gently brushing the inferior turbinate of both nostrils 
using a 2.5 or 3 mm interdental brush (Harris et al., 2004). Colon tissue was obtained by small 
superficial rectal forceps biopsies described in Sousa et al.,2012.  
2.1.1 DNA and RNA Analysis  
 
2.1.1.1 DNA Extraction  
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Blood samples were collected in EDTA tubes and anonymously coded, before being stored 
at 4ºC. The rectal biopsies collected were immediately frozen in liquid nitrogen, and then 
transferred to –80◦C until DNA extraction.  
For DNA extraction the Wizard® Genomic DNA Purification Kit Technical (Promega, USA) 
was used as follow:  
Before DNA extraction the tubes containing the blood, samples were inverted 2-3 times. 
Cell Lysis Solution was added to the Blood samples in a ratio of 2:1, Cell Lysis Solution: 
Sample, in a sterile 15 ml centrifuge tube. Next, the two solutions were mixed by inverting the 
tube 5–6 times, followed by 10 min incubation at room temperature. After lysis of the red blood 
cells, samples were centrifuged at 2,000 × g for 10 min at room temperature. The supernatants 
were discarded without disturbing the visible white pellet. The white blood cells were lysed 
after incubation with Nuclei Lysis Solution. Protein Precipitation Solution was added to the 
nuclear lysate and samples were centrifuged at 2,000 × g for 10 min at room temperature. The 
supernatants were transfered to a 15 ml centrifuge tube containing 3 ml of isopropanol at room 
temperature. Afterwards, the solutions were mixed by inversion, until the white thread-like 
strands of DNA formed a visible mass. The DNA was pelleted by centrifugation at 2,000 × g 
for 1 min at room temperature. After discarding the supernatant, the DNA pellets were washed 
with 70% ethanol. After centrifugation at 2,000 × g for 1 min at room temperature, the 
supernatant was discarded, and the DNA pellets were air dried, 10 to 15 min. DNA 
Rehydration Solution was added according to the pellet size and incubated for 1 hour at 65°C.  
For the rectal biopsies, 600µl of Nuclei Lysis Solution was added to 10–20 mg of fresh or 
thawed tissue in a 1.5 ml tube, followed by 30 min incubation at 65°C. Before proceeding with 
the DNA extraction, 3µl of RNase Solution was added to the nuclear lysate, and samples were 
mixed by inverting the tube 2–5 times, followed by a 30 min incubation at 37°C. DNA extraction 
was performed as above, starting at the Protein Precipitation Solution step.  
2.1.1.2 RNA Extraction  
 
RNA from Rectal Biopsies and Nasal cells was extracted using the Nucleo Spin RNAII Kit 
(Macherey-Nagel, Duren, Germany).  
Before collecting the Nasal Epithelial Cells, a 1.5 ml microcentrifuge tube was prepared per 
sample containing 350 μl extraction Buffer RA1 supplemented with 1% (v/v) β-
mercaptoethanol. After collecting the nasal cells, the nasal brush was immersed in the 
supplemented RA1 buffer, with the brush being passed through a cut p200 tip.  
The frozen rectal biopsies samples were immersed in Buffer RA1 supplemented with 1% 
(v/v) β-mercaptoethanol and 30 mg of tissue were disrupted using a p1000 tip.  
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The cell lysates were cleared after filtering the samples in a NucleoSpin® Filter, and 
centrifuged for 1 min at 11,000 x g. To homogenize the flow-through 350 μl of 70% ethanol 
were added. The homogenized lysate was loaded in a NucleoSpin® RNA Column, followed 
by sample centrifugation at 11,000 x g for 30 sec. Subsequently, 350 μl Membrane Desalting 
Buffer (MDB) were added and samples were centrifuged at 11,000 x g for 1 min, to allow the 
membrane to dry. A DNase reaction mix was added directly to the membrane and incubated 
at room temperature for 15 min.  Three washes were performed, one with Buffer RAW2 and 
the other two with Buffer RA3, all of them followed by centrifugation at 11,000 x g for 30 sec. 
The RNA samples were eluted in 60 μl RNase-free H2O, and centrifuged at 11,000 x g for 1 
min.  
Every step was executed in a RNAse free environment to avoid RNA degradation. RNA 
extracted samples were quantified using the Nanodrop 200 spectrophotometer (Thermo 
Fisher Scientific, USA), and their purity was assessed by the A260/A280 ratio. Only the RNA 
samples with a A260/A280 ratio above 2.0 were used for following analysis.    
2.1.1.3 cDNA synthesis 
 
cDNA was generated from 1 μg of RNA sample. On ice, in a sterile, nuclease-free 
microcentrifuge tube, a reaction mixture was prepared containing 1 µg of RNA, 300 ng of 
random hexamer primers, 0.5 mM of dNTP mix (10 mM each) and Nuclease-free water up to 
16 µl. Denaturation of secondary structures of the RNA molecule was performed by incubating 
the reaction at 65°C for 5 min, followed by a brief incubation of the reaction on ice. To each 
RNA sample mix 4 µL of a Reverse transcription mix was added, containing 1x reaction Buffer 
(10x – 2 µL), 40 Units of Ribonuclease Inhibitor (1 µL), and 200 Units of M-MuLV Reverse 
Transcriptase (1 µL).  The reactions were briefly centrifuged and incubated at 25°C for 10 min, 
followed by 50 min incubation at 50°C. Heat inactivation of the reverse transcriptase was 
performed by incubating the samples at 85°C for 5 min. The cDNA products were stored at -
20°C. All the reagents used for cDNA synthesis were from NZYtech (Lisbon, Portugal). 
 
2.1.2 PCR reactions to identify CFTR mutations 
 
To detect CFTR mutations both the DNA and cDNA samples were analysed as follows: a 
pre-reaction mix was prepared containing 10 pmol/µL of forward and reverse primer mix, 1 
Unit of Taq Polymerase (NZYtech), 1x of Polymerase Buffer solution (10x, NZYtech), 3 µL 
MgCl2 (50 mM), 25 µM dNTPs mix, and water up to a final volume of 49 or 45 µL, for DNA 
and cDNA reactions, respectively. 
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All these steps were performed in a DNA/RNA free environment to avoid contamination of 
the reagents, and samples and reaction mix were kept on ice to avoid unspecific amplification. 
The PCR reactions were incubated in a T-Professional thermo-cycler (Biometra), using the 
heating-cooling cycles described in Table 2.2. After the thermo-cycling, each reaction was 
analysed by an agarose gel electrophoresis. Samples were separated in a 2% (m/v) agarose 
(Lonza) gel in TAE buffer with 1 Unit of RedSafe (Chembio), for 40 min at 120 Volts. After 
electrophoresis the PCR products were visualized by exposing the gel to UV light in a dark 
container coupled to a Kodak photographic machine (Kodak EDAS 290 Electrophoresis 
Documentation System). Image analysis was performed using the Kodak EDAS 290 
Electrophoresis Documentation System software. 
Table 2.2 - PCR program used for the detection of CFTR and β-actin transcripts by RT-PCR 
 
PCR analysis of the cDNA samples was performed using nine different primer 
combinations, in order to cover the complete CFTR coding region (Table 2.4). For each PCR 
reaction 5μl of cDNA sample were used. 
Different mutations were identified through three different techniques: Amplification 
Refractory Mutation System (ARMS), Tetra-ARMS and Restriction Fragment Length 
Polymorphisms (RFLP). For each PCR reaction 50 ng of DNA sample were used.  
2.1.2.1 ARMS Technique  
 
Identification of F508del, G542X and N1303K mutations was carried out using the ARMS 
PCR technique. Different primer combinations were used, as shown in Table 2.3, with different 
PCR fragment sizes expected. For each mutation two separate PCR reactions were done with 
primers set to detect the wildtype or mutant allele. 
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Table 2.3 - PCR primers and condition for ARMS-PCR 
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Table 2.4 - Primer sets used for the nine PCR reactions and F508del-ARMS, and respective sequence, position in CFTR mRNA and expected PCR product size 
PCR reaction 
cDNA 
Region 
Primer 
name 
Sequence 
Temperature 
Annealing 
cDNA 
Position 
Fragment 
Length 
(bp) 
1 5’NC- 5’NC 5’- GCATTAGGAGCTTGAGCCCA - 3’ 62ºC 77-96 
743 
Ex6a AC1L 5’ – GAAACCAAGTCCACAGAAGGC – 3’ 64ºC 819-799 
2 Ex5 CF Ex5.F 5’ – CTCCTTTCCAACAACCTGAAC – 3 62ºC 679-699 
751 
Ex9 CF9AS 5’ – GTACTGAAGAAGAGGCTGTC – 3’ 60ºC 1429-1408 
3 Ex8 B3R 5’ – AATGTAACAGCCTTCTGGGAG – 3’ 52ºC 1318-1338 
431 
Ex11 Ex11L 5’ – TATATTGTCTTTCTCTGCAAACTTGG – 3’ 70ºC 1724-1749 
4 
(see also below) 
EX10 CF10N 5’ – GGCACCATTAAAGAAAATATCATCTT – 3’ 58ºC 1630-1655 
207 
EX10 CF10M 5’ – GGCACCATTAAAGAAAATATCATTGG – 3’ 58ºC 1630-1655 
5 Ex11 C1R 5’ – GTGGAGGTCAACGAGCAAGA – 3’ 62ºC 1778-1797 
904 
Ex14a CF14a.R 5’ – AAGGAATGTGGTCCATGTAG – 3’ 58ºC 2663-2682 
6 Ex13 D2R 5’ – GCAAACTTGACTGAACTGGA – 3’ 58ºC 2530-2549 
730 
Ex17a D2L 5’ – GTTGTTTGAGTTGCTGTGAG – 3’ 58ºC 3240-3259 
7 Ex16 E2R 5’ – GATGACCTTCTGCCTCTTAC – 3’ 54ºC 3082-3101 
700 
Ex19 E2L 5’ – CTGTGAGATCTTTGACAGTC – 3’ 58ºC 3762-3781 
8 Ex18 Ex18.F 5’ - AACTCCAGCATAGATGTGG – 3’ 56ºC 3574-3592 
829 
Ex22 Ex22.R 5’ – GCCAAGCACATCAACTGCA – 3’ 58ºC 4184-4202 
9 Ex21 Ex21.F 5’ – CTATGAACAGTGGAGTGATC – 3’ 58ºC 4050-4069 
549 
Ex24 F2L 5’ – CATGTCAACATTTATGCTGC – 3’ 56ºC 4579-4598 
Specific primers for detection of the F508del mutation using the ARMS technique  
4. ARMS for normal sequence at F508 EX10 CF10N 5’ – GGCACCATTAAAGAAAATATCATCTT – 3’ 58ºC 1630-1655 
207 4. ARMS for mutant F508del sequence EX10 CF10M 5’ – GGCACCATTAAAGAAAATATCATTGG – 3’ 58ºC 1630-1655 
4. Common ARMS reverse primer Ex12 561AL 5’ – CAAATCAGCATCTTTGTATACTG – 3’ 62ºC 1814-1836 
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2.1.2.2 Tetra – ARMS Technique  
 
The DNA samples were further analysed for an additional 7 CFTR mutations, as show in 
Table 2.5. For each sample, PCR reactions were set, comprising the wildtype allele, mutant 
allele and control primers.  
Table 2.5 - PCR and condition for tetra-primer AMRS-PCR. 
 
Mutation Primer Sequence 5’ to 3’ Tm Annealing (ᵒC) Amplicon size 
A561E 
C>A 
Forward inner primer (A allele):                
AAT TTC CAT TTT CTT TTT AGG GA 
Reverse inner primer (C allele): 
AAT ATA CAA AGA TGC TGA TTT GTA TTG   
Forward outer primer (5' - 3'): 
GTG AAT CGA TGT GGT GAC CA  
Reverse outer primer (5' - 3'): 
CTG GTT TAG CAT GAG GGG GT               
51ᵒC 
 
51ᵒC 
 
60ᵒC 
 
62ᵒC 
54 
327 bp (A allele) 
 
148 bp (C allele) 
 
426 bp 
 (from two outer 
primers) 
R334W 
C>T 
Forward inner primer (T allele):                 
CAC TAA TCA AAG GAA TCA TCC GCT 
Reverse inner primer (C allele): 
GAA TGA GAT GGT GGT GAA TAT TTT ACG 
Forward outer primer (5' - 3'): 
GGA AGG CAG CCT ATG TGA GA 
Reverse outer primer (5' - 3'): 
GCA AAG TTC ATT AGA ACT GAT C  
56ᵒC 
 
56ᵒC 
 
60ᵒC 
 
62ᵒC 
52 
137 bp (T allele) 
 
215 bp (C allele) 
 
410 bp 
(from two outer 
primers) 
R1066C 
C>T 
 
Forward inner primer (C allele):                
CAA GCT TAA AAG GAC TAT GGA CAC GTC 
Reverse inner primer (T allele): 
CTG CCG TCC GAA GGC CCA 
Forward outer primer (5' - 3'): 
TTC AAA GAA TGG CAC CAG TGT 
Reverse outer primer (5' - 3'): 
ATA ACC TAT AGA ATG CAG CA  
58ᵒC 
 
62ᵒC 
 
60ᵒC 
 
54ᵒC 
50 
278 bp (C allele) 
 
228 bp (T allele) 
 
462 bp 
(from two outer 
primers) 
G576A 
G>C 
Forward inner primer (G allele):                 
GAT TTG TAT TTA TTA GAC TCT CCT TTA GG  
Reverse inner primer (C allele):  
TTT TTC TGT TAA AAC ATC TAG GTT TG 
Forward outer primer (5' - 3'): 
GTG AAT CGA TGT GGT GAC CA 
Reverse outer primer (5' - 3'): 
CTG GTT TAG CAT GAG GGG GT 
52ᵒC 
 
51ᵒC 
 
60ᵒC 
 
62ᵒC 
52 
288 bp (G allele) 
 
192 bp (C allele) 
 
426 bp 
(from two outer 
primers) 
P205S 
C>T 
Forward inner primer (C allele):                 
GCA CAT TTC GTG TGG ATC GAT C    
Reverse inner primer (T allele): 
AGG AGT GCC ACT TGC AAC GA      
Forward outer primer (5' - 3'): 
TTA GTG TGC TCA GAA CCA CG  
Reverse outer primer (5' - 3'): 
GAA ACC AAG TCC ACA GAA GGC     
57ᵒC 
 
56ᵒC 
 
60ᵒC 
 
64ᵒC 
52 
96 bp (C allele) 
 
185 bp (T allele) 
 
240 bp  
(from two outer 
primers) 
I148N 
T>A 
Forward inner primer (T allele):                 
CCA TTT TTG GCC TTC ATC ATA T   
Reverse inner primer (A allele): 
AAA CAT AGC TAT TCT CAT CTG CAT TCT AT  
Forward outer primer (5' - 3'): 
TGT GTT GAA ATT CTC AGG GT    
Reverse outer primer (5' - 3'): 
TTG TAC CAG CTC ACT ACC T                                       
53ᵒC 
 
54ᵒC 
 
56ᵒC 
 
56ᵒC 
52 
156 bp (T allele) 
 
270 bp (A allele) 
 
376 bp 
(from two outer 
primers) 
711+1 G>T 
Forward inner primer (G allele): 
AAC CTG AAC AAA TTT GAT GGA G 
Reverse inner primer (T allele): 
CCT AAA AGA TTA AAT CAA TAG GTA CAC AA 
Forward outer primer (5' - 3'): 
TTG TAC CAG CTC ACT ACC T 
Reverse outer primer (5' - 3'): 
AAC TCC GCC TTT CCA GTT GT 
58ºC 
 
58ºC 
 
56ºC 
 
60ºC 
54 
89 bp (G allele) 
 
356 bp (T allele) 
 
395 bp 
(from two outer 
primers) 
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2.1.2.3 RFLP Technique  
 
The G85E and 3272-26 A>G mutations were analysed using the Restriction fragment 
length polymorphisms (RFLP) PCR method. The PCR reactions were performed as described 
above (Materials and Methods, section 2.1.2). For analysis 10 μl of the amplified product were 
used, after verification of expected PCR product in an agarose gel: 318 bp for G85E and 267 
bp for 3272-26 A>G. Each PCR product was incubated with 1 U of HinfI and BtsI restriction 
enzymes (New England BioLabs, UK) for 1h at 37°C and 55°C, respectively. Digested 
products were analysed on a 2% agarose gel.  
For the G85E Wildtype allele three fragments are expected with 55, 91, and 172 bp, while 
only two fragments are expected for the mutant allele, a 91 and a 227 bp fragments. For the 
3272-26 A>G Wildtype allele, only one fragment 318 bp is expected, and two fragments of 
134 and 137 bp are expected in a mutant allele, as shown in Table 2.6. 
Table 2.6 - PCR primers and condition for RFLP technique 
 
 
 
2.1.3 Quantitative Analysis of CFTR Transcripts  
 
The analysis of the transcripts is important to understand mutation effect on the RNA. One 
technique used to measure transcripts levels is quantitative real-time PCR (qRT-PCR) which 
allows us to monitor the progress of a PCR reaction as it occurs in real time, and this 
combination of amplification and detection not only increases the accuracy of PCR product 
quantification but also eliminates the need for post-PCR manipulations. Two main 
experimental procedures can be followed, based on the use of either fluorescently labelled 
gene-specific probes (e.g., Taqman) or dyes that intercalate double-stranded DNA during 
product extension (e.g., SYBR Green). We used the SYBR Green method for relative 
quantification of CFTR transcripts from a group of experimental vs. control samples, using a 
housekeeping gene as an internal control. This technique can be used to measure changes 
in CFTR mRNA abundance following experimental manipulations in cell cultures or to confirm 
altered expression of the CFTR gene in native tissues from patients vs. controls. 
qRT-PCR was performed in a 96-well plate, with experimental and control samples. Each 
cDNA sample was analysed in triplicate and reactions were prepared as previously described 
(Ramalho et al., 2011). For G542X/G576A-R668C patient analysis, primers were designed 
using the Primer3 software (http://frodo.wi.mit.edu/). The primers were designed to identify the 
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full-length exon 13 (5′- TTAGCAAGTATACAAAGATGCTGATTT-3′), and the exclusion of exon 
13 promoted by the G576A mutation (5′- AATTTCTTTAGCAAGCTGTGTCTG-3′) products of 
the G576A-R668C allele (common reverse primer: 5′-GCTGCTACCTTCATGCAAAA-3′).  
A set of G542X specific primers (G542X reverse primer: 5′-GTGTGATTCCACCTTCTCC-
3′; wt reverse primer: 5′- GTGTGATTCCACCTTCTCA-3′; common Forward primer: 5′-
CAACTGTGGTTAAAGCAATAGTGT-3′) was also used to compare abundance of transcripts 
from the two separate alleles. Quantification of each cDNA was performed using the Evagreen 
system (Biorad) in a BioRad Cx96. After normalization to β-actin the samples were analysed 
according to the ddCT method, and fold change between full length and alternatively spliced 
products was calculated using the following formula: FC = 2(−ddCT). 
2.1.4 Statistic Analysis  
 
Statistical analyses were performed with SPSS software (v. 19; SPSS Inc, Chicago, IL, USA) 
and a p value < 0.05 was accepted to indicate a statistically significant difference.  
Data presented in Chapter 1 (section III. Results & Discussion) included 187 Portuguese 
participants, 136 with respiratory disease and 51 healthy controls. Results are presented 
stratified by individuals, gender, age and as totals. 
Associations between different respiratory diseases and a control group were assessed using 
Fisher's exact test, that can assess for independence between two variables when the 
comparing groups are independent and not correlated. The Fisher's exact test runs an exact 
procedure especially for small-sized samples. 
2.1.5 Ussing Chambers 
 
To assess the intestinal CFTR-mediated Cl- secretion in the patient, rectal biopsy 
specimens were mounted and analysed in micro-Ussing chambers perfused in Ringer solution 
under open-circuit conditions, as previously described (Sousa et al., 2012). Briefly, Amiloride 
(Amil) was added to block electrogenic sodium (Na+) absorption through ENaC and 
indomethacin was applied for 40-60 min to inhibit endogenous cAMP formation through 
prostaglandins (Sousa et al., 2012). As reported, cAMP-dependent and cholinergic Cl- 
secretion in human rectal tissues relies on functional CFTR. Thus, we used 3-isobutyl-1-
methylxantine (IBMX basolateral) and forskolin (Fsk basolateral) to activate cAMP-dependent 
Cl- secretion and carbachol (CCH, basolateral) for cholinergic co-activation (Mall et al., 2000). 
The percentage of CFTR function was calculated for maximal CFTR activation and normalized 
to the corresponding mean value for the reference non-CF control group. 
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Values were obtained from quantification of the equivalent short-circuit (Ieq-sc-
CCH/IBMX/Fsk) from the original tracings.  
 
3 CFTR NMD-PTC mini-gene model 
 
A mCherry-wt-intron14/15/16-CFTR-eGFP (hereinafter referred to as mCherry-wt-eGFP) 
mini-gene and a mCherry-G542X-intron14/15/16-CFTR-eGFP (hereinafter referred to as 
mCherry-GX-eGFP) mini-gene model were constructed. This mini-gene model allowed us to 
identify factors involved in the NMD pathway and to detect read-trough compounds. The fused 
mCherry at the N-terminus of the mini-gene allowed us to detect NMD inhibition by detection 
of red fluorescence using fluorescence microscopy and the eGFP (enhanced green 
fluorescent protein) fused at the C-terminus allowed us to detect read-trough compounds by 
detection of green fluorescence as illustrated in Figure 2.8.  
The CFTR mini-genes were previously produced using a "sticky feet PCR" strategy to 
introduce the CFTR introns - IVS14, IVS15, and IVS16 -  consecutively into the 
pCDNA5/FTR/CFTR mammalian expression vector carrying the complete wt-CFTR (Masvidal 
et al., 2014). Thus, the "triple mini-gene" consists of a full 4.5 kb CFTR cDNA plus full length 
of the intron 14 (2274 bp), inserted between cDNA exons 14/15; a short length version of the 
intron 15 618 bp– IVS15art (containing the first 5’ 259 bp and the last 3’ 350 bp of the normal 
IVS15) inserted between exons 15/16; and the full length intron 16 (670 bp) inserted between 
exons 16/17. Herein, cloning of the mCherry coding sequence and eGFP coding sequence, 
upstream and downstream of the CFTR mini-gene, respectively, was done using the same 
cloning method as for the IVS’s.  
To induce NMD the nonsense mutation, in this study the G542X mutation, must be 
recognized as a PTC and this only occurs if an intron is downstream of the nonsense mutation 
(Da Costa et al., 2017). 
NMD and PTC read-through studies described in the third and fourth chapters were 
performed using this triple-colour CFTR mini-gene model.  
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Figure 2.8- Schematic representation of the three-colour CFTR NMD reporter. (A) The CFTR 
mini-gene construct used here (inserted into the pCDNA5-CFTR vector) with the G542X mutation 
(from herein called mCherry-wt-eGFP) contains IVS14, 15 and 16, mCherry (red) at the N-terminus, 
and eGFP (green) at the C-terminus as well as the Flag tag at exon 17 (for plasma membrane 
localization). (B) Scheme of NMD fluorescence assay: when NMD takes place, no green 
fluorescence (right) occurs and only basal red fluorescence is detected and if the transcript escapes 
NMD, red fluorescence will be increased (middle), whereas if PTC read-through also takes place, 
green fluorescence will be detected, along with an increase in red fluorescence (left). 
3.1 Production of the CFTR G542X mutation by site-directed 
mutagenesis 
 
The nonsense mutation G542X in exon 12 (the most common nonsense mutation in CF 
patients) was introduced in the mCherry-wt-eGFP using the KOD Hot Start Kit (Invitrogen, 
USA), with a complementary pair of mutagenic primers described in Table 2.7.   
After site-directed mutagenesis plasmids were isolated (using the kit NZYMiniprep from 
NZYtech (Lisbon, Portugal)) and sequenced by automatic DNA sequencing to confirm the 
introduction of the mutation.  
Table 2.7 - Primers and PCR conditions 
 
 
 
A 
B 
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3.2 Production of stable cell lines and cell culture maintenance  
 
Stable cells lines carrying the wt and the G542X mini-genes were generated using the 
Human embryonic kidney 293 Flp-In (HEK293 Flp-In) cells (Invitrogen, Carlsbad, CA), 
hereinafter referred to as HEK Flp-In, a cell line derived from HEK293 cells and containing 
both Flp-In and T-REx systems.  
The creation of each of the isogenic stable cells is made possible by the Flp-In system (Life 
Technologies). In this study the cells used were the HEK Flp-In that already contain the 
flippase recombination target (FRT) site linked to zeocin resistance gene in their genome. By 
co-transfecting these cells with both the flippase (Flp) recombinase plasmid, pOG44, and an 
expression plasmid containing the gene of interest flanked by FRT site in both end, and the 
hygromycin resistance gene.  The presence of the Flp recombinase induces the integration of 
the fragment in the plasmid flanked by the FRT site in recombinase target site present in the 
cells genome leading to the stable expression of the gene of interest, loss of the zeocin 
resistance and acquisition of resistance to Hygromycin B. Using this system only a single copy 
of the fragment of the plasmid of interest is integrated per cell, originating a cell population 
with isogenic expression of the gene of interest, after selection with Hygromycin B. 
Parental HEK Flp-In cells were cultured in Eagle Minimal Essential Medium supplemented 
with L-glutamine (EMEM, Lonza) supplemented with 10% (v/v) foetal bovine serum (FBS, 
Gibco) and supplemented with 200 µg of zeocin (Invitrogen).  
HEK Flp-In cells stable cell lines were generated by transfection with the pOG44 plasmid 
and each mini-gene, simultaneously, in a proportion of 3:1 for a total 2 µg of DNA, using the 
Lipofectamine 2000 Transfection Reagent (Invitrogen # 12566014). Stable cell lines were 
selected 48h after transfection with 200 µg/ml of Hygromycin B (Life Technologies). 
supplemented medium. Cultures were maintained at 37ºC in a humidified atmosphere of 5% 
(v/v) CO2. 
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4 HTS – NMD and PTC read-through screens 
 
4.1 Screen Assay for NMD and PTC read-through  
 
HEK Flp-In mCherry-wt-eGFP and mCherry-GX-eGFP cells were grown to confluence and 
split 24 h before seeding. For the shRNA screen 1x103 cells/well were seeded in 384 well 
plates. For the PTC read-through compound assay and for siRNA confirmation, 1x103 
cells/well were seeded in 96 well plates. Cells were seeded using a MulitdropTM Combi 
peristaltic dispenser (Thermo Scientific #5840300).  
 
4.1.1 NMD Screen of the RNA-related shRNA library 
 
A subset of the shRNA library from the RNAi Consortium (TRC), Broad Institute (kindly 
provided by Dr L. Moita) Oberdoerffer et al., 2009; Mishra et al., 2010) was used to generate 
loss-of-function cellular phenotypes for a collection of genes with a known or predicted 
involvement in transcript processing. In this screen 425 different genes were evaluated, with 
an average of 5 shRNAs per gene. shRNA information is described in Table S 4.3 and the 
target sequences are provided in The RNAi Consortium webpage (The RNAi Consortium, 
2017). 
The cell lines stably expressing the wt and mutant mini-genes were transduced using 3 µl 
of non-concentrated shRNA lentiviral supernatant, and 8 mg ml -1 polybrene was added per 
well. The plates were spun at 2200 rpm for 90 min at 37°C. After spin, cell media was replaced 
with fresh media. Forty-eight hours post infection, staining was performed (refer to section 
4.2).  
 
4.1.1.1 Confirmation of selected hits from the shRNA screen by additional siRNAs 
 
Candidate genes related to NMD were defined as a ‘hit’ if two or more shRNAs increased 
mCherry expression by standard deviation from the mean of the controls (cells transduced 
with lentivirus encoding a scrambled-shRNA). Hit candidate genes were further validated in a 
confirmation screen, using a siRNA library targeting the candidates.  
96-well plates were coated with customized siRNAs (Dharmacon™ siRNA Libraries) for 
solid-phase reverse transfection. The protocol used is adapted from a previously reported 
(Erfle et al., 2007). An aqueous 0.2% (w/v) gelatine solution was prepared and filtered with 
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0.45µM pore size filter, and a 0.4M glucose solution was prepared in Opti-MEM (Gibco 
#51985). The transfection mix was prepared by mixing 277 µL of the sucrose/Opti-MEM 
solution, 323 µL of Lipofectamine® 2000 (Invitrogen # 12566014) and 161.5 µL doubly distilled 
water. This transfection mix was distributed into a 96- conic well plate (6 µL/well, “Plate A”). In 
parallel, 10 µL of 0.2% gelatine solution was distributed into another 96-conic well plate (30 
µL/well, “Plate B”). In a new 96-well plate, 3.5 µL of the transfection mix (“Plate A”) was mixed 
with 2.5 µL of a 20 µM siRNA solution per well (“Plate C”). After 20 min incubation, 3.5 µL of 
the 0.2% gelatine solution (from “Plate B”) was added. From each well of the “Plate C” 8.5 µL 
of the transfection + siRNA + gelatine was diluted 50-fold with doubly distilled water. Finally, 
50 µL of each well were transferred to a 96-well imaging plate, lyophilized and stored in an 
anhydrous atmosphere before cell seeding. HEK Flp-In cells were seeded into the 96-well 
imaging plate at a cell density of 2 x 104 cells/well. After 48 hours of incubation, staining was 
performed (refer to section 4.2). 
 
4.1.2 Screen of compounds for read-through of the G542X mutation 
 
As described above, for the read-through compounds screen 96 well plates were coated 
with poly-L-lysine solution and 1x103 cells/well were seeded on top. A library of 24 chemically 
synthesized compounds were tested, synthesised and kindly provided by C. Moiteiro lab 
(FCUL, Lisboa, Portugal). After 24h, the compounds were added to the cells at three different 
concentrations: 5 μM, 1 μM, and 0.5 μM. The cells are incubated for 48 h. Each assay plate 
included several controls: the vehicle (DMSO, 0.5%), three positive controls: 1 µM SMG1 
(NMD Inhibitor; kindly provided by Martin Mense), 600 µM geneticin (G418; Sigma-Aldrich, 
#A-1720), and 10 µM PTC124. After 48h of incubation with the compounds, the cells were 
stained (refer to section 4.2). 
 
4.2 Staining  
 
Cell culture medium was removed, and cells were washed with ice cold PBS+/+ (PBS 
supplemented with 0.7mM CaCl2 and 1.1mM MgCl2) using a manual 96 channel pipette 
liquidator (LiquidatorTM 96, Mettler Toledo #17010335). The cells were then incubated with 
3% (w/v) paraformaldehyde for 20 min at 4ºC and transferred to room temperature for the 
remaining staining procedure. Cells were then washed three times with PBS and incubated 1 
h with a Hoechst 33342 solution (200 ng/mL, Sigma #B2261). The cells were washed 3 times 
with PBS. Before imaging the cells were kept overnight with PBS at 4ºC. 
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4.3 Image Acquisition  
 
Cell imaging was performed with an automated Leica DMI 6000B widefield epifluorescence 
microscope equipped with a metal halide light source (EL6000), a 16 bit 2048 x 2048 pixel 
resolution CMOS camera (Hamamatsu Orca-Flash4.0) and a 10x HC PL APO objective with 
a numerical aperture of 0.4. Three fluorescence channels were acquired: Hoechst (cell nuclei), 
mCherry (N-terminal CFTR) and GFP (C-terminal CFTR). The Hoechst channel was used for 
contrast-based autofocus. Each well was imaged at 5 non-overlapping fields, to obtain a 
representative coverage of the cell population. 
 
4.4 Image Analysis  
 
Automated high content image analysis was performed with open source software tools: 
image quantification was performed using CellProfiler [PMID: 21349861] and statistical 
analysis was performed using shinyHTM (https://github.com/hmbotelho/shinyHTM), an 
application based in R (Team, 2017). Using CellProfiler, each cell was segmented by 
thresholding on the nuclear staining and allowing for a 1 pixel dilation (estimating the 
cytoplasm location). Cells touching the image border, containing too large or too small nuclei, 
having elongated nuclei (eccentricity > 0.8) or having more than ~1% of their pixels saturated 
were not considered for the analysis. The morphological filters aim at disregarding damaged, 
dead or mitotic cells, which do not represent a physiological epithelium. After background 
correction using the dark frame / flat field method, mCherry and GFP fluorescence intensities 
were measured in every cell. In this system, the integrated mCherry fluorescence signal in 
each cell is proportional to the extent of NMD inhibition, which is the amount of CFTR 
transcripts which escape NMD and produce a truncated protein: 
𝑁𝑀𝐷 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 ∝ mCherry Integrated Fluorescence 
The efficiency of PTC read-through in each cell is proportional to the eGFP fluorescence 
and represents the full-length CFTR:  
𝑃𝑇𝐶 𝑅𝑒𝑎𝑑𝑡ℎ𝑟𝑜𝑢𝑔ℎ 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 ∝ 𝑒𝐺𝐹𝑃 𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 
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The integrated fluorescence is represented according with the above formula:  
𝐴 = ∑ 𝐼𝑝𝑖𝑥𝑒𝑙
𝑛
𝑖=1
 
𝐵 = 𝑀𝑒𝑑𝑖𝑎𝑛𝑎 (𝐴), 𝑖𝑚𝑎𝑔𝑒 𝑋 
 𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 = 𝐵 
Each image was characterized by the median value of “NMD inhibition” and “PTC read-
through efficiency”. After imaging at least 4 image fields in triplicate, the shinyHTM software 
was used to perform quality control (QC) and statistical analysis. The QC aimed at excluding 
out of focus images and images with high background fluorescence. After averaging the NMD 
Inhibition and PTC Read-through efficiency for all images relating to the same 
shRNA/siRNA/compound treatment passing QC, the effect of each shRNA/siRNA and 
compound towards NMD Inhibition/read-through efficiency was expressed as a deviation 
score versus the appropriate negative control:  
𝑁𝑀𝐷 𝑆𝑐𝑜𝑟𝑒 =  
NMD Inhibition𝑖 − NMD Inhibition𝑁𝑒𝑔𝐶𝑡𝑟𝑙
𝑆𝐸𝑀NMD Inhibition,𝑁𝑒𝑔 𝐶𝑡𝑟𝑙
 
𝑃𝑇𝐶 𝑅𝑒𝑎𝑑𝑡ℎ𝑟𝑜𝑢𝑔ℎ 𝑆𝑐𝑜𝑟𝑒 =  
𝑃𝑇𝐶 𝑅𝑒𝑎𝑑𝑡ℎ𝑟𝑜𝑢𝑔ℎ𝑖 − 𝑃𝑇𝐶 𝑅𝑒𝑎𝑑𝑡ℎ𝑟𝑜𝑢𝑔ℎ𝑁𝑒𝑔𝐶𝑡𝑟𝑙
𝑆𝐸𝑀𝑃𝑇𝐶 𝑅𝑒𝑎𝑑𝑡ℎ𝑟𝑜𝑢𝑔ℎ,𝑁𝑒𝑔𝐶𝑡𝑟𝑙
 
The negative control (NegCtrl) for compound-based assays is the vehicle (DMSO) and for 
the shRNA or siRNA assays is a non-targeting “Scrambled” version of the nucleic acid. In the 
formula, NMD Inhibition and PTC read-through are the median NMD inhibition or PTC read-
through values obtained in individual images; SEMXXX,Neg_control is the standard error of the 
mean for median ‘NMD Inhibition‘ or ‘PTC read-through‘ recorded upon ‘Scrambled’ treatment. 
We consider the effects those whose magnitude is larger than twice the negative control SEM 
to be significant (|Deviation Score| > 2). 
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III RESULTS & DISCUSSION 
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Chapter 1 - Incidence of mutations in the CFTR gene in Portuguese 
individuals with respiratory diseases. 
1. Abstract 
Background: It is estimated that 4% of the Caucasian population are carriers of CFTR 
gene mutations. However, there are studies suggesting that there is a higher incidence of 
CFTR mutations in individuals with several other respiratory diseases such as Disseminated 
Bronchiectasis (BD), Bronchopulmonary Aspergillosis, Sinusitis, Chronic Obstructive 
Pulmonary Disease (COPD) or Bronchial Asthma (BA). While in BD, several studies have 
shown an increased incidence of CFTR gene mutations in comparison to control groups, in 
the case of BA, previous studies have yielded controversial results. 
Objective: Our goal is to screen individuals with chronic non-CF lung diseases, namely 
DB, BA and COPD for the presence of the 12 most frequent CFTR mutations found in 
Portuguese patients with CF. 
Methods: A total of 136 individuals with non-CF respiratory diseases (asthma, n=54; 
COPD, n=51) and DB, n=31) referred by Hospital Lisboa-Norte and 51 controls were assessed 
for the presence of CFTR mutations, using three different techniques: 1) ARMS (amplification 
refractory mutation system) technique; 2) Tetra- ARMS; 3) and Restriction Fragment Length 
Polymorphisms (RFLP), optimized in our laboratory to allow rapid detection in DNA or RNA 
samples followed by sequencing. In cases where CFTR mutations were detected, we further 
analyzed RNA samples and performed CFTR-mediated ion transport measurements in rectal 
biopsies. 
Results and Discussion: Our data show that 7 (out of 136) patients with non-CF 
respiratory diseases displayed CFTR mutations in one allele vs none in the control group. We 
analysed the correlation of CFTR gene mutations with each of the three respiratory diseases 
investigated. Regarding BA our data did not show an increase in mutation frequency. For DB, 
we found a non-statistically significant increase in the frequency of CFTR gene mutations, in 
agreement with previously published independent reports. Regarding COPD however, we 
found a statistically significant increase in CFTR gene mutations. 
Conclusion: This work confirmed the importance of CFTR gene mutations on non-CF 
respiratory diseases in Portuguese patients leading to a better perception of the epidemiology 
and etiology of these diseases. These results also lead to the identification of groups of 
patients who may benefit from the new therapeutic compounds currently under development 
to correct the basic CFTR protein defect in CF. 
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2. Introduction 
Cystic Fibrosis (CF) (OMIM #219700) is the most common autosomal recessive disease in 
the Caucasian population, with an estimated incidence of 1: 3,500-4,000 births in Portugal 
(WHO, 2004). The most relevant clinical aspects of CF classical manifestation are: 
progressive lung disease brought about by dehydration of the epithelial airway surface liquid 
(ASL) and a failure in MCC, leading to recurrent bacterial infections and a chronic inflammatory 
response; pancreatic dysfunction; male infertility and elevated concentrations of chloride (Cl-) 
in sweat. However, although the classic CF manifestation is well defined, its pathophysiology 
is not yet fully understood. This disease has pleotropic manifestations presenting a great 
variability of clinical phenotypes (Bergougnoux et al., 2015; Clarke et al., 2015; De Boeck and 
Amaral, 2016). 
CF is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator 
gene (CFTR, MIM*602421). Currently, more than 2,000 variants have been identified for this 
gene (Cystic Fibrosis Mutation Database, 2017), of which the p.Phe508del mutation is the 
most frequent, with a 70% worldwide incidence of CF chromosomes (in ~ 90% of CF patients). 
About 1 in 30 Caucasians, 1 in 65 Africans and 1 in 90 Asians carry a mutation in the CFTR 
gene (Nielsen et al., 2016). Due to the high number of sequence variants found in the CFTR 
gene, their consequences in terms of disease manifestation are not yet fully understood. 
Moreover, there are studies that suggest the  association of CFTR mutations with several 
other respiratory diseases (Bombieri et al., 1998) such as diffuse Bronchiectasis (BD) (Pignatti 
et al., 1995), bronchopulmonary aspergillosis (Miller et al., 1996), Sinusitis (Wang et al., 2000), 
Chronic Obstructive Pulmonary Disease (COPD) (Pignatti et al., 1996; Dahl and 
Nordestgaard, 2009) and Bronchial Asthma (Dahl et al., 1998a).  
A detailed screening of the CFTR gene revealed the presence of CFTR mutations, or rare 
variants, in patients with DB and in patients with COPD (Ngiam et al., 2006; Bienvenu et al., 
2010). However, studies that assess the association between asthma and the defective CFTR 
gene have produced conflicting results (Ngiam et al., 2006; Douros et al., 2008). Indeed, the 
main challenge of large genetic analyses is the interpretation of unknown CFTR sequence 
variations, this problem is heightened when rare or unique variants are identified and when 
the molecular consequences are very mild or unknown. Carriers of CFTR mutations have 
been identified in a higher number among patients with DB and bronchial hypersecretion 
compared to the general population (Bombieri et al., 1998). Increased frequency of the 
p.Phe508del allele  has been  reported in French patients with bronchial hypersecretion, in 
German patients with DB, and in French patients with DB and elevated sweat chloride 
concentration (Gervais et al., 1993).  
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The high prevalence of asthma in patients with CF has been known for a long time. 
However, it is still unclear whether carriers of CFTR mutations are susceptible to asthma. 
Some studies have reported a positive association between the presence of CFTR mutations 
and asthma (Dahl et al., 1998b; Tzetis et al., 2001; Ngiam et al., 2006), while other studies 
have shown no association (de Cid et al., 2001; Douros et al., 2008; Dixit et al., 2013).  
Due to the presence of some similarities in the clinical manifestations of COPD and CF, 
investigators have sought to determine whether there is a link between CFTR gene mutations 
and the risk of COPD. Much attention has been given to the most common CF-causing 
mutation, p.Phe508del and several studies have failed to demonstrate that carriers are at 
increased risk for COPD (Dahl and Nordestgaard, 2009; Raju et al., 2014). However, a meta-
analysis of 13 microarray data sets focused on CF-related differential gene expression has 
confirmed striking similarities in gene expression profiles between CF and COPD (Clarke et 
al., 2015). These studies strongly suggest that loss of CFTR function in CF and COPD may 
define common pathogenic pathways for both diseases. Individuals with COPD not only 
present a decrease in respiratory epithelial cell CFTR function but also  display significant 
correlations between the clinical manifestations of COPD and the level of CFTR suppression 
in their lower respiratory tract (Cantin, 2016). 
These chronic respiratory diseases are responsible for increasing morbidity and mortality 
in developed countries, with excessive costs in terms of health care and reduced labour 
productivity. Thus, it is important to identify possible therapeutic targets and to better 
characterize the pathophysiology associated with each of them.  
Therefore, it is of interest to determine if the presence of CFTR mutations is associated 
with an elevated risk of asthma, DB and COPD. For that purpose, we carried this study by 
screening the most frequent CFTR mutations in Portuguese CF-patients in a cohort of 
Portuguese individuals with chronic lung diseases. Subsequently, we wanted to determine 
whether the CFTR variations found in these subjects have an influence on their lung disease 
and possibly identify potential genotype-phenotype correlations.  
The sample population analysed consisted of 187 Portuguese individuals, divided in two 
distinct groups. The first group included subjects with one of the following respiratory disease: 
asthma (n=54), COPD (n=51) and bronchiectasis (n=31) and the second group included 
healthy control individuals (n=51). We have also used a group of 27 CF patients, as a control 
for the methodologies used to detect the CFTR mutations. The most common CFTR mutations 
in Portugal chosen to be analysed in this study and the different techniques used to detect 
these mutations are shown in Table 3.8. For detailed information on the techniques and 
protocols used in this study see chapter II (Materials and Methods). 
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Table 3.8 – The 12 most common CFTR mutations in Portuguese CF patients (WHO, 2004) and 
techniques used for their detection 
 
*mutation analysed jointly with Arsénia J. Massinga. 
 
3. Results 
The clinical phenotypes of the group of patients with respiratory diseases and control 
subjects analysed in this study are shown in Table 3.9. A total of 136 individuals with non-CF 
respiratory diseases such as asthma, DB and COPD were analysed. The control group (n=51) 
consisted of subjects presenting no chronic respiratory symptoms or diseases, named here 
healthy control.  
Table 3.9 – The different groups of individuals analysed in this study. 
 
A total of 187 individuals (patients and controls) were screened for the 12 most common 
CFTR mutations previously described to occur in Portuguese CF-patients, using three 
different techniques, ARMS, Tetra-ARMS and RFLP (Table 3.8). We used three different 
techniques, because for two mutations (F508del and G542X) we already had the optimized 
protocol implemented and for the others we chose the most appropriate technique to identify 
the DNA alteration. For all the patients under study blood samples were taken, DNA was 
extracted and diluted to 50 ng/µl for use in the different PCR techniques (see Materials and 
Methods). The results shown in Figure 3.9, were obtained using the ARMS methodology for 
the detection of the p.Phe508del mutation. In this technique two reactions were performed: i) 
reaction I which is specific for the wt sequence in the region of the p.Phe508del mutation, 
where PCR amplification is only expected if the sequences in the CFTR alleles are normal; 
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and ii) reaction II which is specific for the recognition of the p.Phe508del sequence, for which 
PCR product amplification is only detected if this mutation is present. From the analysis of 
these PCR products, it is possible to observe that individuals a, b and d do not carry the 
p.Phe508del mutation since there is only amplification for reaction I. Individuals c and e are 
carriers of the p.Phe508del mutation, since there was product amplification for both reactions. 
Finally, individual f is homozygous for the p.Phe508del mutation since amplification is only 
visible in reaction II, and no amplification was observed for reaction I. 
 
 
 
Figure 3.9. Detection of the p.Phe508del mutation using the ARMS technique. Representative 
results obtained for 5 patients from the current study and internal control do the technique (CF patient 
homozygous for p.Phe508del). I corresponds to the PCR reaction with primers specific for the normal 
sequence; II corresponds to the PCR reaction with primers specific for the allele with the mutation 
F508del; Lanes 1, 2, 3, 4, 7 and 8 from individuals a, b and d do not have the F508del mutation; 
lanes 5, 6, 9 and 10 from individuals c and e are heterozygous for the F508del mutation; lane 11 and 
12, individual F is homozygous for F508del. M – marker 100bp. Electrophoresis on 1% agarose gel. 
Figure 3.10A shows an example for the detection of the p.G85E mutation by Restriction 
Fragment Length Polymorphisms (RFLP) analysis (see details in the Material and Methods) 
in which differences in the length of DNA fragments obtained following restriction digestion 
indicate the presence/absence of a mutation. After PCR amplification of a segment of genomic 
DNA, a restriction enzyme (HinfI - New England BioLabs, UK) was used to cut this fragment 
and the resulting DNA fragments were separated according to their size by agarose gel 
electrophoresis. The technique relies on differences in the normal and mutant DNA sequences 
at particular restriction sites, which lead to DNA fragments of different lengths when the DNA 
is cut by this restriction enzyme. In Figure 3.10, individuals a and c do not carry the G85E 
mutation, in contrast with individual b, who is a carrier of this mutation and individual e who 
has this mutation in both CFTR alleles. For the p.G576A mutation we use the tetra-ARMS 
technique. In contrast to conventional ARMS PCR that amplifies the two alleles in two different 
PCR reactions, tetra-ARMS PCR amplifies both wt and mutant alleles together with a control 
fragment, in a single PCR reaction tube. The method employs four primers to amplify a non-
allele specific larger fragment containing the mutation site and allele specific amplicons 
representing each of the two allelic forms. Figure 3.10B shows an example of the results 
obtained for the analysis of DNA from 5 individuals with a suspicion of CF. Only individual d 
carries this mutation, while the other four individuals do not. 
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Figure 3.10. Detection of the p.G85E and p.G576A mutations using the RFLP and Tetra-ARMS 
techniques, respectively. (A) Representative results obtained for detection of G85E mutation in 3 
individuals from the current study and 2 internal controls (CF patients heterozygous (b) and 
homozygous (e) for p.G85E). Product amplification of the wt allele shows the appearance of three 
fragments of 55, 91 and 172 bp respectively, while the mutant alleles shows two fragments of 91 
and 227 bp. Individuals a, c and d (lanes 1, 3 and 4, respectively) do not have the p.G85E mutation. 
Individual b (lane 2) is heterozygous for G85E mutation, as four different fragments of 55, 91,172, 
227 bp are observed. This indicates that one allele has wt sequence and the other one has the 
mutated sequence. Individual e (lane 5) is homozygous for the p.G85E mutation, as the two expected 
fragments for this mutation are observed. PCR negative control (nc, lane 6-) using water. (B). Results 
obtained for detection of p.G576A mutation in 3 patients from the current study and 1 internal control 
(CF patient heterozygous (d) for p.G576A). With this technique three different fragments with 
different sizes are expected, one from the outers primers (PCR control), another from the wt 
sequence and a third one from the mutated sequence. In this case, PCR control – 426bp; wt – 288bp; 
mut – 192bp, respectively. Individuals a, b and c (lanes 1, 2 and 3, respectively) do not have the 
p.G576A mutation, as two fragments corresponding to wt and PR control were observed. Individual 
d (lane 4), is heterozygous for the p.G576A mutation, with detection of three different fragments. 
PCR negative control using water (nc, lane 5). Both electrophoresis was run on 2% agarose gels 
and MM – marker 100bp. 
 
Analysis of the 12 CFTR mutations in all the 187 individuals, led to the identification of 
CFTR mutations in 7 subjects (6 with 1 mutation and 1 with 2 mutations) with non-CF 
respiratory diseases and none in the healthy control group. Specifically, CFTR mutations were 
found in 1 out of 54 patients with asthma (p>0.05), in 2 out of 31 patients with DB (p>0.05) 
and in 4 out of 51 patients with COPD (p≤0.05) one of which was a compound heterozygote 
(see Table 3.10).  
Table 3.10- Global results for the CFTR mutation identification on the 136 patients and 51 controls 
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Four CFTR variants were found, F508del, G542X, G576A and R668C (see Table 3.11). 
Table 3.11- CFTR variants identified in the subjects analysed in this study. 
 
Based on the CFTR2 database (https://www.cftr2.org), these CFTR variants are in two 
categories: severe mutations (CF) and unclassified variants (UV). The two CF mutations were: 
p.Phe508del which was found in five patients, and p.Gly542X which was detected in only one 
patient. The UVs were: p.Gly576Ala and p.Arg668Cys, both found in two patients with COPD. 
These have been reported to segregate as a complex allele p.[Gly576Ala; p.Arg668Cys] 
(Casals et al., 2004; El-Seedy et al., 2012). In one case, through the analysis of the CFTR 
gene in other family members, it was possible to confirm that these two variants are indeed 
present in the same allele. To address the effect of these two UVs, we conducted a separate 
analysis of the CFTR RNA levels and protein function of this specific COPD patient (see case 
report below). 
A statistical analysis using a Chi-square test was performed to assess whether there was 
a correlation between CFTR mutations and the respiratory diseases analysed in this study. 
The incidence of CFTR mutations in these patients showed no significant correlation between 
CFTR mutations and asthma or bronchiectasis (p=0.33 and 0.07, respectively). However, we 
found a positive association between CFTR mutations and COPD (p=0.03) – see Table 3.12.  
Table 3.12- Statistical analysis for the results obtained in this study. 
 
  
58 
 
4. Discussion  
This study was conducted in 187 individuals, namely 136 subjects with chronic non-CF 
respiratory diseases and 51 healthy control individuals, to determine if there is a possible 
association between CFTR mutations and asthma, disseminated bronchiectasis (DB) and 
COPD in Portuguese patients. Genotyping was performed for 12 of the most common CFTR 
mutations in Portugal, of which the p.F508del, the p.G542X mutations and the p.G576A-
R668C complex allele were found in heterozygosity in 7 of these patients (5%).  
We investigated the association of CFTR gene mutations in heterozygosity with asthma 
and we have not found an association in contrast with previous studies (Dahl et al., 1998a, 
2005; Lowenfels et al., 1998). Dahl and colleagues (Dahl et al., 2005), studying a Danish 
population, reported that there is a positive association between F508del mutation carriers 
and asthma. Lowenfels, et al. (Lowenfels et al., 1998) conducted a multinational survey in 
1113 obligate CFTR gene mutation heterozygotes and 688 controls, where they found that 
Incidence of asthma in CF heterozygotes was 9.6%, similar to was reported by Dahl, et al. 
(Dahl et al., 1998a). Contradictory results were obtained by Schroeder et al (Schroeder et al., 
1995), in the United States, since these authors claim that carriers of p.F508del are somewhat 
protected against asthma and in this study they found that the odds ratio (OR) for asthma in 
carriers of F508del is 0.31 (95% CI: 0.107-0.909). Finally, the Epidemiology on the Genetics 
and Environment of Asthma (EGEA) study in France showed that 3.2% of asthma cases and 
2.9% of controls were F508del heterozygotes. This difference was not statistically significant 
(de Cid et al., 2001). Our results showed that the group of asthma patients did not have a 
significant difference in CFTR mutations compared to the control group.  
Similarly, we did not find an association of CFTR gene mutations in DB patients vs the 
control group, despite the high percentage of carriers (6.5%) that we found in this group. 
Indeed, the incidence of the p.F508del mutation was found to be 2-fold increased in our group 
of DB patients when compared to the control group, however this difference was not 
statistically significant. Previous reports from other groups did not encounter a statistically 
significant higher incidence of CFTR mutations in DB patients either (Bombieri et al., 1998; 
Ngiam et al., 2006). According to published data, heterozygosity for p.F508del appears to 
predispose for DB and asthma, but its involvement in other pulmonary diseases remains 
unproven. It is thus possible that a larger cohort could have confirmed this observation. 
The most significant proportion of CFTR mutations carriers that we identified was in the 
COPD group (6.8%) and this observation was found to be statistically significant (p≤0.03) 
namely for the p.F508del mutation (3.9%). Thus, our study showed that CFTR mutations 
represent a statistically significant risk factor for development of COPD disease. This is not 
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surprising as one major cause of COPD is cigarette smoke (CS) and several studies have 
demonstrated that it induces CFTR internalization and dysfunction (Clunes et al., 2012; 
Hassan et al., 2014). It is thus likely that having only one functional copy of CFTR increases 
the susceptibility to not just CS but also to other respiratory pollutants. 
In our study we focused only on the analysis of common CFTR gene mutations/variants in 
Portugal and their association with COPD, asthma and DB. We have shown an association 
between CFTR mutations and COPD. Future studies should be performed using a larger 
cohort so as to detect minor to modest genotype disease association. Additionally, other CFTR 
mutations should be included in the screening panel. 
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Chapter 1.1 – Case Report 
Case Report Analysis – Identification of the influence of the unknown variant complex allele 
p.[Gly576Ala; p.Arg668Cys] in the COPD phenotype. 
1. Abstract 
Background: Cystic fibrosis (CF) is a genetic disease caused by mutations in the CFTR 
gene, whose classic phenotype is the presence of bronchiectasis, chronic sinusitis and 
pancreatic insufficiency. Diagnostic criteria are based on evidence of CFTR dysfunction (e.g., 
sweat Cl- test) and/or identification of 2 CF-causing mutations in the CFTR gene together with 
a consistent clinical phenotype. In cases of difficult diagnosis, other functional studies of CFTR 
may be used. 
Aim: The main objective of this study was to correlate clinical phenotype with levels of 
functional CFTR in patient-derived tissue (rectal biopsy) of a 67-year old COPD (smoker) 
female patient carrying two CFTR mutations: a nonsense mutation (G542X) that leads to 
transcript degradation by NMD and a complex allele (G576A-R668C), with G576A being 
responsible for alternative splicing (exon 13 skipping) and leading to the production of normal 
and aberrant transcripts to variable extents.  
Methods: Various parameters (FEV1, sweat chloride) were determined for this patient. For 
the functional characterization we used freshly isolated rectal biopsies to assess: 
measurements of CFTR-mediated chloride secretion in micro-Ussing chamber, Forskolin-
Induced Swelling (FIS) assay in intestinal organoids and levels of the G542X/G576A-R668C-
CFTR transcripts by quantitative RT-PCR (qRT-PCR). 
Results and Discussion: This patient was followed up in Pulmonology consultation after 
hospitalization at the age of 56 due to an exacerbation of chronic bronchitis. The patient was 
medicated with ipratropium bromide (normalizing symptoms) and antibiotic therapy. Her 
respiratory function was stable (FEV1 / FVC-79%, FEV1prev.-104%), and her diffusing 
capacity for carbon monoxide (DLCO) was decreased but normalized when corrected for 
alveolar volume. The patient’s CT scans showed no changes and  microbiological isolates 
were persistently negative. A sweat test was also negative and faecal elastase assay excluded 
pancreatic insufficiency. Rectal biopsies were performed to assess CFTR-mediated Cl- 
secretion by Ussing chamber and to generate intestinal organoids. As both excluded major 
CFTR dysfunction, a diagnosis of CF was rejected. 
Conclusion: Two CFTR mutations were identified in this COPD patient and the complex-
allele is of unknown prognosis, the clinical phenotype was not suggestive of CF, which was 
corroborated by the functional tests of the CFTR protein leading to the exclusion of CF. 
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Analysis of the CFTR gene may lead to the identification of mutations of uncertain pathological 
significance. In selected cases the functional study of the CFTR protein may be a valuable aid 
to confirm/ exclude a diagnosis of CF. 
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2. Introduction 
Cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) are chronic airway 
diseases with different causes that share some features in pathologic changes and clinical 
presentation. Both these disorders are characterized by chronic mucosal and airway 
inflammation, each with distinct pathophysiologic features, but a common increase in the 
infiltration of neutrophils triggered by a variety of inflammatory mediators (Sehnert et al., 2002; 
Chilvers, 2010). The pathologic processes in these diseases seem to involve progressive 
inflammatory responses with elements of tissue remodelling, airway obstruction and reduction 
in expiratory flow rates. COPD is a rising cause of morbidity and mortality worldwide, and 
Portugal is no exception. In 1990, COPD was the 6th most common cause of death worldwide 
and was ranked 12th for DALYs (disability- adjusted life years) (Cardoso et al., 2013). It was 
projected that by 2020 it will have risen to the 5th rank, and be the third most common cause 
of death (Cardoso et al., 2013). The prevalence of COPD rises steeply to above 10% amongst 
people who are aged over 40 (Bárbara et al., 2013).  
The national prevalence for COPD was estimated to be 9.0% and 5.3% in two previous 
studies conducted in selected age groups (≥40 years old in one study and between 35 and 69 
years old in the other); there was an additional  study carried out in the Lisbon area that 
showed a prevalence of 14.2% (in (≥40 years old patients ) (Bárbara et al., 2013; Cardoso et 
al., 2013; Araújo et al., 2017).  
Several groups have reported that smokers with COPD have decreased CFTR function in 
both the upper and lower airways, suggesting that dysfunctional CFTR may also play a role in 
the pathogenesis of COPD ((Ghosh et al., 2015)). In addition, CFTR dysfunction was found to 
be associated with chronic bronchitis symptoms and dyspnea, indicating that abnormal CFTR 
may be particularly important towards causing mucus retention. These findings are supported 
by in vitro studies showing reduced airway surface liquid (ASL) height and impaired MCC 
caused by cigarette smoke exposure (Eickmeier et al., 2010; Dransfield et al., 2013; 
Muthuswamy et al., 2014). 
Here, we present a clinical case of a 67-year-old woman with COPD who is a smoker. She 
was followed-up by the Pulmonology consultation since the age of 56, after hospitalization due 
to an exacerbation of chronic bronchitis. During this time, the patient was medicated with 
ipratropium bromide, (normalizing symptoms) and antibiotic therapy. 
The main objective of this work was to correlate clinical phenotype with levels of functional 
CFTR in patient-derived tissue (rectal biopsy) in this 67-year COPD (smoker) female patient 
who carries two CFTR mutations, namely: a nonsense mutation (G542X), that leads to 
degradation by NMD and one complex allele (G576A-R668C),  with G576A leading to 
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alternative splicing (exon 13 skipping) and the production of normal and aberrant transcripts 
to variable extents. To this end, various parameters (FEV1, sweat chloride) were determined 
for this patient. For the functional characterization we used freshly isolated rectal biopsies to 
assess: CFTR-mediated Cl- secretion in micro-Ussing chamber, Forskolin-Induced Swelling 
(FIS) assay in intestinal organoids; and assessed the levels of G542X/G576A-R668C-CFTR 
transcripts by quantitative RT-PCR (qRT-PCR).  
Altogether, results from this study may help to provide a better understanding of the impact 
of the G576A-R668C variation on clinical phenotype and to establish/ exclude a CF diagnosis 
for this patient, with key clinical implications for personalized therapeutic intervention. 
3. Results  
Patient clinical presentation 
This patient was followed up in Pulmonology consultation since the age of 56, after 
hospitalization due to an exacerbation of chronic bronchitis, being medicated with ipratropium 
bromide (normalizing symptoms) and antibiotic therapy. Her respiratory function was stable 
(FEV1 / FVC-79%, FEV1prev.-104%), and her diffusing capacity for carbon monoxide (DLCO) 
was decreased but normalized when corrected for alveolar volume, the microbiological 
isolates were persistently negative and CT scans showed no changes. A sweat test was 
negative and faecal elastase assay excluded pancreatic insufficiency. (Table 3.13).  
 
Table 3.13 - Clinical Phenotype of 67-yr old female smoker COPD patient 
 
 
 
 
*Diffusing capacity for carbon monoxide 
 
Assessment of CFTR-mediated Cl- secretion in rectal biopsies by Ussing chamber 
Rectal biopsies were performed to assess CFTR-mediated Cl- secretion by Ussing 
chamber since these measurements were previously shown to constitute a valuable biomarker 
for CF diagnosis and prognosis (Mall et al., 2000; Sousa et al., 2012). To assess the intestinal 
CFTR-mediated Cl- secretion in the patient, rectal biopsy specimens were mounted and 
analysed in micro-Ussing chambers perfused in Ringer solution under open-circuit conditions, 
as previously described (Sousa et al., 2012) (see also the Materials & Methods section). 
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Briefly, Amiloride (Amil) was added to block electrogenic sodium (Na+) absorption through 
ENaC and indomethacin was applied for 40-60 min to inhibit endogenous cAMP formation 
through prostaglandins (Sousa et al., 2012). As reported, cAMP-dependent and cholinergic 
Cl- secretion in human rectal tissues relies on functional CFTR. Thus, we used 3-isobutyl-1-
methylxantine (IBMX basolateral) and forskolin (Fsk basolateral) to activate cAMP-dependent 
Cl- secretion and carbachol (CCH, basolateral) for cholinergic co-activation (Mall et al., 2000). 
Values obtained from quantification of the equivalent short-circuit (Ieq-sc-CCH/IBMX/Fsk) 
from these original tracings (Figure 3.11, Table 3.14) were in agreement with those reported 
previously for non-classical CF (Sousa M et al, 2012). These results indicate that the G576A-
R668C variant can be considered as a non-classical CF mutation.  
 
 
Figure 3.11 - Original Ussing chamber tracings representing CFTR-mediated Cl- secretion in 
rectal biopsies from a patient with the G542X/G576A-R668C genotype. Representative tracing 
of the subject with the G542X/G576A-R668C genotype showing the effect on the transepithelial 
voltage of cholinergic (CCH, 100µM), and cAMP-dependent (IBMX, 100µM + Fsk, 2µM, basolateral) 
stimulation. [Data obtained in collaboration with Nikhil T Awatade, included here with permission] 
Table 3.14 - Summary of CFTR-mediated Cl- secretion in rectal biopsies with the G542X/G576A-r668c 
genotype. 
(Rte - Transepithelial resistance). (n=2). Data ± SEM. 
 
FIS assay in rectal organoids with the G542X/G576A-R668C genotype 
In order to further assess CFTR function as well as the efficacy of CFTR modulators ex 
vivo, i.e., to assess whether this combination of CFTR mutations will respond to existing and 
novel CFTR modulators (in case of a possible diagnosis of CF), the technique of intestinal 
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organoids, as described by the Beekman group (Dekkers et al., 2013), namely the forskolin 
swelling (FIS) assay was used.  
Firstly, we carried out the FIS assay in organoids from the COPD patient without any 
treatment (Figure 3.12) to determine the levels of CFTR channel activity. To this end, we 
stimulated organoids with increasing doses (0.05 to 3 µM) of the CFTR channel agonist Fsk 
(Figure 3.12A). These FIS assay data were then used to calculate the absolute area under 
the curve (AUC), assuming the baseline=100% for 60min (Figure 3.12B). 
Figure 3.12– FIS assay in G542X/G576A-R668C rectal organoids. (A) Time-course tracings of 
the Fsk- induced surface area increase relative to t=0 (normalized area) of G542X/G576A-R668C 
organoids at different Fsk concentrations (0.05 to 3 µM) averaged from three independent 
experiments. (B) Organoids swelling results from the FIS assay at different Fsk concentrations 
expressed as the area under the curve (AUC) (baseline=100%, t=60min). Data are mean±SD (n=3). 
[Data obtained in collaboration with Nikhil T Awatade, included here with permission]. 
These data indicate that these organoids exhibit normal CFTR activity, as shown by 
enhanced swelling during increasing Fsk concentration, consistently to the data obtained for 
the fresh biopsies in the Ussing chamber. These data area also consistent with what has been 
previously described for patients with one CFTR causing mutation and no mutations in the 
other allele (Dekkers et al., 2013).  
Relative quantitative transcript analysis 
To determine the effect of the G542X mutation and the G576A-R668C polymorphism at the 
CFTR transcript level, RNA was extracted from both colonic tissue and organoids from the 
COPD patient and analysed by quantitative Real Time PCR (qRT-PCR). This analysis allows 
us to assess both the degradation of transcripts resulting from the G542X mutation through 
nonsense-mediated decay (NMD) and the skipping of exon 13 (Δ13) resulting from the G576A-
R668C complex allele, as previously described for G576A (Pagani et al., 2003). In this analysis 
we used two control samples: RNA from a patient with the F508del/G542X genotype and RNA 
from a non-CF individual, to validate the set of primers for each mutation/polymorphism.  
Relative qRT-PCR analysis using primer pairs specific for the G542X mutation (Figure 
3.13) shows that  transcript levels from the G542X and the non-G542X alleles in patient-
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derived materials are present in a ratio of 19:81 in biopsies and of 18:82 in organoids. Relative 
qRT-PCR analysis using primer pairs specific for the exon 13 skipping (occurring for the 
transcript from the G576A-R668C complex allele) shows that Δ13 and full-length transcripts 
(including those from G542X, since skipping of this exon occurs normally for all individuals) 
are present in a ratio of 30:70 (in the intestinal biopsy) and of 51:49 (in organoids) (Figure 
3.14, Table 3.15). 
These data suggest that two abnormal CFTR transcripts are present: the G542X transcript 
and the alternatively spliced transcript derived from the G576A-R668C allele. With the G542X 
specific primer  relative transcript levels are expected to be very low, because this is a 
nonsense mutation. This mutation leads to significant degradation of the respective transcripts 
by nonsense-mediated mRNA decay (NMD) which acts as a surveillance mechanism to 
prevent production of truncated (non-functional) proteins. From these data we estimate a 
degradation of around 80% for the G542X transcripts. Using primers specific for the exon 13 
skipping we obtained more full-length transcripts derived from the control samples (HC – 
healthy control and F508del/G542X) than from the index patient which indicates that the 
G576A/G668C is implicated in the exclusion of the exon 13 from the CFTR transcripts.  
Table 3.15 - Relative abundance of G542X/G576A-R668C CFTR transcripts as a % of total CFTR mRNA. 
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Figure 3.13 - Relative abundance of CFTR transcripts resulting from the G542X mutation 
quantified by qRT-PCR in in rectal biopsies and organoids from the COPD patient with the 
G542X/G576A-R668C genotype. To assess the abundance of the transcripts we used primers 
specific for the G542X mutation. RNA from another patient with the F508del/G542X genotype and a 
non-CF individual were used as controls. Data shown here are mean values (see Methods) using 
RNA extracted from rectal biopsies (n=3) or intestinal organoids (n=3). 
 
Figure 3.14 - Relative abundance of CFTR transcripts resulting from exon 13 skipping quantified by qRT-
PCR in rectal biopsies and organoids from the COPD patient with the G542X/G576A-R668C genotype. To 
assess the abundance of the transcripts we used primers specific for exon 13 skipping. RNA from another patient 
with the F508del/G542X genotype and a non-CF individual were used as controls. Data shown here are mean 
values from qRT-PCR experiments (see Methods) using RNA extracted from rectal biopsies (n=3) or intestinal 
organoids (n=3). 
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4.Discussion  
The G576A variant is currently described as a non-CF causing mutation in the CFTR2 
database (www.cftr2.org/2017) (Figure 3.14 - Relative abundance of CFTR transcripts resulting from 
exon 13 skipping quantified by qRT-PCR in rectal biopsies and organoids from the COPD patient with the 
G542X/G576A-R668C genotype. To assess the abundance of the transcripts we used primers specific for exon 
13 skipping. RNA from another patient with the F508del/G542X genotype and a non-CF individual were used as 
controls. Data shown here are mean values from qRT-PCR experiments (see Methods) using RNA extracted from 
rectal biopsies (n=3) or intestinal organoids (n=3). 
, Table 3.16). However, some studies have detected this mutation in individuals with both 
classical CF symptoms and in patients who have evidence of a clinical disease only in a 
subgroup of the organ systems qualifying to have a CFTR-related disorder (CF-RD) or "CFTR-
opathies". These forms, including late-onset pulmonary disease, congenital bilateral absence 
of vas deferens (CBAVD), or idiopathic pancreatitis frequently show a genetic diagnostic 
challenge due to the unclear genotype–phenotype correlation (Pignatti et al., 1995). Pagani 
and colleagues (Pagani et al., 2003) have showed that the G576A mutation leads to exon 13 
skipping and an increase of aberrant transcripts when the R668C change in exon 14 is also 
present. The authors describe exonic regulatory sequences involved in the splicing process 
and highlighted the importance of analysing missense changes, even if they have been found 
in normal chromosomes, because they can affect the levels of CFTR expression. 
Table 3.16 – Number of alleles and Classification of studied mutations in the CFTR2 database. 
 
In summary, in this study we have analysed a 67-year COPD (smoker) female patient with 
the G542/G576A-R668C genotype for CFTR function and CFTR mRNA expression in patient-
derived materials, so as to correlate clinical phenotype with functional CFTR levels. Despite 
the 2 CFTR mutations identified, the expressed phenotype is not suggestive of CF, which was 
confirmed by the functional analysis of the CFTR protein: normal activity results for CFTR-
mediated Cl- secretion assessed in micro-Ussing chamber and by FIS assay in intestinal 
organoids. Although about 2,000 CFTR mutations have been reported in the CFTR gene, most 
do not have an established/ excluded pathogenic role. While the Mediterranean mutation 
G542X is described as having a deleterious role, the G576A mutation was initially considered 
neutral and was not associated with classical CF. However, this variant induces changes in 
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the splicing process (exon 13 skipping), leading to the production of normal and aberrant 
transcripts. Thus, the variable levels of resulting abnormal transcripts can be related to 
different phenotypes and CFTR-related diseases. It is estimated that only about 10% of the 
ionic transport preserved is necessary to ensure that there are no manifestations of the CF 
disease. 
Analysis of the CFTR gene may lead to the identification of mutations of uncertain 
pathological significance and their study can help lessen the therapeutic and psychological 
burden. The phenotypic heterogeneity of CF, disease-modifying genes and environmental 
factors give rise to different expressions that render the interpretation of the genotype 
challenging. In select cases the functional study of the CFTR protein may be a valuable aid. 
In conclusion, despite the observation that two CFTR mutations were identified in this 
COPD patient and that the complex-allele is of unknown prognosis, analysis of the CFTR 
function was very relevant, since we could observe that the levels of CFTR activity were within 
the normal range leading to the exclusion of a diagnosis of CF. Nevertheless, it is very likely 
that the patient’s CFTR genotype (that greatly reduces the expression of normal CFTR 
transcripts) potentiated the pathological effects of tobacco, and can be related to the 
development of more acute respiratory symptoms than those that would be observed in an 
individual with normal copies of the CFTR gene. 
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Chapter 2 - mRNA-based Detection of Rare CFTR Mutations 
Improves Genetic Diagnosis of Cystic Fibrosis in Populations with 
High Genetic Heterogeneity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data included in this chapter are included in (with minor alterations)  
Felício V, Ramalho AS, Igreja S, Amaral MD (2017) mRNA-based Detection of Rare 
CFTR Mutations Improves Genetic Diagnosis of Cystic Fibrosis in Populations with High 
Genetic Heterogeneity. Clin Genet 91: 476-481. [PMID: 27174726] 
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1. Abstract 
Even with the advent of next generation sequencing complete sequencing of large disease-
associated genes and intronic regions is economically not feasible. This is the case of cystic 
fibrosis transmembrane conductance regulator (CFTR), the gene responsible for cystic 
fibrosis (CF). Yet, to confirm a CF diagnosis proof of CFTR dysfunction needs to be obtained, 
namely by the identification of two disease-causing mutations. Moreover, with the advent of 
mutation-based therapies, genotyping is an essential tool for CF disease management. There 
is, however, still an unmet need to genotype CF patients by fast, comprehensive and cost-
effective approaches, especially in populations with high genetic heterogeneity (and low 
p.F508del incidence), where CF is now emerging with new diagnosis dilemmas (Brazil, Asia, 
etc). Herein, we report an innovative mRNA-based approach to identify CFTR mutations in 
the complete coding and intronic regions. We applied this protocol to genotype individuals with 
a suspicion of CF and only one or no CFTR mutations identified by routine methods. It 
successfully detected multiple intronic mutations unlikely to be detected by CFTR exon 
sequencing. We conclude that this is a rapid, robust and inexpensive method to detect any 
CFTR coding/intronic mutation (including rare ones) that can be easily used either as a primary 
approach or after a routine DNA analysis. 
 
Keywords: CF diagnosis; genotyping; intronic mutations; rare mutations; splicing. 
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2. Introduction 
Cystic fibrosis (CF; MIM# 219700) the most frequent, life-threatening monogenic disorder 
in Caucasians, is dominated by the respiratory disease, the main cause of morbidity and 
mortality. Other CF symptoms include pancreatic insufficiency (PI), gastrointestinal, elevated 
chloride (Cl−) in sweat (the basis of the most common diagnostic test) and male infertility, with 
wide clinical variability in organ involvement (reviewed in (Rowe et al., 2005)). 
CF is caused by mutations in a single gene the cystic fibrosis transmembrane conductance 
regulator gene (CFTR; MIM #602421; GenBank NM 000492.3), one of the largest human 
genes with 27 exons spanning ∼190 kb and encoding a Cl− channel. Although one single 
mutation – p.F508del – accounts for ∼70% of CF chromosomes, ∼2000 CFTR gene variants 
were reported (Cystic Fibrosis Mutation Database, 2017), posing considerable challenges to 
the establishment of a genetic CF diagnosis, particularly in populations of low p.F508del 
incidence. 
Classical CF diagnosis is suggested by characteristic clinical features, a CF sibling or, more 
recently, by a positive (Newborn screening) NBS result (Levy et al., 2016). Nevertheless, to 
confirm a CF diagnosis, evidence of CFTR protein dysfunction is required (De Boeck et al., 
2006; Farrell et al., 2008; Amaral, 2014), namely by identification of two CFTR mutations of 
established disease liability (Sosnay et al., 2013; CFTR2, 2018), two abnormal sweat-Cl− tests 
(≥ 60 mEq/l), distinctive transepithelial nasal potential difference measurements or 
absence/reduced CFTR-mediated Cl− secretion in rectal biopsies (Ratjen and Döring, 2003). 
However, non-classical CF, with borderline sweat-Cl− levels (30–60 mEq/l) symptoms 
suggestive of CF and/or a familial CF history, often lead to no (or just one) CFTR mutation 
identified by routine panels (Feldmann et al., 2003). This is particularly striking in populations 
with high genetic heterogeneity (and low p.F508del incidence), where CF is now emerging 
with new diagnosis dilemmas (Brazil, Asia, etc), due to these regional differences. Also, 
extended NBS programmes which identify a significant proportion of asymptomatic NBS-
positive individuals (Farrell et al., 2008; Levy et al., 2016), require fast and cost-effective 
genetic analyses to identify the CF-causative mutations, along with clinical follow up. 
Moreover, new mutation-specific therapies using CFTR modulators, are now in the clinic (De 
Boeck and Amaral, 2016), with knowledge of the genotype being thus critical for adequate 
patient management. 
Herein, we report a fast and inexpensive mRNA-based protocol to identify CFTR mutations 
in the complete coding and intronic regions using just nine polymerase chain reactions (RT-
PCR), and one assay for p.F508del. Robustness is shown by its successful application to 
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genotype eight individuals with a suspicion of CF but with only one or no CFTR mutation 
identified by routine methods. 
3. Results 
CFTR mutation analysis using nine RT-PCR reactions and p.F508del by amplification-
refractory mutation system (ARMS) 
We established an mRNA-based protocol to detected CFTR mutations which covers the 
complete coding region using nine RT-PCR reactions (Figure 3.15A, Table 2.4). In case no 
previous panel of mutations had been analysed before, reaction no. 4 should be performed in 
duplicate with two different forward primers (4N, 4M), both using the same reverse primers 
(see end of Table 2.4) so as to identify/exclude the most prevalent mutation. This p.F508del-
ARMS specifically amplifies either the normal or transcripts containing the p.F508del 
sequence (Figure S 3.1). The fragments resulting from the nine RT-PCR reactions (Figure 
3.15B) cover the complete coding analysis of the CFTR gene and through their DNA 
sequencing any mutation lying on this region can be detected. Also, comparing the size of the 
RT-PCR products obtained with the expected ones, identifies aberrant transcripts resulting 
from splicing mutations and/or deletions and insertions, as shown here in transcripts from four 
CF individuals (Figure 3.16 and Figure 3.17). 
Figure 3.15 - mRNA-based cystic fibrosis transmembrane conductance regulator (CFTR) 
mutation analysis. (A) Diagram showing the distribution of nine reactions used to analyse the 
complete CFTR coding region and also to detect consequences of splicing mutations that lead to 
alternative transcripts. *Reaction 4 can be performed in duplicate with two different forward primers 
so as to detect the p.F508del mutation by the amplification-refractory mutation system (ARMS) 
technique (see text and Figure 3.16 for details). (B) Representative result of the nine polymerase 
chain reaction (RT-PCR) products plus the two p.F508del-ARMS reactions (see also Table 2.4). 
Products of the nine RT-PCR reactions were analysed by 2% (w/v) agarose gel electrophoresis 
(lanes 1–9) covering the entire coding region of CFTR RNA. Results from the two ARMS reactions 
are also shown: one specific for the normal sequence at the F508 site and another specific for 
p.F508del (lanes 4N and 4M, respectively). M – 100bp molecular weight markers. 
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Detection of a CFTR mutation deep in intron 10 
Applying the exon 10-12 PCR strategy (Figure 3.16A) to individual P8 (Figure 3.16B, lane 
1) led to observation of an upper band (311 bp) in addition to the expected one (207 bp) 
revealing the presence of a cryptic exon (104 bp) resulting from the inclusion of a region within 
IVS10.  
Sequencing of genomic DNA (gDNA) from individual P8 in the IVS10 region confirmed the 
presence of 1584+18672A>G, a previously reported mutation (Costantino et al., 2010) which 
lies deep in IVS10 and thus would escape identification by extended DNA analysis of exons 
and flanking sequences. 
 
Figure 3.16 - Detection of a mutation leading to the generation of a cryptic exon from IVS10. 
(A) Polymerase chain reaction (PCR) strategy for the cystic fibrosis transmembrane conductance 
regulator (CFTR) transcripts in the exon 10-12 region using the non-p.F508del specific forward 
primer (see Figure 3.15A). (B) Results of 3% (w/v) agarose gel electrophoresis of PCR products in 
this region from three individuals with a suspicion of CF or no CFTR mutations identified (P7, P8, 
P11) and one p.F508del-homozygous patient (ΔF) as a control. For the RT-PCR products of 
individual P8 (lane1), an upper band (of 311bp) is observed in addition to the faint band of the 
expected size (207bp). As expected this RT-PCR resulted in no amplification products for the 
p.F508del-homozygous individual (lane 3) because only the primer specific for the normal sequence 
was used (see Figure 3.15A). NC corresponds to the negative control (H2O) of the PCR. (C) 
Sequencing of the upper band in lane 1, revealed the presence of a cryptic exon (of 104bp) resulting 
from inclusion of a region within IVS10. 
 
Detection of various splicing mutations 
Figure 3.17 provides examples of mutations successfully identified in the regions of: (a) 
exons 1-6a; (b) exons 11-14a; (c) exons 13-17a; and (d) exons 16-19. P1 mRNA had an 
additional lower band in the exon 1-6a region (Figure 3.17A). cDNA sequencing confirmed 
that this results from exon 5 skipping (not shown), and is thus probably caused by an IVS5 
mutation. Sequencing of P1 gDNA IVS5 identified the 711+3A>T (HGVS: c.579+3A>T) 
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mutation. 
Transcripts from all individuals showed a lower band in the exon 11-14a region (Figure 
3.17B), confirming that low levels of exon 12 skipping are a common occurrence even in non-
CF individuals due to the presence of neutral single-nucleotide polymorphisms (Steiner et al., 
2004). However, because in P4 this band was of high intensity, we performed IVS12 gDNA 
sequencing which identified the 1812-1G>A (HGVS: c.1680-1G>A) mutation. 
For P1 and P4, an additional lower band in the exon 13-17a region was detected (Figure 
3.17C) and its sequencing confirmed that it corresponds to exon 16 skipping (not shown), 
which is suggestive of an intronic mutation. This was confirmed by IVS16 gDNA sequencing, 
which identified 3120+1G>A (HGVS: c.2988+1G>A) in both P1 and P4. 
RT-PCR products in the exon 16-19 region (Figure 3.17D) revealed an additional higher 
band in P3 which, given its length (∼25 extra nts, not shown), was hypothesised to correspond 
to an extended exon 17a due to the previously characterised 3272-26A>G (HGVS: c.3140-
26A>G) mutation (Amaral et al., 2001), which is common in Portugal. Indeed, sequencing of 
IVS17a gDNA confirmed this mutation in P3. 
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Figure 3.17 - Application of the polymerase chain reaction (RT-PCR) strategy to successfully 
detect multiple splicing mutations. Examples of four out of the nine RT-PCR reactions to analyse 
cystic fibrosis transmembrane conductance regulator (CFTR) transcripts in the regions of: (A) exons 
1-6a; (B) exons 11-14a; (C) exons 13-17a; and (D) exons 16-19. Images show PCR strategy with 
primers used (left panels) and respective data for the transcripts of individuals under study (right 
panels). (A) Detection of 711+3A>T (HGVS: c.579+3A>T). RT-PCR products in the exon 1-6a region 
evidence an additional lower band in P1, not occurring in P2-P4. Based on size, this is probably due 
to a mutation causing IVS5 skipping which was confirmed by gDNA sequencing (IVS5) identifying 
711+3A>T in P1. (B) Detection of 1812-1G>A (HGVS: c.1680-1G>A). RT-PCR products in the exons 
11-14 a region show a lower band in all individuals analysed, corresponding to IVS12 skipping. InP4, 
this lower band is of higher intensity that in the others, probably due to a mutation enhancing IVS12 
skipping, as confirmed by sequencing of gDNA, identifying 1812-1G>A in P4. (C) Detection of 
3120+1G>A (HGVS: c.2988+1G>A). Analysis of CFTR mRNA in the exon 13-17a region shows an 
additional lower band in both P1 and P4, which is absent in P2 and P3. Based on size, this is probably 
due to a mutation causing IVS16 skipping, as confirmed by sequencing of gDNA, which identified 
3120+1G>A in both P1 and P4. (D) Detection of 3272-26A>G mutation (HGVS: c.3140-26A>G). RT-
PCR products in the exon 16-19 region show an additional higher band in P3 which is absent in the 
others. By sequencing this band, it was found to have∼25 extra nts (not shown) and gDNA 
sequencing (IVS17a) identified 3272-26A>G in P3. M-DNA molecular mass markers 100bp (a, c) or 
1kb (b). 
 
 
79 
 
4. Discussion 
In the era of mutation-specific therapies for CF, it is critical to determine the patients’ 
genotype for adequate clinical management. Given its large size and the very high number of 
gene variants reported there is a need to establish robust, yet inexpensive methods to identify 
CFTR gene mutations. 
CFTR genetic analysis panels, which should achieve a mutation detection rate>95%, fail 
to do so in populations with lower p.F508del incidence e.g. in Southern Europe, and even 
more so in those with high genetic heterogeneity, namely in South-America, Asia or Africa, 
making this goal extremely challenging. Even with the advent of NGS, complete sequencing 
of large disease-associated genes and intronic regions is economically not feasible. Often 
these approaches still fail to identify intronic mutations because only the exons and the intronic 
flanking regions are sequenced. Due to the large size of introns, it is not cost effective to 
sequence them fully and thus it was estimated that 1–5% of CF alleles remain to be 
determined (Groman et al., 2002). Consequently, there is an unmet need to genotype CF 
patients by fast, comprehensive and cost-effective approaches. 
The simple, inexpensive mRNA-based protocol reported here covers the complete CFTR 
coding region in just nine RT-PCR reactions which, despite requiring sequencing are 
considerably less expensive than the usual 28 gDNA PCR reactions (Bonini et al., 2015). This 
approach also directly identifies aberrant transcripts resulting from intronic splicing mutations 
and gene deletions/insertions. Although gDNA sequencing should follow to identify the 
causative mutation, it will be limited to one (or two) intron(s). Using just one additional RT-
PCR p.F508del-ARMS reaction, this approach also detects the most frequent CF mutation. 
One disadvantage, however, is the requirement of specific tissue (e.g. nasal or rectal). 
Nevertheless, collection of nasal cells is a simple procedure (Beck et al., 1999) which is 
becoming increasingly used. 
The robustness of the approach was shown here by its application to successfully detect 
multiple mutations in eight different individuals with a suspicion of a CF diagnosis, including 
several in the introns, including for example the c.1584+18672A>G mutation, associated with 
classical CF (Costantino et al., 2010) which causes an insertion of a cryptic 104 bp exon 
between IVS10 and 11. Because this mutation lies deep within IVS10, it would be very unlikely 
to be detected by conventional approaches. 
Other mutations identified included: 711+3A>T (HGVS: c.579+3A>T) causing IVS5 
skipping and (when in trans with R334W) associated milder CF disease and pancreatic 
sufficiency (Casals et al., 1997); 1812-1G>A (HGVS: c.1680-1G>A) promoting IVS12 skipping 
and originally described in Spain in association with severe CF, PI and lung colonisation 
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(Chillón et al., 1994); 3120+1G>A (HGVS: c.2988+1G>A) abrogating IVS16 splicing is 
reported to be common in African/Afro-descendant patients (9–14% of CF chromosomes) in 
association with a severe clinical phenotype (Carles et al., 1996) and is also common in Brazil 
(Cabello et al., 2001); 3272-26A>G (HGVS: c.3140-26A>G) was reported in Portugal creating 
abnormal splicing in IVS17a and is associated with milder CF (Amaral et al., 2001). 
5. Concluding remarks 
Based on the successful detection of mutations in this cohort of CF patients, we conclude 
that the rapid, easy-to-perform mRNA-based method described here is a robust approach to 
detect rare coding or intronic CFTR mutations. It can be easily performed either as a first 
screen or after the routine DNA analysis. It is also significantly less expensive than NGS 
approaches. Furthermore, it already shows the functional consequences of mutations in case 
they occur at the RNA level. 
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6. Supplementary Information  
 
Figure S 3.1- Representative results of the F508del-specific ARMS technique. Analysis by 2% 
(w/v) agarose gel electrophoresis of F508del-specific ARMS products for 3 individuals with a 
suspicion of CF (A,B,C). For the cDNA of each individual, two PCR reactions were performed: I with 
the F508del-specific primer; II - with primer specific for the normal sequence at the F508del site (see 
also Table 2.4). In all reactions, an additional PCR product is generated (‘Control PCR’) to control 
for PCR amplification. Individual A (lanes 1,2) is homozygous for F508del mutation, since there was 
only specific amplification in reaction I (lane 1); individual B (lanes 3,4) does not have the F508del 
mutation, since there was only specific amplification in reaction II (lane 4); individual C (lanes 5,6) is 
heterozygous for F508del, since there was specific amplification in both reactions I (lane 5) and II 
(lane 6); NC (lanes 7,8) PCR negative control (water instead of cDNA). 
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Chapter 3 - A High-Throughput shRNA Screen to Identify Genes 
Rescuing CFTR Mutations Bearing Premature Termination Codons 
(PTCs). 
1. Abstract 
Background: Nonsense mutations, which introduce premature stop codons (PTCs) 
account for about 8% of the ~2,000 CFTR gene variants reported in the CFTR Mutation 
Database. These mutations usually lead to extensive transcript degradation by nonsense-
mediated mRNA decay (NMD) thus preventing protein production. PTC mutations are 
therefore usually associated with classical severe CF phenotypes. Several drugs promoting 
PTC suppression (or read-through) such as aminoglycoside antibiotics and Ataluren have 
shown some in vitro ability to suppress PTCs, albeit unspecifically, and show toxicity and low 
efficacy . Nevertheless, they have been under trial for CF, but were discontinued due to lack 
of demonstrated efficacy. There is thus an unmet need to treat patients with these mutations 
and novel therapeutic strategies should be explored. 
Aim: Our aim is to identify novel genes which when knocked-down rescue either NMD of 
these transcripts or show PTC read-through (or both) and to validate them as novel drug 
targets. 
Methods: To achieve this goal, we have used a CFTR mini-gene model (i.e., full-length 
CFTR cDNA with introns IVS14, 15 and 16; legacy name IVS13, 14a and 14b) harbouring the 
G542X mutation (at exon 12; legacy name 11), which recapitulates NMD process shown in 
vivo. The mini-gene features mCherry and eGFP tags at the CFTR N- and C-termini, 
respectively which allow the assessment of total  CFTR protein levels (mCherry) as a readout 
of NMD and rescue of full-length protein (eGFP) as a readout of read-through. The construct 
also has a Flag-tag which becomes extracellular once the mCherry-Flag-G542X-CFTR-eGFP 
protein reaches the plasma membrane (which may not occur to all full-length proteins 
produced given the random insertion of amino acids in read-through). This construct was 
transfected into HEK293 Flp-In cells for stable expression, in parallel with a similar wt-CFTR 
construct. To validate this NMD reporter assay, we used the NMD inhibitor - SMG1 inhibitor 
(InhSMG1) as a positive control. The NMD correction was assessed by: (i) semi-quantitative RT-
PCR; (ii) high-throughput (HT) microscopy analysis. 
Results and Discussion: Our RT-PCR data show that levels of G542X-CFTR transcripts 
in non-treated and InhSMG1 treated cells were: 20% and 60%, respectively. By fluorescence 
microscopy we could not determine the presence of eGFP fluorescence in InhSMG1 treated cells 
because SMG1 inhibition only prevents NMD but has no read-through activity. However, we 
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observed a 5-fold increase in mCherry fluorescence, indicating a good dynamic range for 
detection of NMD suppression, thus validating the reporter assay for HT microscopy. Next, we 
used this CFTR-NMD reporter to identify novel NMD factors by screening a previously 
validated shRNA library – a subset of The RNAi Consortium (TRC) – which is enriched in 
shRNAs targeting genes with a previously described, or proposed involvement in transcript 
processing (425 genes). We selected 24 genes for additional validation: 11 genes with a NMD 
score ≥ 2 and more than 2 shRNAs with the same phenotype; 2 genes with a NMD score ≥ 2 
and one shRNA that showed read-through activity; and 11 genes resulting from a HTS screen 
designed to identify CFTR splicing regulators (unpublished data). These splicing-related 
genes (S Igreja & MD Amaral, unpublished data) were also analysed because a relationship 
between NMD and splicing has been previously described. Our confirmation screen was 
inconclusive, since the NMD scores obtained were very low. 
Conclusion: Some of the genes identified within this screen are potential drug targets due 
to their effects in inhibiting NMD, when knocked-down. To validate the 24 genes we are 
currently conducting validation assays including RT-PCR (qRT-PCR), and Western blot 
assays. 
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2. Introduction 
Cystic fibrosis (CF) is the most common autosomal recessive disorder affecting 
approximately 85,000 individuals worldwide and around 34,000 individuals in Europe. 
Mutations in the CF Transmembrane conductance Regulator (CFTR) gene lead to absence 
or dysfunction of the CFTR protein, which is involved in the regulation of Cl-/HCO3- ion 
transport across the apical membrane at the surface of the epithelia. Mutated CFTR channels 
result in malfunctioning lungs, pancreas, and other organs. Indeed, defective CFTR protein 
leads to decreased airway surface liquid (ASL height) and dehydration, defective muco-ciliary 
clearance (MCC), mucus-clogged airways, recurrent bacterial infections, progressive loss of 
lung function with extensive lung damage, and eventually respiratory failure (Cutting, 2015; 
De Boeck and Amaral, 2016).  
Until recently CF was just managed at the level of its symptoms, with patients being 
prescribed antibiotics, anti-inflammatory and mucolytics, to help alleviate infections, chronic 
inflammation and excessive production and thickness of mucus. However standard medical 
care is still far from providing appreciable levels of life quality for the patients. 
Intensive drug discovery efforts have resulted in recent progress and approval of new 
CFTR-modulator therapies. These include CFTR correctors (lumacaftor and tezacaftor) that 
improve mutant protein folding and trafficking, and a potentiator (ivacaftor) that increases 
chloride channel activity. Approval of Kalydeko™ (ivacaftor) marked a milestone in CF 
therapeutics development, and with the advent of personalized medicine, these approaches 
could potentially revolutionize CF care and management (Amaral and Blach, 2015; Cutting, 
2015; Schneider et al., 2017). 
There are approximately 2,000 mutations described in the CFTR gene, comprising 
missense (39%), frameshift (16%), splicing (11%) and nonsense (8%) mutations; large (3%) 
and in-frame (2%) deletions or insertions; promotor mutations (1%); presumed no-pathological 
variants (13%) and unknown mutations (7%) (Cystic Fibrosis Mutation Database, 2017). 
According to their functional defects seven classes of mutations have been proposed (De 
Boeck and Amaral, 2016; Cystic Fibrosis Mutation Database, 2017). Most of these mutations 
cause CFTR protein defects by impairing protein translation, folding and stability, trafficking, 
and/or function.  
However, many challenges remain in designing therapies for CF patients that present 
mutations in the CFTR gene which cannot be treated with the approved therapeutics (Fajac 
and Wainwright, 2017; Kerem, 2017; Marson, 2017). Among the ~2,000 CFTR gene variants 
reported, a significant fraction (~24%) generate PTCs, including: 8.4% nonsense and 15.7% 
frameshift mutations. PTC mutations lead to a significant reduction, or total absence, of normal 
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CFTR mRNA and protein expression, and are commonly associated with a severe clinical 
phenotype (Keeling et al., 2014a). Reduction in the levels of transcripts occurs via the mRNA 
surveillance mechanism termed Nonsense-Mediated mRNA Decay (NMD) which selectively 
degrades mRNAs harboring PTCs. To date, there are no CFTR modulator therapies to treat 
patients harboring PTC mutations, and although aminoglycoside antibiotics (used in the 
standard treatment of CF lung infections) and Ataluren/PTC-124 have shown some ability to 
suppress PTCs in vitro, they are unspecific, and show low efficacy. Nevertheless, they have 
been under clinical trials for CF, but were discontinued due to lack of demonstrated efficacy. 
As such, there is an unmet need to find novel therapeutic strategies to treat these patients. 
NMD is an essential RNA quality control and gene regulatory mechanism conserved among 
eukaryotes. This surveillance mechanism detects and ensures the rapid degradation of PTC-
harbouring mRNAs that could potentially result in the synthesis of C-terminally truncated 
proteins. Hence, the quality control function of NMD is centered on protecting the cell from 
expressing deleterious dominant-negative or gain-of-function (toxic) truncated proteins. 
Additionally, this regulatory mechanism also plays an important role in modulating the 
phenotypes resulting from diseases caused by PTCs (Linde et al., 2007; Kervestin and 
Jacobson, 2012; Peixeiro et al., 2012). The efficiency of the NMD pathway can vary by as 
much as 4-fold among the general population. Importantly, these differences in NMD efficiency 
may influence and modulate the clinical severity of numerous disorders, possibly due to 
changes in mRNA abundance, which influences the levels of truncated protein which may still 
retain residual function (or full-length protein produced by basal PTC read-through). (Khajavi 
et al., 2006; Keeling et al., 2014b). Furthermore, variable levels of NMD among patients can 
also influence the effectiveness of nonsense suppression therapies. Patients who express 
higher levels of PTC-containing mRNA, due to less efficient NMD, are expected to respond 
more robustly to suppression/read-through therapies, compared to patients who express lower 
levels of PTC-mRNA due to highly efficient NMD (Wilschanski et al., 2003; Linde et al., 2007). 
Based on its role in regulating the abundance of PTC-containing transcripts, the NMD 
pathway represents a potential therapeutic target for diseases caused by PTCs. Numerous 
regulatory subunits have been implicated in the NMD pathway, including the core NMD factors 
UPF1, UPF2, and UPF3 as well as other factors that influence the phosphorylation status of 
UPF1, such as SMG-1, SMG-5, SMG-7, SMG-8, and SMG-9 (Kervestin and Jacobson, 2012; 
Schweingruber et al., 2013; Yamashita, 2013; Lykke-Andersen and Heick Jensen, 2015). 
Therefore, it seems plausible that increasing the level of PTC-containing mRNAs, by inhibiting 
NMD through the use of drugs that target NMD factors, would be a good therapeutic strategy. 
This, could potentially alleviate some disease phenotypes by increasing the expression of 
truncated polypeptides that could still retain some residual function, but especially in 
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combination with agents promoting read-through of the PTCs which would enable the 
production of "full-length" functional proteins (Keeling et al., 2014b; Mutyam et al., 2016; Liang 
et al., 2017). 
Herein, our aim was to identify novel factors that modulate NMD of CFTR transcripts 
bearing PTCs. For this purpose, we have generated a novel triple-tagged CFTR NMD-PTC 
read-through reporter mini-gene (see section II – Material and Methods) which enables the 
detection of both NMD inhibition and PTC read-through. This mini-gene model was then used 
to screen a library of 425 genes, with a known or predicted involvement in transcript 
processing (Moura-Alves et al., 2011). The screening of these 425 genes yielded 11 hits. 
Using two different criteria, we have identified 11 top hits, i.e. genes which when suppressed 
inhibit NMD. Some of these NMD inhibitors were selected for further confirmation in an 
independent siRNA screen.  
3. Results 
3.1 Development and validation of stable cell lines for the HTS assay 
To identify factors involved in NMD, which may be potential therapeutic targets, we have 
generated an NMD-PTC CFTR mini-gene model (i.e., full-length CFTR cDNA with mCherry at 
the C-terminus and eGFP at the N terminus plus introns IVS14, 15 and 16; legacy name 
IVS13, 14a and 14b), similar to a previously reported gene model (Igreja et al., 2016) but 
containing the NMD inducing G542X mutation in IVS12 (Figure 3.18). This mini-gene construct 
also bears a flag-tag at the CFTR 4th extracellular loop, which becomes extracellular once the 
mCherry-Flag-G542X-CFTR-eGFP protein reaches the plasma membrane (which may not 
occur to all full-length protein produced given the random insertion of amino acids in read-
through). Due to the presence of G542X, this construct leads to a lower production of CFTR 
transcripts (Figure 3.19A).  
 
Figure 3.18 - Schematic representation of three possible assay readouts. Possible results 
obtained from the mCherry-GX-eGFP construct. Construct without any treatment leads to almost no 
fluorescence, since we have degradation by NMD. Inhibition of NMD leads to a truncated protein, 
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since we still have G542X mutation and the transcripts stop at this point. Full-length protein with 
mCherry and eGFP fluoresce once no NMD occurs and we have read-through the mutation.  
To validate our NMD report, we first analysed the construct’s performance by Western blot 
(WB) and semi-quantitative RT-PCR to ensure that the introduction of mCherry and eGFP with 
the three introns did not influence folding and traffic to the membrane (Figure 3.19) or lead to 
the production of a truncated protein in the wt construct.  
For WB validation, HEK Flp-In cells stably transfected with the mini-gene were treated with 
DMSO for 48 h and protein was extracted. For semi-quantitative validation, cells stably 
transfected were treated with DMSO and SMG-1 inhibitor, a previously described NMD 
inhibitor (Yamashita, 2013) (kindly provided by M. Mense, CFFT labs) which was used as a 
positive control. SMG-1 is a member of the phosphoinositide 3-kinase-related kinase (PIKK) 
family that plays a critical role in NMD. SMG-1 directly phosphorylates UPF1 helicase, a key 
component of NMD, upon recognition of a PTC in the spliced mRNA, during the initial round 
of translation (Kervestin and Jacobson, 2012; Celik et al., 2015; Fatscher et al., 2015; Lykke-
Andersen and Heick Jensen, 2015).  
Figure 3.19 - Representative characterization of the wt and mutant NMD constructs by semi-
quantitative RT-PCR and Western blot. (A) Quantification of CFTR transcripts by semi-quantitative 
RT-PCR for the wt-mCherry-wt-eGFP and mCherry-GX-eGFP constructs after cells treated with 
DMSO and InhSMG1. (B) WB shows the mCherry-GX-eGFP construct (lane 1) resulting in no CFTR 
protein production, as expected, due to the presence of the G542X mutation; mCherry-wt-eGFP 
(lane 2) showing both the core-glycosylated (band B) and the fully-glycosylated (band C) forms; and 
three different wt-CFTR constructs of smaller size: complete wt-CFTR-eGFP cDNA with eGFP in C-
terminal (lane 3); complete cDNA mCherry-wt-CFTR with IVS’s 14, 15 and 16 and m-Cherry in N-
terminal (lane 4); and finally complete cDNA CFTR wt with intron 14, intron 15 and intron 16 (lane 
5), all evidencing the presence of both band B and band C. 
We can conclude that all wt mini-genes produce normal CFTR protein, i.e., with both fully 
glycosylated (band C) and core-glycosylated (band B) forms. Additionally, it was possible to 
confirm that no normal protein was produced from the G542X mutant, since no CFTR protein 
was detected.  
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After confirmation and validation of the constructs by RT-PCR and WB, we analysed the 
expression of mCherry and eGFP tags in both constructs under DMSO or InhSMG1 conditions 
by fluorescence microscopy to validate the assay (Figure 3.20). To this end, HEK Flp-In cells 
stably transfected with the construct were treated with DMSO and InhSMG1 and were imaged 
after Hoescht staining (see Materials and Methods, section 4.2). 
 
 
Figure 3.20 - Representative microscopy images of the NMD/PTC assay under control 
conditions. (A) Microscopy images of the stable mCherry-wt-eGFP (left column) and the mCherry-
GX-eGFP HEK cells (middle and right columns) treated with DMSO (left and middle columns) or with 
the InhSMG1 compound, an NMD inhibitor used as positive control (right column). Images show: 
Hoechst staining of the nuclei (top row), mCherry (middle row) and eGFP (bottom row). Scale 
bar=25µm. (B) Quantification of the data in A (n= 3). * means p < 0.05. 
The expression of the mCherry-GX-eGFP NMD reporter was noticeable after 48 h of 
incubation, being significantly higher in cells treated with InhSMG1 vs control cells, i.e., under 
DMSO (Figure 3.20). These results show the suitability of our model reporter to study NMD 
and its sensitivity to detect the effects of the inhibition of factors that influence NMD. 
Quantification of the data shown in Figure 3.20B revealed a 119% increase in the average 
fluorescence intensity of the positive control versus DMSO, which was found to be statistically 
significant, thus indicating that this assay had an adequate dynamic range to be used in a HT 
screen.  
3.2 HT shRNA Primary screen 
To identify putative novel factors that inhibit NMD, which can be used to counteract the 
degradation of transcripts bearing PTCs, we used the above model in a high-throughput 
screen (HTS) of a shRNA library (NMD primary screen) containing factors with a known or 
predicted involvement in mRNA processing (Moura-Alves et al., 2011). The model was also 
A B 
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used to screen an siRNA library with 24 genes selected from the primary screen (NMD 
confirmation screen). Finally, the same cellular model was used to validate the most relevant 
targets using two different techniques: WB and qRT-PCR (Figure 3.21).  
 
The primary screen was performed using a library of 425 genes (Table S 4.3) with an 
average of 5 shRNAs per gene in a total of 1967 shRNAs. To analyse this library, we used HT 
microscopy and image quantification, the latter was performed using CellProfiler. Statistical 
analysis was performed using shinyHTM (See Materials & Methods – section 4). After image 
acquisition we used CellProfiler and shinyHTM to apply a quality control (QC) to each well and 
each cell, in order to exclude out of focus images, images with high background fluorescence, 
and also to discard samples in which cells had too large or too small nuclei, or cellular damage, 
as well as apoptotic and mitotic cells (See Material & Methods – section 4.3). Each image was 
characterized by the median value of "NMD inhibition" and after averaging the NMD Inhibition 
score for all images relating to the same shRNA and which passed QC, the effect of each 
shRNA towards NMD Inhibition was expressed as a deviation score versus the appropriate 
negative control. The distribution of scores for each shRNA is shown in Figure 3.22. Of these, 
75 shRNAs were shown to inhibit NMD with an NMD score ≥ 2 (Table S 3.1). By applying 
more stringent criteria, namely an NMD score ≥ 2 and at least 2 different shRNAs targeting 
the same gene (Figure 3.23 and Table S 3.1), as previously described (Moura-Alves et al., 
2011), 11 genes were identified as top hits (Table 3.17). These were selected for further 
confirmation. Unexpectedly, some of the genes which when knocked-down inhibited NMD, 
also promoted read-through activity (Figure 3.24 and Table S 3.1). Therefore, we also selected 
two of these genes (that have an NMD score ≥ 2 but just 1 shRNA with the same phenotype) 
for further confirmation (Table 3.17). The complete list of genes and respective scores are 
shown in Table S 3.1. 
After hit selection we performed a confirmation screen using siRNAs for the 13 genes 
selected and we also included 11 genes which were identified in a parallel screen for splicing-
associated genes (Figure 3.21, Table 3.18 and refer to section 3.3). We included these genes 
because the splicing process is closely associated with NMD, as such we thought it would be 
relevant to determine their effect on NMD. Some of the splicing hits were also identified in the 
NMD screen, however these either failed to pass the  QC analysis  or did not meet the 
restricted criteria. In summary, we selected 24 genes to be validated through a confirmation 
siRNA screen. Notwithstanding, the results of this confirmation screen were inconclusive, 
since the NMD scores obtained showed very low values possibly due to low transfection 
efficiency. Nevertheless, we selected 4 genes with higher values (Table S 3.2). Since the 
confirmation screen was inconclusive, we are currently performing validation studies for the 
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24 genes using different approaches including qRT-PCR and WB (data not shown; ongoing 
work performed by S Igreja, L Clarke & MD Amaral). 
 
Figure 3.21 – Workflow diagram of the study to identify novel genes which inhibit NMD or 
show PTC read-through. Data from the NMD primary screen using a shRNA library, a siRNA screen 
i.e. confirmation screen using top hits from the NMD primary screen and from a splicing primary 
screen (performed by Igreja S. & Amaral MD). Ongoing validation studies using WB and qRT-PCR. 
See text for details. 
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Figure 3.22 - Distribution of the shRNA scores for HTS NMD assay. (A) The distribution is 
determined according to the individual shRNA deviation from the negative control. NMD inhibitors 
are identified by having a ‘NMD score’ above +2, as described in Materials and Methods. (B) 
Distribution of top hits with a NMD score ≥ 2 and at least 2 shRNAs with the same phenotype.  
The screen was performed using the HEK Flp-In cell line stably transfected with the G542X-
mCherry-Flag-eGFP construct (abbreviated as mCherry-GX-eGFP cells). Analysis was 
performed using mCherry signal measured after 48h of incubation with the shRNAs. The N-
terminal mCherry allows the quantification of the total CFTR protein being expressed in 
individual cells and its integrated fluorescence signal in each cell is inversely proportional to 
the extent of NMD and thus proportional to NMD inhibition. This is defined as the amount of 
CFTR transcripts that escape NMD and give rise to a polypeptide (independently of whether 
it is truncated or not). NMD inhibition can then be determined in individual cells using the 
mCherry fluorescence: 
𝑁𝑀𝐷 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 ∝ mCherry Integrated Fluorescence 
The InhSMG1 was used as a positive control and a ‘scrambled’ shRNA as negative control. 
After nuclei staining, image acquisition was performed in a Leica DMI 6000B widefield 
epifluorescence microscope. Fluorescence intensities were measured using CellProfiler, and 
statistical analysis was performed in shinyHTM (see Materials and Methods). Results are 
presented according to the NMD score:  
𝑁𝑀𝐷 𝑆𝑐𝑜𝑟𝑒 =  
NMD Inhibition𝑖 −  NMD Inhibition𝑁𝑒𝑔𝐶𝑡𝑟𝑙
𝑆𝐸𝑀NMD Inhibition,𝑁𝑒𝑔 𝐶𝑡𝑟𝑙
 
 
Figure 3.23 - Representative images for two top shRNA hits inhibiting NMD. Representative 
microscopy images obtained from the stable mCherry-GX-eGFP HEK cells, 48h after being infected 
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with the library of shRNAs. Images show cells treated with: Scrambled shRNA (negative control, left 
column), InhSMG1 (positive control middle left column) and two hit shRNAs that inhibit NMD (middle 
right and right columns) as seen by the increased mCherry fluorescence (middle row). NMD score 
values for NMD are shown underneath. Scale bar = 20µm. 
 
Figure 3.24 - Representative images for two top shRNA hits exhibiting read-through activity. 
Representative microscopy images obtained for the stable mCherry-GX-eGFP HEK cells 48h after 
being infected with the shRNA library. Images show cells treated with: Scrambled shRNA (negative 
control, left column), InhSMG1 (positive control, middle left column) and two shRNA hits both inhibiting 
NMD and enhancing read-through activity (middle right and right columns) as seen by the enhanced 
mCherry (middle row) and eGFP (bottom row) fluorescence. The respective NMD score values for 
genes that have read-through activity are shown underneath. Scale bar = 20µm. 
Table 3.17 - Top shRNA hits for NMD with NMD score ≥ 2 and targeted by two or more shRNAs* 
 
*Identification of 11 hits after application of both criteria 
** Gene Name from UniProt Consortium (UniProt, 2018) 
*** Knocked-down genes that lead to read-through activity, (NMD score ≥ 2 but just 1 shRNA with the 
same phenotype) 
 
The top 11 genes that when knocked-down lead to NMD inhibition are listed in Table 3.17. 
Here we provide a brief description of each of them. 
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FLJ20273/RBM47 (RNA-binding protein, isoform CRA_d) constitutes the basic machinery 
for C to U RNA editing (Fossat et al., 2014). RBM47 encodes a protein that binds molecules 
of messenger RNA.  
A2BP1/ RBFOX1 (RNA binding protein fox-1 homolog 1) is an RNA-binding protein that 
regulates alternative splicing events by binding to 5-UGCAUGU-3 elements. It was shown to 
regulate alternative splicing of tissue-specific exons and of differentially spliced exons during 
erythropoiesis (Kuroyanagi, 2009; Gene Cards, 2018).  
NOVA2 (NOVA Alternative Splicing Regulator 2) is a protein coding gene. Gene Ontology 
(GO)annotations related to this gene include nucleic acid binding and RNA binding (Gene 
Cards, 2018).  
C21orf66/ PAXBP1 (PAX3 and PAX7 Binding Protein 1) encodes a protein that may bind 
to GC-rich DNA sequences, which suggests its involvement in the regulation of transcription 
(Gene Cards, 2018).  
NHP2L1/SNU13 (Small Nuclear Ribonucleoprotein 13) is a protein coding gene (Gene 
Cards, 2018) that binds to the 5-stem-loop of U4 snRNA and may play a role in the late stage 
of spliceosome assembly. The protein undergoes a conformational change upon RNA-binding 
(UniProt, 2018).  
WTAP (WT1 Associated Protein) is a protein coding gene that acts as an mRNA splicing 
regulator (Gene Cards, 2018).  
C10orf116/ADIRF (Adipogenesis Regulatory Factor) is a protein coding gene that plays a 
role in fat cell development by promoting adipogenic differentiation and stimulates 
transcription initiation. The protein is an adipocyte lineage-specific nuclear factor which 
regulates master adipogenesis transcription factors during early differentiation. However, the 
precise functional properties of this gene have yet to be identified. According to its GO it seems 
to be involved in distinct biological processes, including: cell differentiation; cellular response 
to cisplatin and positive regulation of transcription from RNA polymerase II promoter .(UniProt, 
2018).  
ERVWE1 (Endogenous Retrovirus Group W Member 1, Envelope) is a protein coding 
gene, which encodes an envelope glycoprotein (syncytin) with a likely involvement in 
trophoblast differentiation.  
HNRPK/HNRNPK (Heterogeneous Nuclear Ribonucleoprotein K) is a protein coding gene 
and is one of the major pre-mRNA-binding proteins that binds tenaciously to poly(C) 
sequences (UniProt, 2018).  
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RAVER1 (Ribonucleoprotein, PTB Binding 1) is a protein coding gene that cooperates with 
PTBP1 to modulate regulated alternative splicing events and also promotes exon skipping 
(Gene Cards, 2018).  
SFRS3 (Serine and Arginine Rich Splicing Factor 3) gene is a member of the 
serine/arginine (SR)-rich family of pre-mRNA splicing factors, which constitute part of the 
spliceosome (Gene Cards, 2018) and functions as a splicing factor that specifically promotes 
exon-inclusion during alternative splicing (UniProt, 2018). 
Two of the hits that lead to PTC read-through (Figure 3.23) - PPWD1 (Peptidylprolyl 
isomerase domain and WD repeat-containing 1) and RPS19 (40S ribosomal protein S19) have 
been previously implicated in the NMD process.  
PPWD1 was found to be part of the catalytically competent form of the spliceosome C 
complex (Jurica and Moore, 2003). It has been associated with the mRNA splicing pathway 
and it was shown to interact with two major proteins in the NMD process (Gene Cards, 2018).  
RPS19 is related to the NMD pathway and is required for pre-rRNA processing and 
maturation of the 40S ribosomal subunits (Fabregat et al., 2017; Gene Cards, 2018; UniProt, 
2018). According to Project (Fabregat et al., 2017), th3 RPS19 protein is related to NMD and 
is part of 6 complexes (i.e. SMG1:UPF1:EJC translated mRNP; UPF1:eRF3 Complex on 
translated mRNA) participating in 5 different reactions (i.e. Formation  UPF1:eRF3 complex 
on mRNA with a premature termination codon). This protein is also related with MAGOH and 
eIF4A3, two important components of EJC (Figure 3.25). 
 
Figure 3.25 - Representative image of the relationship between genes with read-through 
activity and NMD factors. PPWD1 and RPS19 represent a relationship with two very important 
factors for NMD to occur, i.e., MAGOH and ElF4A3 (Da Costa et al., 2017; Gene Cards, 2018). 
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3.3 Hit confirmation by secondary screen - siRNA confirmation screen 
The top hits from the NMD screen, i.e., those with an ‘NMD Score’ above +2 and targeted 
by at least 2 shRNAs with the same phenotype (Figure 3.23), were further validated using 
siRNAs targeting these genes. 13 hit genes from the primary screen were included in the 
confirmation screen (Table 3.17). In addition, we included siRNAs targeting 11 additional 
genes (Table 3.18) which were identified in a parallel HT screen for splicing associated genes 
(S Igreja & MD Amaral, unpublished data). We analysed these genes, because a relationship 
between splicing and NMD has been previously described with certain factors involved in 
splicing being also required for NMD to occur. Indeed, it is well known that many genes 
involved in the splicing process are also fundamental for NMD (Kashima et al., 2006; Moura-
Alves et al., 2011; Da Costa et al., 2017; Iwatani-Yoshihara et al., 2017). 
Table 3.18 – Genes identified by the HTS shRNA splicing screen* that were assessed for their effects on 
NMD 
 
*Identification of 11 hits in an independent splicing screen (S Igreja & MD Amaral, unpublished data) 
** Gene Name from UniProt Consortium (UniProt, 2018) 
                  - -  Genes discarded by QC in NMD Screen 
 
The genes included in the confirmation screen which were top hits in the splicing screen 
were also previously analysed in our NMD screen. However, they were excluded, either during 
the QC or because they did not meet the more restricted criteria used to identify the top hits.  
Here we provide a brief description of each of them. 
EIF4A3 (Eukaryotic initiation factor 4A-III) is an ATP-dependent RNA helicase, and a core 
component of the splicing-dependent multiprotein EJC deposited at splice junctions on 
mRNAs (Chan et al., 2004). Iwatani-Yoshihara and colleagues (Iwatani-Yoshihara et al., 2017) 
have shown in a recent study that eIF4A3 inhibitors supress NMD. 
SREK1 (Splicing regulatory glutamine/lysine-rich protein 1) encodes a member of a family 
of serine/arginine-rich (SR) splicing proteins containing RNA recognition motif (RRM) 
domains. The encoded protein interacts with other SR proteins to modulate splice site 
selection. It participates in the regulation of alternative splicing by modulating the activity of 
other splice factors (Gene Cards, 2018; UniProt, 2018). 
97 
 
HNRNPUL1 (Heterogeneous Nuclear Ribonucleoprotein U Like 1) is a protein coding gene. 
An important paralog of this gene is HNRNPU. It acts as a basic transcriptional regulator, 
represses basic transcription driven by several virus and cellular promoters, and plays a role 
in mRNA processing and transport. This protein binds avidly to poly(G) and poly(C) RNA 
homopolymers in vitro.  
XRCC6 (X-Ray Repair Cross Complementing 6) is a DNA repair gene and together with 
XRCC7 forms an integral part of the double strand break repair (DSBR) pathway. The two 
genes are thought to play an important role in the repair of lethal double strand damage on 
DNA. The complex functions as a single-stranded DNA-dependent ATP-dependent helicase 
(Singh et al., 2018; UniProt, 2018).  
CCNA1 (Cyclin A1) the protein encoded by this gene belongs to the highly conserved cyclin 
family, whose members are characterized by a dramatic periodicity in protein abundance 
through the cell cycle. Cyclins function as regulators of CDK kinases. This cyclin binds both 
CDK2 and CDC2 kinases, which have two distinct kinase activities, one appearing in S phase, 
the other in G2, and thus regulate separate functions in cell cycle (Gene Cards, 2018; UniProt, 
2018). 
RPL23A (Ribosomal Protein L23a) this gene encodes a ribosomal protein that is a 
component of the 60S subunit. The protein belongs to the L23P family of ribosomal proteins. 
It is located in the cytoplasm. The protein may be one of the target molecules involved in 
mediating growth inhibition by interferon. In yeast, the corresponding protein binds to a specific 
site on the 26S rRNA. As is typical for genes encoding ribosomal proteins, there are multiple 
processed pseudogenes of this gene dispersed through the genome (Moin et al., 2017; Gene 
Cards, 2018; UniProt, 2018). 
TPR (Translocated Promoter Region, Nuclear Basket Protein) this gene encodes a large 
coiled-coil protein that forms intranuclear filaments attached to the inner surface of nuclear 
pore complexes (NPCs). The protein directly interacts with several components of the NPC. It 
is required for the nuclear export of mRNAs and some proteins (Gene Cards, 2018; UniProt, 
2018). 
GCFC2 (GC-Rich Sequence DNA-Binding Factor 2) is a factor that represses transcription. 
It binds to the GC-rich sequences (5-GCGGGGC-3) present in the epidermal growth factor 
receptor, beta-actin, and calcium-dependent protease promoters. It is involved in pre-mRNA 
splicing through the regulation of spliceosome C complex formation. It may also play a role 
during late-stage splicing events and turnover of excised introns (Gene Cards, 2018; UniProt, 
2018). 
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S100A9 (S100 calcium binding protein A9) is a calcium- and zinc-binding protein which 
plays a prominent role in the regulation of inflammatory processes and immune response. The 
protein is a member of the S100 family of proteins containing 2 EF-hand calcium-binding 
motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells 
and are involved in the regulation of a number of cellular processes such as cell cycle 
progression and differentiation. S100 genes include at least 13 members which are located 
as a cluster on chromosome 1q21. This protein may function in the inhibition of casein kinase 
and altered expression of this protein is associated with cystic fibrosis (Kerkhoff et al., 1999; 
Gene Cards, 2018; UniProt, 2018). 
SAFB2 (Scaffold Attachment Factor B2) the protein encoded by this gene, along with its 
paralog (scaffold attachment factor B1), is a repressor of estrogen receptor alpha. The 
encoded protein binds scaffold/matrix attachment region (S/MAR) DNA and is involved in cell 
cycle regulation, apoptosis, differentiation, stress response, and regulation of immune genes. 
SAFB2 can function as an estrogen receptor corepressor and can also inhibit cell proliferation. 
Recently, the multifunctional capabilities of SAFB proteins have shown that they play crucial 
roles in DNA repair, mRNA processing and RNA regulation, as well as in interactions with 
chromatin-modifying complexes (Norman et al., 2016; UniProt, 2018). 
ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2) or 
U2AF1L2 (U2(RNU2) Small Nuclear RNA Auxiliary Factor 1-Like 2) encodes an essential 
splicing factor. It  interacts selectively with the 3-splice site of U2- and U12-type pre-mRNAs 
and promotes different steps in U2 and U12 intron splicing. It is recruited to U12 pre-mRNAs 
in an ATP-dependent manner and is required for assembly of the prespliceosome, a precursor 
to other spliceosomal complexes. For U2-type introns, it is selectively and specifically required 
for the second step of splicing (Gene Cards, 2018; UniProt, 2018). 
Gene Ontology 
We have used Panther and DAVID programs to understand the interaction of these genes 
with NMD and to characterize them regarding protein class, molecular function, cellular 
components and biological process. Figure 3.26 shows the distribution of protein classes, 
gene ontology analysis (Biological Process (BP), Molecular Function (MF), Cellular 
components (CC)) and pathways for the 24 genes selected for validation. The top hits from 
the shRNA primary screen, as well as, the genes from the splicing screen were analysed by 
PANTHER gene ontology (GO) (Mi et al., 2013) and characterized by protein class, with these 
classes being mainly: RNA binding proteins (A2BP1; SREK1), mRNA splicing factors 
(RAVER1;NOVA2; HNRPK; SFRS3; RAVER1), ribosomal proteins (NHP2L1; RPS19; 
RPL23A), transcription factors (C21orf66; GCFC2), isomerase (PPWD1), DNA helicase 
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(XRCC6), Signalling molecule (S100A9), Ribonucleoprotein (ZRSR2), Kinase activator 
(CCNA1) and for 8 genes no function was defined(FLJ20273; WTAP; C10orf116; ERVWE1; 
eIF4A3; HNRNPUL1; SAFB2; TPR). 
We separated our genes according to protein classes. The most evident class in the 
analysis of protein classes performed in PANTHER gene ontology (GO) is the Nuclei Acid 
binding class, with RNA binding protein as the most expressive in a subclass analysis. As for 
GO analysis, mRNA metabolic process has the highest percentage in BP, nucleic and binding 
is the most expressive in MF, and cell part, followed by nucleus, represent the locations with 
higher presence of the genes studied in this work. 
A 
B 
  
100 
 
 
 
 
 
 
 
 
 
 
Figure 3.26 – Schematic representation of protein classes, Biological Process, Molecular Function, Cellular components and pathway for 24 hits selected for 
validation. A) Analysis of protein classes performed in PANTHER gene ontology (GO) (PANTHER, 2018) B) Pathway analysis performed using Reactome (Reactome, 2017). 
C) Biological Process D) Molecular Function and E) Cellular components identified in DAVID P<0.05 
C D 
E 
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Confirmation Screen 
The siRNA confirmation screen consisted in reverse transfecting cells (see Materials and 
Methods) for 48h with siRNAs targeting the previously selected hit genes (hits from the NMD 
and splicing screens) as well as with UPF1 siRNA and SMG1 siRNA, which were used as 
positive controls, and ‘scrambled’ siRNA, which was used as a negative control. As a control 
for the transfection efficiency, an siRNA targeting CFTR was used (Figure 3.27).  
 
 
 
 
 
Figure 3.27– Positive and negative siRNA controls for the NMD confirmation assay. (A) 
Representative images obtained for the stable mCherry-GX-eGFP HEK cells 48h after being infected 
with the under ‘scrambled’ (left column), CFTR (middle left column), SMG1 (positive control, middle 
right column) and UPF1 siRNAs (positive control, right column). (B) Summary of the mCherry 
fluorescence quantification for different siRNA controls (n= 3). * means p < 0.05. Scale bar = 20µm. 
In total, 24 genes were tested (plus controls) with each gene being targeted by two different 
Silencer Select™ siRNAs (Dharmacon). Image acquisition and image analysis were 
performed in the same conditions as described above for the shRNA primary screen. As 
shown by the overall siRNA distribution and respective NMD scores ( 
Figure 3.28 and Table S 3.2) in this assay we have lower levels of mCherry fluorescence 
and lower NMD scores when compared to the shRNA assay (Figure 3.22). This may be due 
to differences in transfection/transduction efficiency. 
Herein, the results showed two siRNAs with a NMD score ≈ 1: UPF1 (used as a positive 
control) and eIF4A3, previously described as related to NMD (Iwatani-Yoshihara et al., 
2017).  
Figure 3.28 shows the average NMD scores from both siRNAs for each gene and Table S 
3.2 shows the NMD scores for each individual siRNA. Analysing individual siRNAs we 
identified 4 genes with higher values such as eIF4A3, ADIRF, SREK1, and RPS19. However, 
when taking into account the NMD score and the images obtained in this confirmation screen 
(Figure 3.29) we conclude that the results from this study were inconclusive (Table S 3.2).  
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Figure 3.28 - Distribution of the siRNA scores for the NMD assay. The distribution is performed 
according to the individual siRNA deviation from the negative control. Results presented as average 
of both siRNA for each gene and SD. NMD scores for each siRNA are presented in supplementary 
material in Table S 3.2. 
 
 
Figure 3.29 – Representative images of top hit siRNAs that inhibit NMD in NMD confirmation 
assay. Stable mCherry-GX-eGFP HEK cells were reverse transfected with the siRNAs for 48h. 
Widefield fluorescence images of non-permeabilized cells. Nuclei were stained with Hoechst 33342 
(top row), mCherry fluorescence (middle row) is proportional to the total amount of expressed CFTR 
by inhibition of NMD and eGFP (bottom row) is proportional to the read-through activity. Fluorescent 
images were obtained under equivalent conditions for all cell lines. Scale bar = 20µm. 
 
4. Discussion  
The aim of this study was to identify putative NMD inhibitors that could be used as potential 
drug targets in CF patients bearing nonsense, or PTC mutations, with the goal of inhibiting the 
degradation of CFTR mRNA molecules containing a PTC. Inhibition of NMD in this case would 
allow an increased expression of a truncated CFTR protein, which in some cases may lead to 
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a partially functioning CFTR channel and therefore alleviate the CF symptoms. In cases where 
truncated CFTR is dysfunctional, this approach could be combined with a read-through drug.  
To achieve our goal, we performed a NMD screen of ~425 genes involved in RNA 
processing (Moura-Alves et al., 2011). This screen was designed to identify the possible role 
of those genes in both NMD and in read-through. Our CFTR mini-gene construct has mCherry 
fused to the N-terminus of CFTR, which enables the quantification of truncated CFTR and the 
identification of NMD inhibitors, with the latter being detected by increased mCherry 
fluorescence. The same construct also has the ability to detect read-through activity from the 
eGFP fused to the C-terminus of CFTR. It was not expected that any of the genes that inhibit 
NMD would also display read-through activity. Nevertheless, we have also acquired eGFP 
images to make the most out of our construct and surprisingly some shRNAs had both NMD 
inhibition and read-through activity.  
Analysis of the data from the primary screen led to the identification of 75 NMD inhibitors. 
However, using more stringent criteria for these data, namely an NMD score ≥ 2 and at least 
2 shRNA with the same phenotype, led to the identification of 11 top hits which when knocked-
down inhibit NMD. Furthermore, in this screen, we have identified 2 additional hits that not 
only inhibit NMD (NMD score ≥ 2 but only one shRNA) but also lead to PTC read-through 
(PPWD1 and RSP19) and thus these were also selected for further confirmation/ validation. 
In the subsequent confirmation screen, we considered the 11 top hits inhibiting NMD, the 2 
hits with read-through activity, and included an additional 11 top hits from another HTS screen 
aimed at identifying CFTR splicing regulators (S Igreja & MD Amaral, unpublished data), since 
it is known that splicing is important for the NMD pathway.  
In the confirmation screen, the mCherry fluorescence detected was much lower than that 
observed in the shRNA screen, as revealed by the lower NMD scores, with this assay being 
thus inconclusive. However, despite the low values of NMD scores (below +1), we selected 
the 4 genes with the highest values, as they may still be of relevance, since they were identified 
in the primary screen (or in the splicing assay) by more than two targeting shRNAs. These 4 
genes include ElF4A3 (Eukaryotic initiation factor 4A-3), Adipogenesis regulatory factor 
(ADIRF), Splicing Regulatory Glutamic Acid And Lysine Rich Protein 1 (SREK1) and 
Ribosomal protein S19 (RPS19). As such, these genes may merit further validation studies. 
Two annotation tools, Panther and DAVID, were used in order to identify a relationship 
between the 24 top hits and the NMD process as well as to characterize them regarding protein 
class, molecular function, cellular components and biological process. From these analyses 
we found that these genes were, mainly: RNA binding proteins (A2BP1; SREK1), mRNA 
splicing factors (RAVER1; NOVA2; HNRPK; SFRS3; RAVER1), ribosomal proteins (NHP2L1; 
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RPS19; RPL23A) and transcription factors (C21orf66; GCFC2). For 8 of them there was no 
function described (FLJ20273; WTAP; C10orf116; ERVWE1; eIF4A3; HNRNPUL1; SAFB2; 
TPR).  From the 24 genes three have been previously associated with NMD, namely eIF4A3, 
RPS19 and RPL23A (Reactome, 2017), thus lending validity to our findings.  
Further validation assays are being carried out (S Igreja and L Clarke) using the same 
cellular model and the 24 top hit shRNAs but different techniques including: i) mRNA studies 
using qRT-PCR to quantify CFTR transcript levels after gene knock-down (also to assess 
gene knock-down), and ii) CFTR protein expression studies by WB after gene knock-down to 
assess the levels and size of the CFTR protein produced from the PTC reporter. After gene 
knock-down we expect with both assays to detect an increase in CFTR expression, higher 
levels of truncated protein when NMD is inhibited and a full-length protein when there is read-
through. Further functional assays in cell models as well as in patient-derived materials will 
also be performed.  
In summary, some of the hits identified in this study are potential drug targets due to their 
effects in NMD inhibition as well as in read-though activity. Further characterization of the 
effects of these hits is being performed in order to clarify our findings. These data will provide 
important insights into the mechanisms of NMD and the establishment of novel therapeutic 
targets for CF as well as for other diseases caused by PTC mutations. 
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5. Supplementary information 
Table S 3.1 - NMD scores obtained for the shRNAs included in screen and genes selected for the 
confirmation screen. 
In green values ≥ 2; In red values ≤ -2; *Hits selected - NMD score ≥ 2 and more than 2 shRNA with the same 
phenotype; **Genes with 1 shRNA but showed read-through activity;  
Gene  shRNA1 shRNA2 shRNA3 shRNA4 shRNA5 
NMD Inhibitors - NMD score ≥ 2 and at least 2 shRNA with same 
phenotype 
*A2BP1 -2.48433 3.281676 3.685467 30.49284  
*C10orf116 0.899565 1.428727 2.754271 4.364878  
*C21orf66 -1.03826 4.55717 1.413343 1.691741 2.243449 
*ERVWE1 -0.17222 0.056118 1.718877 2.782407 3.474885 
*FLJ20273 -0.44888 1.52091 2.146793 2.911569 3.191739 
*HNRPK -0.94397 -0.74048 -0.39985 2.962398 5.463193 
*NHP2L1 -0.56273 0.01882 2.26331 2.378306  
*NOVA2 -1.55207 -0.31615 0.010921 2.24212 8.072233 
*RAVER1 -0.46702 -0.07187 0.002271 4.400525 8.258601 
*SFRS3 -3.908 -0.65785 -0.49501 5.202004 7.942901 
*WTAP -0.81297 0.376567 2.385369 4.735453  
NMD Inhibitors - NMD score ≥ 2 and read-through activity 
**RPS19 -1.55477 0.08194 0.228747 0.769386 11.62153 
**PPWD1 -0.34214 0.165852 0.679684 13.41716  
NMD Inhibitors - NMD score ≥ 2  
BRUNOL5 -0.87094 -0.24261 0.875964 1.046141 3.050342 
BUB3 0.115852 0.46406 0.549187 1.779212 3.428402 
C21orf70   2.778576   
C22orf19 0.108738 1.458908 1.722982 2.730848  
C9orf10 0.165911 0.543766 0.760546 1.152692 2.141336 
CCNA1     3.272812 
CDC5L   2.20066   
CSN3 -1.61898 -1.1716 0.068931 1.831277 2.491595 
CWF19L1   2.873986   
DDX23 -0.9204  -0.21927 2.817693  
DHX15 -1.10553 -1.07588 -1.03918 -0.48396 4.317799 
DHX35 -1.49195 -0.82291 -0.23592 4.745279  
DHX9 -4.76641 -0.73264 2.830572   
EFTUD2 -2.33143 -1.8362 -1.47057 -1.249 2.062674 
eIF3S6 -1.40078 -0.82183 -0.57031 0.248509 2.04996 
ERCC3 -0.1574 0.811894 2.273763   
ET -0.46807 -0.09725 0.243443 0.836318 4.000796 
EXOSC9  -0.85383   2.343932 
FIP1L1 -0.10109 0.224414 1.396537 1.854061 2.236685 
FKBP3 -0.29883 0.446929 0.496339 3.13548  
HNRNPG-T 2.931171    
HNRPA3 -1.16279 -1.0297 0.059505 0.245841 3.055327 
HNRPAB -0.84189 -0.60706 -0.27304 -0.23085 2.907348 
HNRPDL -0.32535 0.742018 1.127231 1.560656 3.095817 
HNRPM -3.77971 -0.77923 -0.48722 1.288242 2.341067 
IMP-3 -2.29055 -1.69925 0.50371 1.047461 8.502965 
IQGAP1  -0.98545 -0.95437 -0.02013 2.581621 
LSM5 -0.73322 -0.42296 0.499236 0.954966 2.410485 
MGC2803 -1.39815 -1.31833 1.01208 2.681422  
NCL -0.41928 0.322678 1.987658 5.023905  
NDUFA1 -0.95005 -0.70911 -0.70724 4.758889  
NIF3L1BP1 -0.76069 0.172208 1.364969 1.728029 3.172771 
PHF5A -0.68119 -0.46046 0.320473 1.157849 4.975865 
PRPF3 -0.77751 -0.70118 0.793365 1.275076 3.204732 
PSIP1 -1.20087 -1.05298 0.792705 1.541428 3.121637 
RBM15 -0.07104 -0.0386 0.886392 1.479354 2.155021 
RBM5 -2.00081 -1.33978 -0.95162 -0.32308 8.833536 
RBM7 0.531051 0.541814 1.056061 1.952503 2.093601 
RBMS1 -1.61086 -1.27824 -0.79916 0.460779 2.664278 
REXO1 0.040288 0.827607 1.090679 1.117308 2.396234 
RPL5     20.48134 
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RPS10 -0.52349 0.71434 1.059318 1.274539 2.175561 
RPS12 -1.67846 0.013077 0.882671 1.281848 3.357818 
SAFB     5.364237 
SF1 -1.19981 -0.7254 0.246876 0.824536 2.25106 
SF3B1 -2.70417 0.408457 1.283139 1.432562 11.34466 
SFPQ -1.97468 0.873791 1.71834 2.746347  
SMC2L1 -1.30606 -0.59665 -0.40809 0.037091 2.23222 
SNRPB -0.11346 0.64251 0.859866 1.212524 4.204409 
SNRPD2 -0.34496 0.801297 0.890274 2.712017  
SNRPE -0.46192 -0.21467 0.524682 1.126053 5.855315 
SNRPF -2.20959 -1.49159 -0.80101 -0.39184 2.587853 
SNRPG -1.30593 -0.1645 0.352851 1.189919 2.668892 
SPPL3 -2.62492 -1.58643 -1.3963 -0.61715 2.403882 
SRP68  4.738389    
TAF15   0.161557  4.183365 
TFIP11 0.559033 1.119317 3.777841   
TIA1 0.466446 0.698534 0.865948 1.078845 2.354701 
TXNL4A -2.4977 0.205364 1.227198 4.905382  
UNK -0.71979 -0.31114 0.378432 1.230809 2.634751 
USP39 -0.25476 -0.07764 1.061227 1.111202 2.896239 
WDR58 -1.40926 -0.54485 -0.0752 4.192081  
NMD Score <2  
ABT1  -0.61378 -0.23544   
ACIN1 -0.71246 -0.38941 -0.11456 0.251148 0.48194 
ADAR -0.67243  -0.55892   
AKAP8   -0.47482 -0.4077 0.355917 
AQR -0.58671 -0.19846 -0.03611 0.65892 1.373401 
ARS2 0.083601 0.382395 0.543988 0.824589 0.96553 
ASCC3L1 -0.61299   0.209014  
BAT1 -0.8303 -0.60656 -0.42396 -0.23013  
BRUNOL4 -1.8647 -1.48681 -1.34469 0.017142 0.05211 
BRUNOL6 -0.76951 0.170021 0.395089 0.429616 0.848098 
C13orf10 -0.55702 0.008379 0.066774 0.310598 0.625026 
C1orf55 -2.06947 -1.5765 -1.44556 -0.59893  
C1orf60 -1.23064 -1.04992 -1.04001 -0.74569  
C20orf14 -1.89534 -0.36183 0.338917 0.62767 1.163451 
C20orf23 -0.77554 -0.71085 -0.5211 -0.45038 -0.0646 
CCDC12 -1.17512     
CCNK   -0.05343 -0.00334  
CD2BP2 -0.04163 0.035462    
CDC2L2   -0.18439   
CDC40 -1.58318 -1.24935 0.307701 1.186813  
CIRBP -0.29052 -0.21638 0.26133   
CLK1 -0.5118 0.817405    
CLK2 0.774646 1.395776 1.586024   
CLK3 0.818235 1.165164 1.21771   
CLK4   -0.19399   
CPSF1 0.05627 0.235202 0.4643 0.610743 0.681733 
CPSF4   0.563664 1.098619  
CPSF6 -1.81097 -0.56576    
CRK7   -0.5864   
CRNKL1 0.021838 0.856865 0.862699 1.481834  
CSDA   0.044994   
CUGBP2 -1.08636 -0.14472 0.472744 1.166095 1.395211 
DDX17 -1.80512 -1.73157 -0.56599 -0.19811 1.040759 
DDX19B -0.44461     
DDX21 -0.81548 -0.80802 -0.64797   
DDX26 -1.14444 -0.21614 0.095638   
DDX39     0.505165 
DDX3X -1.94888 -1.35609 -1.07705 -0.47248  
DDX41 -1.89424 -0.82122 -0.11195 0.336407 1.285402 
DDX46 -1.43344 -0.98543 0.248099 0.839602 1.72313 
DDX49 0.582235     
DDX5 -3.80564 -0.64583 0.533204 0.551716 0.770214 
DDX54 -0.36157  0.546958   
DDX6 -0.12974 0.186016 0.81049 1.431298  
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DEK -1.4057   0.671538  
DGCR14 0.30217 0.360572 0.482401 0.64592  
DHX16 -1.13009 0.940763    
DHX38 -0.36999 0.940187 1.180129 1.882155  
DHX8 -1.74942 -1.11539 -0.95593   
DIDO1 -1.08082 -0.93597 -0.25924 -0.16402 -0.11968 
DKFZP434K1421 -1.22908 -1.13852 -0.87208 -0.68467  
DNAJC6 -0.71955 -0.17647 0.358456   
EDG2  -0.72678    
EEF1A1 -0.6412 -0.60086    
EIF2S2 -0.57715 -0.20509 0.134062 0.354268 0.505729 
EIF3S10 -1.92762 -1.56785 -0.38213 0.114027  
EIF3S2 -1.66545 -0.86532 -0.02587 1.031553  
EIF3S6IP -1.10051 -0.92186 -0.58984 -0.52155  
EIF4A2 -0.84548 -0.77853    
ELAVL1   -0.32145  1.027211 
ELAVL2 -1.10209 -0.44847 0.481084  0.937548 
ELAVL3 -1.33655 -1.16332 0.341588 0.767035 1.959175 
ELAVL4 -0.98592  -0.67131 -0.39731  
EP400 -1.10434     
EWSR1 0.275174 0.662949 1.31748   
EXOSC1 -1.31488 -0.55533  0.21508  
EXOSC10   -0.7311 -0.28571  
EXOSC2   -0.48346   
EXOSC4 -0.50216 -0.4134    
EXOSC5 -0.6683     
EXOSC8    0.63773  
FAU -1.50898 -0.04326    
FLJ21827 -0.29165 -0.29165 -0.1916 0.309771 1.136376 
FMR1 -0.67246     
FUBP1  -0.41532 0.103434 0.120281  
FUS -3.52006     
FUSIP1 -1.13224 -0.34542 1.004971 1.611562  
G10  -1.55843    
GNB2L1 -0.46131 -0.06434 0.640207 1.791583  
GPATC1  1.798199    
GTL3   -0.4869 -0.25107  
HCFC1   -0.23727   
HDAC2 -2.12749  -1.35959   
HIST1H2BC -2.26224 -1.28114 -0.86882 -0.01647 0.442854 
HIST2H2AA -1.63346 -1.44005 -1.1643 -0.76187 -0.19981 
HMGB1    -0.37239  
HMGB3   -0.01808 0.011483  
HNRPA0  -0.41432    
HNRPA1  -0.29395    
HNRPA2B1 -0.29588 1.588016    
HNRPD -1.19934 -0.75512 0.479612 0.520578  
HNRPF -0.9636 -0.76659 -0.62359 0.183963 0.575126 
HNRPH1 -1.11884 -0.65265 -0.02526   
HNRPH2 -0.97081     
HNRPH3 -0.11457 0.029616 0.101019 0.54148 1.220772 
HNRPL   -0.11369   
HNRPR -2.84198 -1.59648 -0.40379   
HNRPU  -0.86078 -0.33176 -0.14474 0.101461 
HNRPUL1 -0.21944 -0.07438 0.179665 0.272219 0.898631 
HSPA5 -0.29033 -0.25485 0.724269   
HSPA8  -1.46326 -0.54999 0.141255 0.148461 
HTATSF1 -0.88519  -0.60912   
IK -2.2932 -1.68004 -1.51722 -1.04771 1.298365 
ILF2  -0.88321  -0.25229  
IMP-1   0.702151 0.759889  
KIAA0773 -0.6129 -0.00437 0.328957 0.609862  
KIAA0853    -0.06261  
KIAA1008 -0.52409 -0.37303 -0.33724   
KIAA1429 -2.61533 -0.49238 -0.35047 -0.15082  
KIAA1542 -1.88442 -1.71671 -1.26581 -0.97816 -0.29087 
KIAA1604 -0.85192 0.135872 0.50995 0.782487 0.822156 
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KIAA1967    0.165934  
KIN -3.05644 -0.56372    
KPNA2 -0.24622 0.460578 1.253501 1.341591  
LOC138046 -0.44538 -0.40656 -0.39908 1.360041  
LSM1 -1.19634     
LSM10 -2.40446 -0.20199 0.780275   
LSM11 -1.63375 -0.64428 -0.61398 -0.59691 0.527945 
LSM2 -2.35605 -1.8355 -1.73923 -1.22363 -1.21195 
LSM3 -0.98667 0.016132 0.317509 0.463717 1.166528 
LSM4 -1.60266 -0.62099 0.270629 0.396055 1.113183 
LSM6 -1.67141 0.130041 0.685616 1.073289  
LSM7 -0.82031 1.006489    
LSM8 -2.5411 -1.94123 -1.66758 -0.70788 -0.55971 
LUC7L -4.97381 -1.02152 -0.84295 -0.75444 0.968934 
MAGOH -0.89775     
MATR3 -1.72636 -0.22112 -0.09041 0.168727 0.789431 
MFAP1 -0.88387 -0.57057 -0.07283 0.150228 0.98512 
MGC13125 -1.50523 -0.70759 -0.58983 -0.02756 1.195198 
MGC14151 -0.86764 -0.31495 -0.10386 0.1584  
MKI67IP -1.2479 -0.80306 -0.26182 -0.25282 -0.22686 
MORG1 -0.9988 -0.76125 -0.6997 -0.57526 1.270044 
MOV10 -1.25625 -1.1628  -0.18906  
MSI1 -1.60685 -0.33479 0.339239   
MSI2 -1.81976 -1.49922 -0.76011 -0.48193  
NCBP2  0.061248 0.770882   
NONO 0.006437 0.282285 0.939975 1.038253 1.185169 
NOSIP -0.74271 -0.13157    
NOVA1 -3.79062 0.278624 0.75934 1.409476  
NUDT21 -1.62603 -0.10591 1.081401 1.46404 1.918313 
NUMA1 -2.42219 -1.78692 -1.47363 -0.99421 0.229912 
NXF1 -0.67364 -0.49479 -0.44851   
PABPC1 -1.28063 -0.50429 -0.25587 -0.24268 0.188624 
PABPC4 -1.48701 -1.07798 -0.6395 0.501127 0.542782 
PABPN1 -1.37014 -1.18002 -0.13678 1.369013 1.718378 
PARP1  -0.31051    
PCBP1 -2.43444 -1.80053 -1.68888 -1.67598 -1.49922 
PCBP2 -1.806 -1.70275 -1.17903 -1.09677 0.790114 
PCBP3 -1.61566 -1.39276 -0.88509 -0.1402 -0.10099 
PIAS1  -0.23237 0.01426   
PLRG1 0.174461     
PNN -0.1808 0.973295 0.985036 1.026435 1.470678 
POLR2A -0.38865  -0.07179   
PPIE -1.03637     
PPIH -0.91836 -0.25443 -0.03082 0.741957  
PPIL3 0.700351     
PPM1G -1.37321 -1.24823 0.277897 0.998333  
PRKRA  0.0065 1.131296   
PRPF18 -0.31645 -0.07822 0.6896 1.08649  
PRPF19 -2.029     
PRPF31 -1.78071 0.131608 0.204972 0.721994  
PRPF38A -0.09205 0.754124 1.112775 1.81236  
PRPF38B -0.07734 -0.05602 0.627529 0.671358 0.714326 
PRPF4 -1.43291 -1.16716 -1.13933 -1.00351 -0.60039 
PRPF4B -1.37479 -1.33845 -0.43069 0.199835 1.021436 
PRPF8 -1.2787     
PSEN1 -1.03759     
PTBP1 -0.28394 1.586401    
RALY -1.09522 -0.57356 -0.32256   
RBM10 -1.66432 -1.56899 -0.99154 -0.80242 0.640903 
RBM12 -1.66394 -1.14578 -0.43405 -0.30187 0.186719 
RBM17 -1.59927 -0.91434 0.320339   
RBM22 -0.66558     
RBM25 -2.21218 -1.73388 -1.36174 -1.10581 -0.67894 
RBM8A -0.75174  -0.05109   
RBM9 -1.63934 -0.23365 -0.13663 -0.06868 1.415805 
RBMX -0.15429 0.110234 1.158987 1.315798 1.970589 
RBMX2 -0.72475 -0.58391 -0.5247   
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RBP7    -0.35094  
REXO2 -0.91284   0.495872  
RKHD3 -0.64815  0.415879 1.046956  
ROD1 -0.44957  -0.0538   
RP13-297E16.1 -1.11762 -0.97467    
RPL22 -1.23437     
RPL31 -0.44586   1.037017  
RPS13 -2.10266  -0.46776   
RPS15A -1.24945 -1.1949 -0.66404 -0.1808 1.417045 
RPS17 -0.32535 0.482113 0.497335 1.141996 1.753097 
RPS18 -0.80698 -0.80475 -0.55411 -0.17773 0.121376 
RPS29 -1.31445 -0.66027 -0.42381 0.02761  
RPS3    -0.66627 -0.01066 
RPS3A -0.84277 -0.5203 -0.19465 0.265373  
RPS4X -0.35903 -0.06459 0.019389 0.512935 1.255321 
RPS4Y1 -0.30554 0.365854 0.741485 1.003683 1.081539 
RPS5 -1.25426 -0.82054 -0.63599 0.329169  
RPS7 -1.63382 -1.60644 -1.59619 -1.07395 0.501845 
RPS8 -0.97177 -0.5912 -0.48387   
RPS9 -1.53924 -1.04837 -1.03234 -0.1248  
RUVBL2 -0.94739  -0.84314   
S100A9 -0.49287 -0.47835 0.260668   
SART1 -1.49035 1.271895    
SDCCAG10 -1.58785 -0.76988 0.094294 1.148426 1.643716 
SF3A1   -0.77381 -0.45307 -0.36894 
SF3A2 -1.55617 -0.90107 -0.52231 0.973411  
SF3A3 -1.57853 -0.65432 -0.22322   
SF3B3 -1.43774 -1.11662 -1.00301 0.103146 1.228029 
SF3B4 -1.72244 -1.426 -0.28744 0.068793  
SF3B5 -0.79033 -0.78 -0.66313 0.852647 1.624967 
SF4 -1.06683 -0.77865 -0.21752 0.79052 0.845222 
SFRS1 -1.81028 -0.85835    
SFRS10 -1.34255 -0.67637 -0.22633   
SFRS11 0.184813 0.602882 1.355507 1.619744  
SFRS12 -0.69983 -0.55148    
SFRS2 -0.71924 0.440807 1.699296   
SFRS5 -0.88751 -0.64129 -0.47357   
SFRS6 -0.85175   -0.10527  
SFRS7 -2.12343 -0.40277 0.405278   
SFRS9 -1.1884 -0.65387 -0.61889 -0.41046  
SIAHBP1   -0.42158   
SKIV2L -1.12505  -0.59334  -0.3883 
SKIV2L2   -0.16408   
SLU7 -1.11624 -0.89092 0.167275   
SMARCA5  -0.43202 -0.06949  
SMC1L1 -1.23743 -0.92925 -0.32772 -0.0414 0.228354 
SMNDC1 -3.73972 -0.17346 0.080503 0.506675  
SMU1 -2.76375 -1.69396 -1.55819 -1.46906 -1.44699 
SNIP1  0.218272    
SNRP70 -1.83624 -0.63064 -0.16231 1.865742  
SNRPA  -0.61593  0.77354  
SNRPA1 -0.95232 0.380631 1.021338 1.123204 1.186756 
SNRPB2  -0.83164 -0.76968 -0.44288  
SNRPC -1.27354 -1.05094 -0.35512 0.218655 1.694308 
SNRPD1 -1.48073  -0.82625 -0.56287  
SNRPD3 0.147244 0.279945 0.421399 0.989564  
SNW1 -4.18288 -0.75606 0.129784 1.772247  
SR140    1.434132  
SRP46 -1.4936 -1.13531 -0.70138 0.600438 1.611693 
SRP9     1.756544 
SRPK1 -0.8564 0.336096    
SRRM1 -2.02229 -1.80726 -1.53304   
SRRM2 -0.50096     
SSB    1.248208  
STK23  1.47662    
SYNCRIP -1.70708    -0.13749 
TCERG1  -0.15322 0.141329 0.254216  
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TDRD3 -1.91626 -1.26384 -1.12926 -0.95558  
THOC1 -0.90493 -0.73185 0.009393 0.968105 1.654829 
THOC3    -0.61596 0.116693 
THOC4 -0.18794 0.490156 0.699093 1.173454  
TIAL1   -0.51921 -0.43368 -0.397 
TNPO1  0.217808    
TNRC4 -0.77096 -0.26485    
TOP1MT -0.6012   0.698441  
TPR  -0.33244    
TPX2 -0.76728 -0.25713 -0.03699 0.161808 0.716331 
TRA2A -0.15151 0.105109 0.872833 1.167509 1.342977 
TTF2   0.508697 0.669166  
TUBA1 -1.86207 -1.03705 0.638501 1.010412 1.697593 
TUBB -0.63363 -0.42303 -0.14273 -0.00473 0.073986 
U2AF1 -0.67474 0.996379    
U2AF1L2 -1.88771 -1.04494 -0.6476 -0.52445 -0.47724 
U2AF1L3 -0.09172 -0.05549 0.041629 0.284019 0.80937 
U2AF2 -0.95663 -0.43314 0.205074 0.341237 0.866395 
VIM -1.04606     
WBP11 -1.61397 -1.48021 -1.47171 -0.35932 -0.28218 
WDR33 -1.49698 -0.92269 -0.23108 -0.07404 0.311411 
WDR57 -0.87848 -0.55487 -0.49529 0.184237 0.226292 
XAB2 0.639141 0.759858 1.591767 1.700442  
XRCC6 -0.76363     
XRN2 -0.89156 -0.48137    
ZFP36L1  -0.50731 -0.40568  0.092285 
ZFR  -0.93326  -0.30983 -0.04945 
ZMAT2 -0.86797 0.054308 0.997064   
ZNF207 -0.75476 -0.45825    
NMD Inhibitors - NMD score ≤ 2 
DNAJC17 -2.02215 -2.01634 -1.89278 -1.72632 -1.66236 
HIST1H2AC -2.42689 -2.11679 -1.10578 -0.9853 -0.11778 
PPIL1 -4.3203 -4.21014 -1.57098 1.703211 7.287349 
PPIL2 -4.65285 -2.44305 1.970461   
PTBP2 -4.79378 -4.34003 -2.92043 1.17505  
RBM3 -2.61533 -2.45619 -2.16576 -0.31195 2.98108 
RNPS1 -4.9294 -4.76843 -4.21523 -0.02207  
RPS15 -2.92649 -2.12388 -1.54915 -1.47169 -1.12428 
RPS25 -2.30935 -2.10215 -1.90552 -1.55616 0.828241 
RY1 -2.59711 -2.24658 -2.07512 -1.30488 -0.80804 
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Table S 3.2 - NMD scores obtained for the confirmation screen with siRNAs and top hits selected. 
In green genes selected. 
Gene siRNA 1 siRNA 2 
UPF1 0.880213 -0.22287 
eIF4A3 0.879692 0.343308 
ADIRF 0.412396 -0.28273 
SREK1 0.360419 -0.21822 
RPS19 0.353367 0.183417 
SAFB2 0.339279 0.120795 
RAVER1 0.305672 0.167189 
ERVW-1 0.222233 0.111169 
SNU13 0.206135 0.128915 
RBFOX1 0.201043 -0.25191 
RBM47 0.152186 -0.21565 
PPWD1 0.151744 -0.0497 
SMG1 0.150184 -0.58914 
XRCC6 0.109657 -0.00828 
ZRSR2 -0.08308 -0.31214 
HNRNPUL1 -0.21455 -0.30723 
CCNA1 -0.2308 -0.37007 
SRSF3 -0.23351 -0.12701 
PAXBP1 -0.2427 -0.23637 
S100A9 -0.25532 -0.02364 
RPL23A -0.26004 -0.07297 
WTAP -0.26535 0.010437 
HNRNPK -0.29844 0.018695 
TPR -0.29856 -0.18991 
GCFC2 -0.32888 -0.24136 
SRSF2 -0.37056 -0.30224 
NOVA2 -0.42081 -0.26277 
CFTR -0.85054 -0.33973 
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Chapter 4 - A Small-Scale Screen to Identify Compounds that 
Correct CFTR Mutations Bearing PTCs. 
Experiments shown in this chapter were performed jointly with Susana Igreja (MD Amaral lab) 
 
1. Abstract 
Background: Among the ~ 2,000 CFTR gene variants reported, a significant fraction 
(~24%) generates a premature termination codon (PTC), including: 8.4% nonsense and 
15.7% frameshift mutations. PTC mutations generally lead to a significant reduction, or total 
absence, of normal CFTR mRNA and protein expression, and are usually associated with a 
severe clinical phenotype. The reduction in transcript levels occurs through the mRNA 
degradation mechanism called NMD (Nonsense-Mediated Decay) that selectively degrades 
transcripts bearing PTCs. Patients expressing higher levels of mRNA containing PTC due to 
less efficient NMD are expected to respond more robustly to suppression / read-through 
therapies when compared to patients expressing lower levels of mRNA due to highly NMD 
efficiency. To date, there are no CFTR modulating therapies specifically targeted to treat 
patients with PTC mutations and, although the aminoglycoside antibiotics (some such as 
tobramycin used in the standard treatment of CF lung infections) and Ataluren / PTC-124 have 
demonstrated some ability to suppress PTCs in vitro, they are non-specific and show poor 
efficacy in vivo. Indeed, these compounds underwent clinical trials for CF but were 
discontinued because of lack of demonstrated efficacy. As such, there is a need to find new 
therapeutic strategies to treat these patients. 
Aim: Our aim is to screen for novel compounds suppressing PTC mutations by automated 
microscopy using a cell-based model, as potential corrective therapies for CF. 
Methods: To achieve this goal, we used a CFTR mini-gene reporter model harbouring the 
G542X mutation. The mini-gene features a mCherry and an eGFP tag at the CFTR N- and C-
termini, which allow the assessment of both the extent of NMD (mCherry) and the full-length 
protein as a readout of read-through. The construct also has a Flag-tag which becomes 
extracellular once the mCherry-Flag-G542X-CFTR-eGFP protein is at the plasma membrane 
(which may not occur to all full-length proteins produced given the random insertion of amino 
acids in read-through). This construct was inserted into HEK293 Flp-In cells for stable 
expression, in parallel with a similar wt-CFTR construct. We used as a negative control DMSO 
and as a positive control G418. 
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Results and Discussion: Our data from this preliminary study show two compounds that 
stand out from the rest, in terms of their high scores. The compound with the highest read-
through score is the G418 our positive control, and PTC124 did not demonstrate any effect. 
Conclusion: To confirm the read-through efficiency, complementary experiments are 
required using other techniques. To validate the top hit compounds, it is necessary to test 
them in patient-derived materials and test them in combination with potentiators and correctors 
for maximal effect. 
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2. Introduction  
Efforts to develop treatments for patients with CF with nonsense mutations have focused 
on strategies to promote suppression of PTCs (also known as translational read-through). 
Translational read-through is accomplished when an amino acid carried by a near- cognate 
aminoacyl transfer RNA is inserted into a polypeptide chain at the erroneous stop codon, 
allowing translation to continue, and partially restoring “full-length” functional protein (Keeling 
and Bedwell, 2011). Several pharmacologic approaches to induce read-through have been 
discovered, yet none has yielded an optimal combination of efficacy and safety.  
Aminoglycoside antibiotics (gentamycin/G418, tobramycin) and the compound Ataluren 
(also known PTC-124 - (3-[5-(2-fluorophenyl)-[1,2,4] oxadiazol-3-yl]- benzoic acid), an orally 
bioavailable non-aminoglycoside compound) have been shown to have the ability to read-
through PTCs, allowing translation of full-length proteins. Since aminoglycosides have severe 
side effects, such as nephrotoxicity and ototoxicity, when used at high concentrations and/or 
when used long-term, the search by High throughput screen (HTS) for non-aminoglycosides 
capable of promoting read-through, revealed the small molecule Ataluren, which evidenced 
some ability to carry out read-through PTCs without severe side effects. This small molecule 
has been tested in patients, albeit with controversial efficacy (Kerem et al., 2014). However, 
the clinical trials results showed that not all the patients responded to the treatment, in 
particular, the patients who are being treated with aminoglycoside antibiotics (to treat bacterial 
infections) were the ones showing worse results. So, a new Phase III trial excluding patients 
under tobramycin was performed, but since it did not meet the end points, Ataluren was 
discontinued. As such, there is an unmet need to find novel therapies to treat patients with 
PTC mutations.  
The main purpose of this study is to restore functional protein production to PTC mutations 
using read-through compounds aimed at the treatment of CF patients. We thus assessed the 
effects of a small library of 24 compounds which are Ataluren/PTC124 analogues/derivatives 
as well as non-PTC124-like compounds chemically synthesised by a group of collaborators 
(Prof. Cristina Moiteiro, FCUL, Lisboa). The screen of the library was performed using HTS 
and using our NMD-PTC reporter (Chapter 3 and Figure 2.8). As mentioned previously 
(Chapter 3), this reporter is suitable to screen compounds by automated HT fluorescence 
microscopy. The construct has the G542X nonsense mutation, mCherry at the N-terminus and 
eGFP fused at the CFTR C-terminus. Because the G542X PTC mutation is present, this 
construct leads to very little expression of truncated CFTR protein and no expression of the 
full-length CFTR protein. Hence, it does not generate eGFP fluorescence. However, if a 
compound has read-through properties it will lead to the production of “full-length” CFTR, 
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which will be detected as an increase in green fluorescence (from eGFP). This reporter 
effectively allows the assessment of the read-through properties of the compounds and thus 
the identification of relevant or “hit” compounds in an automated, expedite way. Through the 
screen of the previously mentioned small library, we have identified new small-molecule 
compounds that induce PTC read-through.  
3. Results and Discussion 
Using the NMD/PTC reporter we evaluated the efficacy of 24 compounds which included 
PT124-like and non-PTC-like compounds, for their read-through activity. The experiments 
were performed using the stable Flp-In HEK cells expressing the mini-gene after incubation 
with the compounds for 48h, using DMSO (0.5% v/v) as a negative control and as positive 
controls G418 (a kwon read-through compound), PTC124 (Ataluren) and the SMG1 inhibitor 
(InhSMG1) (Figure 3.30). The assay was used in automated high-content microscopy in the 96-
well plate format (see Materials and Methods). To avoid ‘edge effects’, controls were localized 
randomly throughout the plate. Image acquisition was performed with an automated Leica DMI 
6000B widefield epifluorescence microscope. The fluorescence intensity was integrated and 
processed using CellProfiler (see Materials and Methods).  
 
Figure 3.30 – Representative images of hit compounds that promote PTC read-through. 
Representative images of HEK 293 Flp-In cells grown for 48h under DMSO, G418, PTC124, SMG1 
inhibitor and top hit compounds. Readouts are shown underneath.  
The C-terminal eGFP allows the quantification of “full-length” protein being expressed in 
each individual cell and thus, the integrated fluorescence signal in each cell is proportional to 
the read-through activity of the compound. This is defined as the amount of CFTR transcripts 
that, by escaping NMD, originate full-length CFTR (independently of whether it is functional or 
not). For this analysis we used the eGFP fluorescence readout, however, it is expected that 
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mCherry fluorescence would also be increased, since transcripts that escape NMD have 
mCherry at N-terminal and if mRNAs are read-though they should also escape NMD. Read-
through efficiency can then be determined in individual cells using a simple fluorescence 
readout: 
 
𝑃𝑇𝐶 𝑅𝑒𝑎𝑑𝑡ℎ𝑟𝑜𝑢𝑔ℎ 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 ∝ 𝑒𝐺𝐹𝑃 𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 
 
Figure 3.31 shows the distribution of the compound’s PTC "Read-through Efficiency" (see 
Materials and Methods for calculation of this parameter). These results show that despite the 
relatively low values for PTC "Read-through Efficiency", some compounds stand out from the 
rest. Also, the highest concentrations do not always give the best results, possibly due to 
toxicity effects. Thus, the optimal concentration in terms of efficacy/toxicity differs between 
compounds.  
 
 
 
 
 
 
 
Figure 3.31 – Distribution of the PTC Read-through Efficiency of compound for the PTC read-
through screening assay: The distribution is performed according to the individual compound value 
from the negative control. Compounds with read-through efficiency are those having a PTC Read-
through Efficiency above +1, as described in Materials and Methods. 
We have identified in this preliminary study two compounds that stand out from the rest, in 
terms of their high scores. The compound with the highest read-through score is the G418, 
compound, used here as a positive control. It is also apparent that InhSMG1 only leads to an 
increase in mCherry fluorescence, which was also expected since this compound leads only 
to inhibition of NMD. Interestingly, the PTC124 compound that was in clinical trials for the 
correction of nonsense mutations and was previously reported to promote read-through, in our 
trial did not demonstrate any effect. 
To further confirm the read-through efficiency of the tested compounds, complementary 
experiments are required using additional techniques, such as, qRT-PCR analysis of 
transcripts and Western blotting to confirm the presence of full-length CFTR. Finally, to 
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validate the top hit compounds, it is necessary to test them in patient-derived materials, 
including nasal primary cells for functional activity or intestinal organoids to determine the dose 
response and to test these compounds in combination with potentiators and correctors for 
maximal effect. 
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IV General Discussion and Perspectives 
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General Discussion  
The growing understanding of human genetics, through the identification of disease 
associated variants, has contributed to our perception of human variability. With this genetic 
knowledge, the specificity of the clinical phenotype and the drug response of each individual 
are better understood. Genetics of CF has been widely studied. The observation that CF is a 
monogenic disease, caused by mutations in the CFTR gene, enables phenotype–genotype 
association studies (including drug response), which consider the wide clinical and laboratory 
spectrum dependent on the combined action of genotype, environment, and lifestyle. Despite 
the enormous advances in CF research since the identification of the CFTR gene in 1989, a 
cure cannot yet be offered to patients suffering from CF. The clinical manifestations of CF are 
complex, and even decades after the description of the disease and identification of the CFTR 
gene, not every spectrum of the disease is known or even understood, including the interaction 
between socioeconomic status and health outcomes (Oates and Schechter, 2016; Brown et 
al., 2017). For the vast majority of patients, the diagnosis of classic forms of CF is established 
early in life and suggested by one or more characteristic clinical features, including a history 
of CF in a sibling or a positive NBS result. Such diagnosis should ideally be supported by 
evidence of CFTR dysfunction through identification of two CF-disease causing mutations, 
two abnormal sweat-Cl- tests, and/or distinctive NPD measurements. The majority of 
treatments for CF aim to reduce its symptoms, such as mucolytics to reduce mucus viscosity, 
antibiotics to keep infection under control, anti-inflammatory drugs to suppress chronic 
inflammation, or digestive enzymes to compensate for pancreatic insufficiency. It is however, 
extremely important to treat the basic defect related to mutations in the CFTR gene so that 
these symptoms can be tackled globally.  
The genetic part that characterizes the disease, determination of genes, their 
polymorphisms and mutations is essential to understand the individual phenotype. 
Furthermore, it is relevant for the study of new therapeutic models, such as conventional drug 
adjustment by individual patient dosage and drug type and response, development of new 
drugs, such as read-through, enhancer, stabilizer, and amplifier compounds. 
The first objective of the present doctoral work was to identify CFTR gene mutations in 
patients with other chronic lung diseases. Since CF is a recessive disease, patients with just 
one CFTR gene mutation (i.e., carriers) are usually asymptomatic. However, several studies 
suggest the association of just one CFTR mutation with other respiratory diseases (Bombieri 
et al., 1998) such as DB (Pignatti et al., 1995), bronchopulmonary aspergillosis (Miller et al., 
1996), sinusitis (Wang et al., 2000), COPD (Dahl and Nordestgaard, 2009) and bronchial 
asthma (Dahl et al., 1998b). With that purpose we analysed the 12 most common CFTR 
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mutations in Portuguese CF patients in non-CF patients with chronic lung diseases, such as 
DB (31 individuals), asthma (54 individuals) and COPD (51 individuals). Such CFTR mutations 
were detected by the ARMS, Tetra-ARMS and/or RFLP techniques.  
Our data has shown that some patients with other respiratory diseases do carry CFTR 
mutations in one allele. We investigated the association of CFTR gene mutations with asthma 
and we have not found statistical significance, in contrast with other studies. We have found 
an increase in the frequency of CFTR gene mutations in patients with disseminated 
bronchiectasis, although it did not reach statistical significance, but these findings are in 
agreement with previous reports from other groups (Bombieri et al., 1998; Ngiam et al., 2006). 
However, we did find a significant increase in CFTR gene mutations in patients with COPD. 
In our study we focused only on the analysis of common CFTR gene mutations/variants. 
Although the F508del, the G542X and the G576A-R668C alleles were more frequent in the 
patient’s group compared to the control group, the independent distribution of the tested CFTR 
mutations showed no statistical significance between COPD patients and controls. Our study 
included a small sample size resulting in a lower capability to detect minor to modest genotype 
disease association, future studies on larger cohorts should be performed.  
In the COPD group we have identified one patient with the G542X mutation, a nonsense 
mutation that leads to the degradation of the transcripts and is associated with a severe 
phenotype. Another mutation identified was the complex-allele G576A-R668C, previously 
described as a polymorphism with varying effects on patient phenotypes. This patient has 
more than 10% of normal CFTR function and no CF phenotype, but from the mRNA analysis 
we conclude that G542X transcripts are degraded and that the G576A-R668C complex-allele 
leads to skipping of exon 13. Additional analysis to properly discriminate the effect of the 
G576A-R668C complex-allele in exon 13 skipping would require samples from a patient 
homozygous for this polymorphism.  
The second objective of the current work was to analyse CFTR expression in native 
tissues (respiratory cells and colon) from patients to identify alterations in mRNA transcripts. 
Specifically, from Portuguese and Brazilian CF patients with unusual CFTR mutations 
potentially affecting gene expression through alternative splicing or NMD. Herein, we 
developed an RT-PCR analysis of CFTR transcripts for a select number of cases. These 
patients have sweat test values and activity of CFTR-mediated Cl- secretion in rectal biopsies 
that are suggestive of CF. RNA was extracted from either freshly-collected nasal epithelial 
cells (obtained by nasal scraping), colon biopsies (used for CF diagnosis) of CF individuals. 
In order to facilitate the identification of mutations, we have designed a mRNA-based protocol 
using just 9 RT-PCR reactions, whereby the complete CFTR coding region is analysed. 
123 
 
Moreover, one of the reactions for detection of the F508del mutation (exons 11-13) is based 
on the ARMS technique. With this 9 reaction technique we can detect any mutation occurring 
in the coding region as well as those that cause alternative splicing thus leading to the 
production of alternative transcripts. 
This protocol is being applied to indirectly identify mutations in patients with total absence 
or residual CFTR-mediated Cl- secretion in rectal biopsies and with only 1 or no CFTR 
mutations identified by routine methods. With this technique we can detect for example a 
cryptic exon between exons 10-11 resulting from a mutation located deep into IVS 10 
(c.1584+18672A>G), which is unlikely to be detected by CFTR exon sequencing. Other 
examples include the p.G576A, c.1717-1G>A, c.1812-1G>A, c.3272-26A>G, c.3120+1G>A 
mutations. We used this protocol in patients with a suspicion of CF and we were able to find 
1 mutation that was already reported but had not been characterized, the 711+3A>T mutation, 
that we have shown causes skipping of IVS 5. We conclude that this is a rapid, robust and 
inexpensive method to detect rare mutations that can be easily used after a first screen. 
Furthermore, it can indicate the functional consequences of mutations in case they occur at 
the mRNA level.  
The third objective of the current work was to identify key players in the NMD pathway by 
automated microscopy screens using a novel CFTR NMD-PTC mini-gene model. To identify 
factors involved in NMD, which may be potential drug targets, we developed an NMD CFTR 
mini-gene model. We have introduced in this mini-gene the G542X mutation in exon 12, which 
is the most common nonsense mutation in CF patients, and known to be related to a 
significantly lower production of CFTR transcripts. The mini-gene also features mCherry and 
eGFP tags at the CFTR N- and C-termini, respectively, which allow the assessment of the 
total CFTR levels (mCherry) and the “full-length” protein (eGFP). The construct also has a 
Flag-tag which becomes extracellular after G542X correction, originating mature mCherry-
Flag-G542X-CFTR-eGFP. To induce NMD the nonsense mutation has to be recognized as a 
PTC. This in turn only occurs if an intron is downstream of the nonsense mutation, which will 
result as a consequence of the presence of proteins that remain at the EJC in the mRNA after 
the splicing process. For this reason, our cellular mini-gene NMD model contains three introns 
(IVS14, 15 and 16) downstream of the G542X mutation. 
This model allowed us to use automated fluorescence microscopy to screen a shRNA 
library – a subset of The RNAi Consortium (TRC) – which is enriched in shRNAs targeting 
genes with a known or predicted involvement in transcript processing (425 genes), with the 
aim of identifying factors involved in the NMD pathway and detecting read-through 
compounds. This construct was stably transfected into HEK293 Flp-In cells, in parallel with a 
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similar wt-CFTR construct. After validation, the CFTR NMD-PTC reporter was used to screen 
the shRNA library using HT microscopy. Analysis of the data obtained from the primary screen 
led to the identification of 75 NMD inhibitors using the NMD score ≥ 2 criteria. When applying 
two different criteria (Z-Score ≥ 2 and at least 2 shRNA with the same phenotype) we obtained 
11 top hits. Strikingly, in this screen for NMD inhibitors we also identified genes that show 
read-through activity. We identified 2 genes with read-through activity, PPWD1 and RSP19, 
and after literature search we selected them for further confirmation assays, since they are 
indirectly linked to NMD. For the confirmation screen (library of siRNAs), we included the 11 
top hits form the primary screen, plus 2 genes from the screen that showed read-through 
activity and 11 genes from a parallel study related with alternative splicing. The results from 
our confirmation screen shown 4 genes with higher values of NMD score, however these 
values are much lower than expected. Thus, we are currently analysing this set of 24 genes 
using two different validation techniques: qRT-PCR and WB. Some of the hits identified within 
this study are potential drug targets due to their effects in NMD inhibition. Future data are 
expected to generate a valuable tool to shed light on the NMD pathway and on novel 
therapeutic targets for CF as well as for other diseases caused by PTC mutations. 
The fourth objective of the current work was to restore functional protein production to 
PTC mutations using read-through compounds ultimately aimed at the treatment of CF 
patients. For this propose we analysed a library of 24 compounds which are PTC124 
analogues/derivatives as well as non-PTC124-like compounds chemically synthesised by a 
group of collaborators. To perform HTS we used our NMD-PTC model (Figure 2.8) as before. 
If the presence of a compound with read-through properties leads to the production of “full-
length” CFTR, this model enables the detection of the CFTR “full-length” protein by monitoring 
green fluorescence by fluorescence microscopy. This model, therefore, allows the 
identification of relevant (or “hit”) compounds in an automated and expedite way. Through the 
screen of the library, we identified new small-molecule compounds that induced PTC read-
through.  
To confirm the read-through efficiency more experiments are needed, using additional 
techniques, such as, WB and analysis of transcripts by semi-quantitative PCR and qRT-PCR. 
Finally, to validate the top hit compounds, it is necessary to test them in patient’s materials, 
including nasal primary cells for functional activity and intestinal organoids to determine a dose 
response and to test these compounds in combination with potentiators and correctors. 
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Concluding remarks and perspectives for future work.  
The studies presented in this dissertation had the overall aims of advancing the current 
knowledge of RNA-processing dysfunction, namely NMD, and of identifying novel compounds 
that modulate this process towards a "personalised medicine" approach. Previous work has 
demonstrated that a significant part (36%) of CF-causing mutations affects splicing efficiency 
and the stability of mRNA molecules. The results obtained in this thesis have indeed provided 
new knowledge pertaining to other respiratory diseases and the presence of CFTR mutations, 
new approaches to detect CFTR mutations in DNA and RNA and contributed to our 
understanding of the effect of NMD inhibition, as well as, read-through activity in the most 
common CFTR nonsense mutation. We have identified 3 relevant genes associated with 
splicing that lead to an increase in CFTR transcripts, overcoming the G542X mutation effect. 
The current results also opened new perspectives which merit further exploration. 
Accordingly, future work should focus on the following aspects: 
1) To further correlate the genotype-phenotype of patients with non-CF respiratory 
diseases, given that we have shown that there is an increased incidence of CFTR gene 
mutations among individuals with COPD. It thus becomes important to understand if 
individuals with one mutation in the CFTR gene have a greater predisposition for these 
diseases, constituting a particular subgroup of COPD disease which could benefit from 
approval CFTR modulators for CF. 
2) To mechanistically validate the top hit genes identified as NMD inhibitors and test the 
possibility of using them as therapeutic targets for nonsense mutations in CF (and 
potentially in other diseases caused by PTC mutations). 
3) More detailed studies need to be carried out to understand the general mechanism of 
action of compounds that show read-through activity to possibly use them in combination 
with NMD inhibitors as potential drugs for PTC mutations. 
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Table S 4.3 – shRNA information 
Gene Name NM_Id Entry Gene Name NM_Id Entry 
DDX3X NM_001356 O00571 SMNDC1 NM_005871 O75940 
DHX15 NM_001358 O43143 SFRS7 NM_006276 Q16629  
SNRP70 NM_003089 P08621 SLU7 NM_006425 O95391 
PRPF18 NM_003675 Q99633 USP39 NM_006590 Q53GS9 
DHX8 NM_004941 Q14562 U2AF1 NM_006758 Q01081 
THOC1 NM_005131 Q96FV9 U2AF2 NM_007279 P26368 
EWSR1 NM_005243 Q01844 DHX38 NM_014003 Q92620 
SF3B4 NM_005850 Q15427 DDX46 NM_014829 Q7L014 
RNPS1 NM_006711 Q15287 PRPF31 NM_015629 Q8WWY3 
SF3A3 NM_006802 Q12874 CDC40 NM_015891 O60508 
SF3A2 NM_007165 Q15428 LUC7L NM_018032 Q9NQ29 
KIN NM_012311 O60870 RBM17 NM_032905 Q96I25 
SF3B3 NM_012426 Q15393 ZMAT2 NM_144723 Q96NC0 
SF3B1 NM_012433 O75533 DHX9 NM_001357 Q08211 
SFRS2 NM_003016 Q01130 PPM1G NM_002707 O15355 
C22orf19 NM_003678 Q13769 SFRS3 NM_003017 P84103 
SFRS10 NM_004593 P62995 SRPK1 NM_003137 Q96SB4 
PABPN1 NM_004643 Q86U42 HNRPF NM_004966 P52597 
SFRS11 NM_004768 Q05519 HNRPR NM_005826 O43390 
SRRM1 NM_005839 Q8IYB3 HNRPM NM_005968 P52272 
SDCCAG10 NM_005869 Q6UX04 RBM3 NM_006743 P98179 
SFRS5 NM_006925 Q13243 DDX26 NM_012141 Q9UL03 
NUDT21 NM_007006 O43809 DDX41 NM_016222 Q9UJV9 
CPSF6 NM_007007 Q16630 RALY NM_016732 Q9UKM9 
CPSF1 NM_013291 Q10570 DHX35 NM_021931 Q9H5Z1 
PPIL2 NM_014337 Q13356 HNRPD NM_031370 Q14103 
PPWD1 NM_015342 Q96BP3 HNRPU NM_031844 Q00839 
PPIL1 NM_016059 Q9Y3C6 THOC3 NM_032361 Q96J01 
SRRM2 NM_016333 Q9UQ35 SFRS12 NM_139168 Q8WXA9 
C21orf66 NM_016631 Q8N6E6 CLK4 NM_020666 Q9HAZ1 
PPIL3 NM_130906 Q9H2H8 CRK7 NM_016507 Q9NYV4 
THOC4 NM_005782 Q86V81 DNAJC6 NM_014787 O75061 
PRPF4B NM_003913 Q13523 RNGTT NM_003800 O60942 
CLK3 NM_003992 P49761 PIAS1 NM_016166 O75925 
CLK2 NM_003993 P49760 HDAC2 NM_001527 Q92769 
CLK1 NM_004071 P49759 RPS3 NM_001005 P23396 
HSPA5 NM_005347 P11021 SNRPD1 NM_006938 P62314 
HNRPA2B1 NM_002137 P22626 RPS16 NM_001020 P62249 
PTBP1 NM_002819 P26599 TNRC4 NM_007185 Q5SZQ8 
Pde4dip NNM_031401   MGC5509 NM_024093 Q9BVC5 
SF1 NM_004630 Q15637 EXOSC10 NM_002685 Q01780 
WTAP NM_004906 Q15007 GNB2L1 NM_006098 P63244 
SFPQ NM_005066 P23246 HNRPA1 NM_002136 P09651 
SART1 NM_005146 O43290 HTATSF1 NM_014500 O43719 
NOVA1 NM_006491 P51513 PRPF19 NM_014502 Q9UMS4 
SFRS1 NM_006924 Q07955 SF3A1 NM_005877 Q15459 
SNW1 NM_012245 Q13573 SNRPA NM_004596 P09012 
PTBP2 NM_021190 Q9UKA9 MAGOH NM_002370 P61326 
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Gene Name NM_Id Entry Gene Name NM_Id Entry 
CDC2L2 NM_024011 Q9UQ88 POLR2B NM_000938 P30876 
STK23 NM_014370 Q9UPE1 MYEF2 NM_016132 Q9P2K5 
RPS13 NM_001017 P62277 RNPC2 NM_004902 Q14498 
FAU NM_001997 P35544 ELAVL2 NM_004432 Q12926 
TOPORS NM_005802 Q9NS56 RP13-297E16.1 NM_005088 Q02040 
NXF1 NM_006362 Q9UBU9 ERCC3 NM_000122 P19447 
UBL5 NM_024292 Q9BZL1 SAFB NM_002967 Q15424 
PARP1 NM_001618 P09874 PLRG1 NM_002669 O43660 
YBX1 NM_004559 P67809 TTF2 NM_003594 Q9UNY4 
EDG2 NM_057159 Q92633 DNAJC8 NM_014280 O75937 
RBM22 NM_018047 Q9NW64 NDUFA1 NM_004541 Q6IBB5 
HSPA1B NM_005346 P0DMV9 VIM NM_003380 P08670 
ZNF207 NM_003457 O43670 EEF1A1 NM_001402 P68104 
DEK NM_003472 P35659 TRNT1 NM_016000 Q96Q11 
SMARCA5 NM_003601 O60264 AKAP8 NM_005858 O43823 
CSDA NM_003651 P16989 TNPO1 NM_002270 Q92973 
KHSRP NM_003685 Q92945 ELAVL4 NM_021952 P26378 
FUBP1 NM_003902 Q96AE4 MBD5 NM_018328 Q9P267 
G10 NM_003910 P41223 RKHD3 NM_032246 Q6ZN04 
ZFP36L1 NM_004926 Q07352 RBBP7 NM_002893 Q16576 
ILF2 NM_004515 Q12905 RBM8A NM_005105 Q9Y5S9 
ILF3 NM_004516 Q12906 XRCC6 NM_001469 P12956 
TCERG1 NM_006706 O14776 LSM1 NM_014462 O15116 
C2orf3 NM_003203 P16383 CCNK NM_003858 O75909 
DIDO1 NM_022105 Q9BTC0 CCNA1 NM_003914 P78396 
QKI NM_006775 Q96PU8 NOSIP NM_015953 Q9Y314 
GTL3 NM_013242 Q9Y6A4 IQGAP1 NM_003870 P46940 
HCFC1 NM_005334 P51610 PPIE NM_006112 Q9UNP9 
TAF6 NM_005641 P49848 PPIH NM_006347 O43447 
ZFR NM_016107 Q96KR1 TOP1MT NM_052963 Q969P6 
PCBP4 NM_020418 P57723 KIAA1008 NM_014953 Q9Y2L1 
TIAL1 NM_003252 Q49AS9 EXOSC2 NM_014285 Q13868 
SR140 XM_031553 O15042 XRN2 NM_012255 Q9H0D6 
HNRPA0 NM_006805 Q13151 REXO2 NM_015523 Q9Y3B8 
HNRPL NM_001533 P14866 DDX54 NM_024072 Q8TDD1 
SIAHBP1 NM_014281 Q9UHX1 MOV10 NM_020963 Q9HCE1 
SNRPB2 NM_198220   EP400 NM_015409 Q96L91 
SF3B14 NM_016047 Q9Y3B4 EXOSC1 NM_016046 Q9Y3B2 
CIRBP NM_001280 Q14011 EXOSC3 NM_001002269 Q9NQT5 
SYNCRIP NM_006372 O60506 DDX1 NM_004939 Q92499 
ELAVL1 NM_001419 Q15717 EXOSC5 NM_020158 Q9NQT4 
HSPA8 NM_006597 P11142 DDX39 NM_005804 O00148 
CUGBP1 NM_006560 Q92879 ADAR NM_001111 P55265 
ABT1 NM_013375 Q9ULW3 EXOSC9 NM_005033 Q06265 
STRBP NM_018387 Q96SI9 DDX49 NM_019070 Q9Y6V7 
KIAA0853 NM_015070 Q5T200 DDX23 NM_004818 Q9BUQ8 
RUVBL1 NM_003707 Q9Y265 EXOSC7 NM_015004 Q15024 
HMGB1 NM_002128 P09429 DDX19B NM_007242 Q9UMR2 
HMGB3 NM_005342 O15347 DDX21 NM_004728 Q9NR30 
GTF2I NM_001518 Q499G6 EXOSC4 NM_019037 Q9NPD3 
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SKIV2L NM_006929 Q15477 KIAA1542 NM_020901 Q9P1Y6 
ASCC3L1 NM_014014 O75643 UNK NM_152302 Q9C0B0 
eIF4A2 NM_001967 Q14240 SNRPF NM_003095 P62306 
SKIV2L2 NM_015360 P42285 TUBB NM_178014 Q5SU16 
PRKRA NM_003690 O75569 LOC138046 NM_173848 Q86SE5 
POLDIP3 NM_032311 Q9BY77 SF3B5 NM_031287 Q9BWJ5 
CHERP NM_006387 Q8IWX8 FLJ21827 NM_020153 Q9NQC8 
KIAA1967 NM_021174 Q8N163 C1orf55 NM_152608 Q6IQ49 
S100A8 NM_002964 P05109 BAT1 NM_004640 Q13838 
S100A9 NM_002965 P06702 DDX17 NM_006386 Q92841 
C1QBP NM_001212 Q07021 C1orf60 NM_023015 Q68E01 
CD2BP2 NM_006110 O95400 SNRPD2 NM_004597 P62316 
RBP7 NM_052960 Q96R05 BRUNOL4 NM_020180 Q9BZC1 
NCBP1 NM_002486 Q09161 XAB2 NM_020196 Q9HCS7 
FMR1 NM_002024 Q06787 LSM10 NM_032881 Q969L4 
NCBP2 NM_007362 P52298 FIP1L1 NM_030917 Q6UN15 
TPR NM_003292 P12270 SNRPD3 NM_004175 P62318 
PSEN1 NM_000021 P49768 BRUNOL5 NM_021938 Q8N6W0 
ROD1 NM_005156 O95758 CRNKL1 NM_016652 Q9BZJ0 
DDX48 NM_014740 P38919 LSM11 NM_173491 P83369 
SSB NM_003142 P05455 REXO1 NM_020695 Q8N1G1 
ERVWE1 NM_014590 Q9UQF0 BRUNOL6 NM_052840 Q96J87 
NCL NM_005381 P19338 LSM5 NM_012322 Q9Y4Y9 
HNRPK NM_002140 P61978 BUB3 NM_004725 O43684 
SMC2L1 NM_006444 O95347 TIA1 NM_022173 P31483 
SMC1L1 NM_006306 Q14683 C10orf116 NM_006829 Q15847 
MSI2 NM_138962 Q96DH6 WBP11 NM_016312 Q9Y2W2 
FKBP3 NM_002013 Q00688 MGC14151 NM_032356 Q9BRA0 
ELAVL3 NM_001420 Q14576 MGC2803 NM_024038 Q9BQ61 
DGCR14 NM_022719 Q96DF8 C20orf23 NM_024704 Q96L93 
MSI1 NM_002442 O43347 MORG1 NM_032332 Q9BRX9 
TXNL4A NM_006701 P83876 MKI67IP NM_032390 Q9BYG3 
KPNA2 NM_002266 P52292 TFIP11 NM_001008697 Q9UBB9 
SNRPE NM_003094 P62304 HNRPA3 NM_194247 P51991 
PNN NM_002687 Q9H307 KIAA1604 NM_020943 Q9HCG8 
SNRPC NM_003093 Q5TAL4 HNRPAB NM_004499 Q99729 
LSM4 NM_012321 Q9Y4Z0 C13orf10 NM_022118 Q5T8P6 
LSM3 NM_014463 P62310 RBM7 NM_016090 Q9Y580 
TUBA1 NM_006000 P68366 TPX2 NM_012112 Q643R0 
SNRPB NM_198216 P14678 NIF3L1BP1 NM_025075 Q6I9Y2 
SNRPA1 NM_003090 P09661 RBM9 NM_014309 O43251 
RBMX NM_002139 P38159 TRA2A NM_013293 Q13595 
A2BP1 NM_145891 Q9NWB1 HNRPDL NM_005463 O14979 
TDRD3 NM_030794 Q9H7E2 NONO NM_007363 Q15233 
SPPL3 NM_139015 Q8TCT6 FLJ20273 NM_019027 A0AV96 
NUMA1 NM_006185 Q14980 RY1 NM_006857 Q8WVK2 
MFAP1 NM_005926 P55081 HIST1H2AC NM_003512 Q93077 
IK NM_006083 Q13123 CSN3 NM_005212 P07498 
KIAA0773 NM_014690 Q86XD5 RBMX2 NM_016024 Q9Y388 
SRP46 NM_032102 Q9BRL6 HIST2H2AA NM_003516 Q6FI13 
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HIST1H2BC NM_003526 P62807 RPS15A NM_001019 P62244 
WDR57 NM_004814 Q96DI7 AQR NM_014691 O60306 
CUGBP2 NM_006561 O95319 RBM5 NM_005778 P52756 
HNRPH3 NM_012207 P31942 PHF5A NM_032758 Q7RTV0 
RAVER1 NM_133452 Q8IY67 RPS17 NM_001021 P08708 
U2AF1L2 NM_005089 Q15696 RBM12 NM_006047 Q9NTZ6 
C20orf14 NM_012469 O94906 MGC13125 NM_032725 Q9BRD0 
PABPC1 NM_002568 P11940 RPS18 NM_022551 P62269 
ARS2 NM_015908 Q9BXP5 MATR3 NM_018834 A0A0R4J2E8 
U2AF1L3 NM_144987 Q8WU68 PRPF38A NM_032284 Q8NAV1 
EFTUD2 NM_004247 Q15029 RPS19 NM_001022 P39019 
PABPC4 NM_003819 Q13310 C9orf10 NM_014612 Q9NZB2 
DNAJC17 NM_018163 Q9NVM6 RPS25 NM_001028 P62851 
PCBP1 NM_006196 Q15365 ET NM_024311 O43934 
IMP-3 NM_006547 O00425 RBMS1 NM_016836 P29558 
LSM2 NM_021177 Q9Y333 DKFZP434K1421 NM_032141 Q9H0G5 
PCBP2 NM_005016 Q15366 RPS29 NM_001032 P62273 
ACIN1 NM_014977 Q9UKV3 BCAS2 NM_005872 O75934 
DDX6 NM_004397 P26196 CPSF4 NM_006693 O95639 
PCBP3 NM_020528 P57721 RDBP NM_002904 P18615 
RBM15 NM_022768 Q96T37 SYF2 NM_015484 O95926 
RPS3A NM_001006 P61247 FAM32A NM_014077 Q9Y421 
RPS4X NM_001007 P62701 CCDC12 NM_144716 J3KR35 
LSM6 NM_007080 P62312 RPS11 NM_001015 P62280 
KIAA1429 NM_015496 Q69YN4 CPSF3 NM_016207 Q9UKF6 
HNRPUL1 NM_007040 Q9BUJ2 C21orf70 NM_058190 Q9NSI2 
RBM10 NM_005676 P98175 RPL5 NM_000969 P46777 
RPS4Y1 NM_001008 P22090 GPATC1 NM_018025 Q9BRR8 
LSM7 NM_016199 Q9UK45 CPSF2 NM_017437 Q9P2I0 
RBM25 NM_021239 P49756 FRG1 NM_004477 Q14331 
RPS5 NM_001009 P46782 RPL22 NM_000983 P35268 
LSM8 NM_016200 O95777 CDC5L NM_001253 Q99459 
RPS7 NM_001011 P62081 CXXC6 NM_030625 Q8NFU7 
PRPF4 NM_004697 O43172 RPL23A NM_000984 P62750 
SF4 NM_021164 Q8IWZ8 CSTF3 NM_001326 Q12996 
RPS8 NM_001012 Q5JR94 RPL31 NM_000993 P62899 
PRPF3 NM_004698 O43395 GRSF1 NM_002092 Q12849 
EIF2S2 NM_003908 P20042 SRP9 NM_003133 P49458 
RPS9 NM_001013 P46781 SAFB2 NM_014649 Q14151 
NHP2L1 NM_001003796 P55769 HSPC148 NM_016403 Q9P013 
EIF3S10 NM_003750 Q14152 SRP19 NM_003135 P09132 
RPS10 NM_001014 P46783 HNRNPG-T NM_014469 O75526 
EIF3S2 NM_003757 Q5U0F4 PRCC NM_005973 Q92733 
PSIP1 NM_021144 O75475 SRP68 NM_014230 Q9UHB9 
RPS12 NM_001016 P25398 HNRPCL1 NM_001013631 O60812 
EIF3S6 NM_001568 P60228 SFRS16 NM_007056 Q8N2M8 
FUSIP1 NM_006625 O75494 HNRPH2 NM_019597 P55795 
WDR33 NM_001006622 Q9C0J8 HNRPLL NM_138394 Q8WVV9 
EIF3S6IP NM_016091 Q9Y262 CTNNBL1 NM_030877 Q8WYA6 
WDR58 NM_024339 Q86W42 PRPF8 NM_006445 Q6P2Q9 
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KIAA1160 NM_020701 Q9ULR0 
SNRPN NM_003097 P63162 
HSPC117 NM_014306 Q9Y3I0 
SNIP1 NM_024700 Q8TAD8 
IMP-1 NM_006546 Q9NZI8 
HYPC NM_012272 Q6NWY9 
ZCCHC8 NM_017612 Q6NZY4 
SPEN NM_015001 Q96T58 
NHN1 NM_144604 Q86VM9 
DDB1 NM_001923 Q16531 
TCERG1  NM_006706 O14776 
HNRPC NM_031314 P07910 
POLR2A NM_000937 A0A0C4DGZ0 
EXOSC8 NM_181503 Q96B26 
SNRPG NM_003096 P62308 
NOVA2 NM_002516 Q9UNW9 
SMU1 NM_018225 Q2TAY7 
C14orf166 NM_016039 Q9Y224 
FUS NM_004960 P35637 
SFRS9 NM_003769 Q13242 
TAF15 NM_003487 Q92804 
RUVBL2 NM_006666 Q9Y230 
PRPF38B NM_018061 Q5VTL8 
HNRPH1 NM_005520 P31943 
RPS15 NM_001018 P62841 
CWF19L1 NM_018294 Q69YN2 
DDX5 NM_004396 P17844 
SFRS4 NM_005626 Q08170 
DHX16 NM_003587 O60231    
SFRS6 NM_006275 Q13247    
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